<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD with MathML3 v1.1 20151215//EN" "JATS-journalpublishing1-mathml3.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink"
         xmlns:mml="http://www.w3.org/1998/Math/MathML"
         xmlns:ali="http://www.niso.org/schemas/ali/1.0/"
         xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
         dtd-version="1.1"
         xml:lang="sl"
         article-type="other">
   <front>
      <journal-meta>
         <journal-id journal-id-type="publisher-id">Zdrav Vestn</journal-id>
         <journal-id journal-id-type="nlm-ta">Zdrav Vestn</journal-id>
         <journal-id journal-id-type="doi">Zdrav Vestn</journal-id>
         <journal-title-group>
            <journal-title>Zdravniški vestnik</journal-title>
            <trans-title-group xml:lang="en">
               <trans-title>Slovenian Medical Journal</trans-title>
            </trans-title-group>
            <abbrev-journal-title>Zdrav Vestn</abbrev-journal-title>
         </journal-title-group>
         <issn publication-format="ppub" pub-type="ppub">1318-0347</issn>
         <issn publication-format="epub" pub-type="epub">1581-0224</issn>
         <issn-l>0350-0063</issn-l>
         <publisher>
            <publisher-name xml:lang="sl">Slovensko zdravniško društvo</publisher-name>
            <publisher-name xml:lang="en">Slovenian Medical Association</publisher-name>
            <publisher-loc xml:lang="sl">Ljubljana, Slovenia</publisher-loc>
         </publisher>
      </journal-meta>
      <article-meta>
         <article-id pub-id-type="doi">10.6016/ZdravVestn.2836</article-id>
         <article-id pub-id-type="publisher-id">2836</article-id>
         <article-categories>
            <subj-group subj-group-type="discipline" xml:lang="en">
               <subject>Medicine and health sciences</subject>
               <subj-group>
                  <subject>Oncology</subject>
               </subj-group>
            </subj-group>
            <subj-group subj-group-type="discipline" xml:lang="sl">
               <subject>Medicina/Zdravstvo</subject>
               <subj-group>
                  <subject>Onkologija</subject>
               </subj-group>
            </subj-group>
            <subj-group subj-group-type="article-type" xml:lang="en">
               <subject>Review article</subject>
            </subj-group>
            <subj-group subj-group-type="article-type" xml:lang="sl">
               <subject>Pregledni znanstveni članek</subject>
            </subj-group>
            <subj-group subj-group-type="heading" xml:lang="sl">
               <subject>Onkologija</subject>
            </subj-group>
         </article-categories>
         <title-group>
            <article-title xml:lang="sl">Hipertermična intraperitonealna kemoterapija</article-title>
            <trans-title-group>
               <trans-title xml:lang="en">Hyperthermic intraperitoneal chemotherapy</trans-title>
            </trans-title-group>
            <alt-title alt-title-type="running-head" xml:lang="sl">Hipertermična intraperitonealna kemoterapija</alt-title>
         </title-group>
         <contrib-group>
            <contrib contrib-type="author" xlink:type="simple">
               <name name-style="western">
                  <surname>Skok</surname>
                  <given-names>Kristijan</given-names>
               </name>
               <xref ref-type="aff" rid="aff1">1</xref>
            </contrib>
            <contrib contrib-type="author" xlink:type="simple">
               <name name-style="western">
                  <surname>Skornšek</surname>
                  <given-names>Nina</given-names>
               </name>
               <xref ref-type="aff" rid="aff1">1</xref>
            </contrib>
            <contrib contrib-type="author" xlink:type="simple">
               <name name-style="western">
                  <surname>Hočevar</surname>
                  <given-names>Marko</given-names>
               </name>
               <xref ref-type="aff" rid="aff2">2</xref>
               <xref ref-type="aff" rid="aff3">3</xref>
            </contrib>
            <contrib contrib-type="author" xlink:type="simple">
               <name name-style="western">
                  <surname>Skok</surname>
                  <given-names>Pavel</given-names>
               </name>
               <xref ref-type="aff" rid="aff4">4</xref>
               <xref ref-type="corresp" rid="corr"/>
            </contrib>
         </contrib-group>
         <aff-alternatives id="aff1">
            <aff xml:lang="sl">
               <label>1</label>
               <institution>Medicinska fakulteta, Univerza v Mariboru, Maribor, Slovenija</institution>
            </aff>
            <aff xml:lang="en">
               <label>1</label>
               <institution>Faculty of medicine, University of Maribor, Maribor, Slovenia</institution>
            </aff>
         </aff-alternatives>
         <aff-alternatives id="aff2">
            <aff xml:lang="sl">
               <label>2</label>
               <institution>Medicinska fakulteta, Univerza v Ljubljani, Ljubljana, Slovenija</institution>
            </aff>
            <aff xml:lang="en">
               <label>2</label>
               <institution>Medicinska fakulteta, Univerza v Ljubljani, Ljubljana, Slovenija</institution>
            </aff>
         </aff-alternatives>
         <aff-alternatives id="aff3">
            <aff xml:lang="sl">
               <label>3</label>
               <institution>Oddelek za kirurško onkologijo, Sektor operativnih dejavnosti, Onkološki inštitut, Ljubljana, Slovenija</institution>
            </aff>
            <aff xml:lang="en">
               <label>3</label>
               <institution>Division of surgery, Institute of Oncology Ljubljana, Ljubljana, Slovenia</institution>
            </aff>
         </aff-alternatives>
         <aff-alternatives id="aff4">
            <aff xml:lang="sl">
               <label>4</label>
               <institution>Oddelek za znanstveno-raziskovalno delo, Univerzitetni klinični center Maribor, Maribor, Slovenija</institution>
            </aff>
            <aff xml:lang="en">
               <label>4</label>
               <institution>Medical research department, University Medical Centre Maribor, Maribor, Slovenia</institution>
            </aff>
         </aff-alternatives>
         <author-notes>
            <fn fn-type="conflict" xml:lang="en">
               <p>The authors have declared that no competing interests exist.</p>
            </fn>
            <fn fn-type="conflict" xml:lang="sl">
               <p>Avtorji so izjavili, da ne obstajajo nobeni konkurenčni interesi.</p>
            </fn>
            <corresp id="corr">Pavel Skok, e-mail: <email xlink:type="simple"/>
            </corresp>
         </author-notes>
         <pub-date pub-type="ppub">
            <month>2</month>
            <year>2019</year>
         </pub-date>
         <pub-date pub-type="epub">
            <month>2</month>
            <year>2019</year>
         </pub-date>
         <volume>88</volume>
         <issue>1–2</issue>
         <fpage>21</fpage>
         <lpage>38</lpage>
         <history>
            <date date-type="received">
               <day>28</day>
               <month>4</month>
               <year>2018</year>
            </date>
            <date date-type="accepted">
               <day>10</day>
               <month>2</month>
               <year>2019</year>
            </date>
         </history>
         <permissions>
            <copyright-statement xml:lang="en">Copyright © 2019, Slovenian Medical Association (SZD)</copyright-statement>
            <copyright-statement xml:lang="sl">© 2019, Slovensko zdravniško društvo (SZD)</copyright-statement>
            <copyright-year>2019</copyright-year>
            <copyright-holder xml:lang="en">Slovenian Medical Association (SZD)</copyright-holder>
            <copyright-holder xml:lang="sl">Slovensko zdravniško društvo (SZD)</copyright-holder>
            <license xlink:href="https://creativecommons.org/licenses/by-nc/4.0/"
                     xlink:type="simple"
                     xml:lang="en">
               <license-p>This is an open access article distributed under the terms of the
          <ext-link ext-link-type="uri"
                            xlink:href="https://creativecommons.org/licenses/by-nc/4.0/"
                            xlink:type="simple">Creative Commons Attribution-NonCommercial
            License</ext-link>, which permits unrestricted use, distribution, and
          reproduction in any medium, provided the original author and source are
          credited and only for non-commercial purposes. </license-p>
            </license>
            <license xlink:href="https://creativecommons.org/licenses/by-nc/4.0/"
                     xlink:type="simple"
                     xml:lang="sl">
               <license-p>To je članek z odprtim dostopom, ki ga lahko uporabite pod pogoji iz
          <ext-link ext-link-type="uri"
                            xlink:href="https://creativecommons.org/licenses/by-nc/4.0/"
                            xlink:type="simple">Creative Commons Priznanje avtorstva-Nekomercialno
            licence</ext-link>. ki dovoljuje distribucijo, predelavo ali
          prilagoditev, ter gradijo na njem, v nekomercialne namene, z navedbo avtorja
          in izvirnega dela.</license-p>
            </license>
         </permissions>
         <abstract xml:lang="sl">
            <title>Izvleček</title>
            <p>V preteklosti so bolnike z zasevki po peritoneju obravnavali kot neozdravljivo bolne s terminalnim stanjem raka, ki se zdravi samo paliativno. Ob takšnem pristopu je bilo povprečno preživetje bolnikov le dva meseca. Zdravljenje teh bolnikov se je v devetdesetih letih prejšnjega stoletja pomembno spremenilo. Nekateri raziskovalci so bili namreč mnenja, da so peritonealni zasevki v določenih primerih samo vrsta loko-regionalne bolezni in se bolnik lahko (p)ozdravi. Eden glavnih zagovornikov te teorije in novega načina zdravljenja je bil Paul Sugarbaker. V sklopu zdravljenja se je začela uporabljati citoreduktivna kirurgija v kombinaciji z intraperitonealno kemoterapijo. Namen kirurškega posega je bila makroskopska odstranitev tumorja, nato pa z intraperitonealno kemoterapijo odstranitev še morebitnih mikroskopskih “preostankov” bolezni. Postopek, pri katerem citostatik med operacijo uvedemo in segrevamo, se imenuje hipertermična intraperitonealna kemoterapija. Hipertermija ima že sama po sebi protitumorski učinek na maligne celice, saj povzroči razgradnjo proteinov, aktivranje lizosomov in apoptozo. Ob segrevanju raztopine citostatika potečejo zapletene kemijske reakcije, ki dodatno povečajo njegovo učinkovitost in povečajo globino prodiranja zdravila v tumorsko tkivo. O najboljših rezultatih te oblike zdravljenja so poročali v primerih psevdomiksoma peritoneja, raka debelega črevesa in danke, karcinoma slepiča, karcinoma jajčnikov in peritonealnega mezotelioma. V prispevku avtorji predstavijo to zahtevno metodo zdravljenja, indikacije in vključitvena merila bolnikov ter sodobna spoznanja o učinkovitosti te metode za določene vrste raka.</p>
         </abstract>
         <trans-abstract xml:lang="en">
            <title>Abstract</title>
            <p>In the past, patients with peritoneal metastases have been treated only with palliative therapy. Their state was deemed to be incurable. The median survival time was approximately two months. The therapeutic approach started to change in the nineties. Some researchers were of the opinion that peritoneal metastases were, in certain cases, only a locoregional disease and consequently, the patient could not only be treated, but cured. One of the main supporters of this theory and new treatment approach was Paul Sugarbaker. The proposed treatment consisted of cytoreductive surgery in combination with intraperitoneal chemotherapy. The purpose of the surgical procedure is macroscopic elimination of the tumour and removal of its microscopic remains via intraperitoneal chemotherapy. The procedure in which we apply a heated chemotherapeutic agent is known as hyperthermic intraperitoneal chemotherapy. Heat on its own has some direct anti-tumour effects. It causes protein denaturation, lysosomal activation and increased apoptotic cell death. If the chemotherapeutic agent is heated, complex chemical reactions take place, which promote its effectiveness and increase the depth of penetration. The best results achieved by this method have been reported in colorectal carcinoma, appendiceal malignancies, ovarian carcinoma and peritoneal mesothelioma. In the paper, the authors present this complex procedure, indications, criteria of patient selection and contemporary knowledge on the effectiveness of this method of treatment for certain types of cancer.</p>
         </trans-abstract>
         <kwd-group xml:lang="sl">
            <kwd>hipertermična intraperitonealna kemoterapija</kwd>
            <kwd>citoreduktivna kirurgija</kwd>
            <kwd>rak debelega črevesa in danke</kwd>
            <kwd>karcinomatoza peritoneja</kwd>
            <kwd>zasevki</kwd>
         </kwd-group>
         <kwd-group xml:lang="en">
            <kwd>hyperthermic intraperitoneal chemotherapy</kwd>
            <kwd>cytoreductive surgery</kwd>
            <kwd>colorectal cancer</kwd>
            <kwd>peritoneal carcinosis</kwd>
            <kwd>metastases</kwd>
         </kwd-group>
         <custom-meta-group>
            <custom-meta>
               <meta-name>TotalReferences</meta-name>
               <meta-value>60</meta-value>
            </custom-meta>
            <custom-meta>
               <meta-name>ReferencesParsed</meta-name>
               <meta-value>57</meta-value>
            </custom-meta>
            <custom-meta>
               <meta-name>ReferencesBillable</meta-name>
               <meta-value>58</meta-value>
            </custom-meta>
            <custom-meta>
               <meta-name>LinkServices</meta-name>
               <meta-value>pubmed-crossref</meta-value>
            </custom-meta>
            <custom-meta>
               <meta-name>ReferencesLinked</meta-name>
               <meta-value>54</meta-value>
            </custom-meta>
            <custom-meta>
               <meta-name>ReferencesLinkedDOI</meta-name>
               <meta-value>43</meta-value>
            </custom-meta>
            <custom-meta>
               <meta-name>ReferencesLinkedPMID</meta-name>
               <meta-value>52</meta-value>
            </custom-meta>
            <custom-meta>
               <meta-name>JournalReferences</meta-name>
               <meta-value>55</meta-value>
            </custom-meta>
            <custom-meta>
               <meta-name>BookReferences</meta-name>
               <meta-value>0</meta-value>
            </custom-meta>
            <custom-meta>
               <meta-name>BookChapterReferences</meta-name>
               <meta-value>1</meta-value>
            </custom-meta>
            <custom-meta>
               <meta-name>ConferenceReferences</meta-name>
               <meta-value>0</meta-value>
            </custom-meta>
            <custom-meta>
               <meta-name>ElectronicReferences</meta-name>
               <meta-value>0</meta-value>
            </custom-meta>
            <custom-meta>
               <meta-name>DissertationReferences</meta-name>
               <meta-value>0</meta-value>
            </custom-meta>
            <custom-meta>
               <meta-name>LegalReferences</meta-name>
               <meta-value>0</meta-value>
            </custom-meta>
            <custom-meta>
               <meta-name>StandardReferences</meta-name>
               <meta-value>0</meta-value>
            </custom-meta>
            <custom-meta>
               <meta-name>OtherReferences</meta-name>
               <meta-value>0</meta-value>
            </custom-meta>
            <custom-meta>
               <meta-name>UnknownReferences</meta-name>
               <meta-value>4</meta-value>
            </custom-meta>
            <custom-meta>
               <meta-name>ReferencesSemiParsed</meta-name>
               <meta-value>0</meta-value>
            </custom-meta>
            <custom-meta>
               <meta-name>ReferencesBookUnparsed</meta-name>
               <meta-value>0</meta-value>
            </custom-meta>
            <custom-meta>
               <meta-name>EditorialStyle</meta-name>
               <meta-value>ICMJE-WHO</meta-value>
            </custom-meta>
         </custom-meta-group>
      </article-meta>
   </front>
   <body>
      <sec id="s1" sec-type="Uvod">
         <label>1</label>
         <title>Uvod</title>
         <p>Karcinomatoza peritoneja (PC) je zasevanje malignoma po peritonealni votlini (<xref ref-type="bibr" rid="b1">1</xref>). Lahko je posledica primarnega peritonealnega malignoma (npr. peritonealnega mezotelioma), razsoja malignoma prebavne cevi (raka slepiča, raka debelega črevesa in danke ali raka želodca), psevdomiksoma peritoneja in ginekoloških vrst raka (rak jajčnikov) (<xref ref-type="bibr" rid="b2">2</xref>,<xref ref-type="bibr" rid="b3">3</xref>). Zasevki v peritoneju so v preteklosti veljali za neozdravljivo in terminalno stanje rakave bolezni, bolnike so zdravili samo paliativno (s sistemsko kemoterapijo – SKT – ali paliativno kirurgijo) (<xref ref-type="bibr" rid="b3">3</xref>). Ob takšnem pristopu je bilo povprečno preživetje bolnikov le dva meseca (<xref ref-type="bibr" rid="b4">4</xref>). V devetdesetih letih prejšnjega stoletja se je takšen pristop pomembno spremenil (<xref ref-type="bibr" rid="b5">5</xref>). Nekateri raziskovalci so namreč menili, da so peritonealni zasevki v določenih primerih samo vrsta loko-regionalne bolezni in bolnika lahko tudi ozdravi (<xref ref-type="bibr" rid="b6">6</xref>). Za enega glavnih zagovornikov te teorije in novega načina zdravljenja velja Paul Sugarbaker (<xref ref-type="bibr" rid="b7">7</xref>).</p>
         <p>V sklopu zdravljenja rakavih bolezni se je začela uporabljati citoreduktivna kirurgija (CRS) v kombinaciji z intraperitonealno kemoterapijo (IPKT). Namen CRS je odstranitev makroskopsko vidnega tumorja. Za odstranitev peritonealnih zasevkov se je v ta namen začela opravljati kirurška peritonektomija z visceralno resekcijo. Drugi pomemben korak zdravljenja teh bolezni pa je loko-regionalna kemoterapija, ki se uporablja med operacijo ali v zgodnjem obdobju po njej (<xref ref-type="bibr" rid="b4">4</xref>). Postopek, pri katerem cito­statik med operacijo uvedemo in segrevamo, se imenuje hipertermična intraperitonealna kemoterapija (HIPEC). Kemoterapijo (KT), ki se uporabi v zgodnjem obdobju po posegu imenujemo EPIC. Namen obeh je odstranitev mikroskopskih ostankov raka (<xref ref-type="bibr" rid="b8">8</xref>).</p>
         <p>Posebnost kombiniranega zdravljenja HIPEC in CRS je dejstvo, da se vse izvaja med operacijo oz. ob operaciji (<xref ref-type="bibr" rid="b8">8</xref>,<xref ref-type="bibr" rid="b9">9</xref>). Uporabnost tega terapevtskega pristopa temelji na patofiziološkem mehanizmu bolezni ter domnevi, ki so jo v angleški literaturi poimenovali »ujetje« tumorskih celic (<italic toggle="yes">angl.</italic> tumor cell entrapment) (<xref ref-type="bibr" rid="b8">8</xref>). Ta predvideva, da se rakaste celice v času kirurškega posega še vedno sproščajo iz prekinjenih limfnih žil ali venske krvi, ki ostane po operaciji. Ob tem je znano, da razsoj raka lahko poteka kot širitev posameznih celic (<italic toggle="yes">angl.</italic> low density seeding) ter se izrazi kot peritonealni zasevek oz. nodularni vsadek, oddaljen od primarnega mesta raka. Druga oblika razsoja je, ko se številne rakaste celice (<italic toggle="yes">angl.</italic> high density seeding) »ujamejo« na površini resekcijskega mesta. Ob tem se ustvari sloj rakastega tkiva, ki se prilagodi na okoliške anatomske strukture (<xref ref-type="bibr" rid="b8">8</xref>). Najosnovnejša vključitvena merila za operacijo so odsotnost sistemskih zasevkov ali zasevkov v jetrih (izjema so 3 dobro omejene žariščne spremembe) in izključno loko-regionalno napredovanje bolezni na peritoneju oz. peritonealnih površinah (<xref ref-type="bibr" rid="b10">10</xref>).</p>
         <p>Za bolnike z rakom peritoneja je nujen multidisciplinarni pristop. O najboljših rezultatih uporabe takšne oblike zdravljenja so poročali pri psevdomiksomu peritoneja, raku debelega črevesa in danke (RDČD), raku slepiča, raku jajčnikov in peritonealnem mezoteliomu (<xref ref-type="bibr" rid="b7">7</xref>,<xref ref-type="bibr" rid="b11">11</xref>,<xref ref-type="bibr" rid="b12">12</xref>). Peritonealni zasevki se sicer lahko pojavijo tudi pri histoloških podtipih tumorjev, ki niso značilni za razsoj v peritonealno votlino. Mednje sodijo rak dojke, melanom, nevroendokrini tumorji (NET) in sarkomi (<xref ref-type="bibr" rid="b13">13</xref>–<xref ref-type="bibr" rid="b15">15</xref>). V zadnjem času je bilo objavljenih nekaj študij, v katerih so poročali o učinkoviti uporabi CRS pri peritonealnih zasevkih NET in sarkoma (<xref ref-type="bibr" rid="b16">16</xref>,<xref ref-type="bibr" rid="b17">17</xref>). Uporaba IPKT pri NET, gastrointestinalnih stromalnih tumorjih (GIST) in sarkomih se ni izkazala za učinkovito in ni dosegla pomembnega podaljšanja preživetja (<xref ref-type="bibr" rid="b4">4</xref>). Smernic za uporabo CRS z ali brez IPKT za karcinom trebušne slinavke, primarni jetrni karcinom, karcinom dojk in melanom trenutno še ni na voljo (<xref ref-type="bibr" rid="b4">4</xref>).</p>
         <p>V prispevku avtorji predstavijo nekaj zgodovinskih dejstev o HIPEC-u, postopke zdravljenja s to zahtevno metodo ter sodobna spoznanja o spodbudnih rezultatih pri posameznih vrstah raka.</p>
      </sec>
      <sec id="s2" sec-type="Zgodovinski razvoj">
         <label>2</label>
         <title>Zgodovinski razvoj</title>
         <p>Weissberger je leta 1955 prvi predstavil koncept IPKT za lokalizirane tumorje peritoneja (<xref ref-type="bibr" rid="b18">18</xref>). Koncept se je nato razširil v ZDA in v osemdesetih letih prejšnjega stoletja so uvedli nove načine zdravljenja pri bolnikih s peritonealnimi zasevki. V 1978 je Dedrick razvil eksperimentalni model za farmakokinetiko IPKT in v 1988 je Fujimoto opisal uporabo hipertermije, ki izboljša uporabnost protitumorskih učinkovin (<xref ref-type="bibr" rid="b18">18</xref>). Kombinirano uporabo CRS z IPKT kot »agresivno« loko-regionalno terapijo je prvič opisal dr. Paul Sugarbaker v devetdesetih letih prejšnjega stoletja (<xref ref-type="bibr" rid="b3">3</xref>). Uporaba tega pristopa je nakazovala možnost bolj učinkovitega zdravljenja s potencialno daljšim preživetjem. Kljub zadržanosti in delitvi mnenj se je ta pristop izkazal kot edini, ki je podaljšal povprečno preživetje nekaterih bolnikov celo do 46 mesecev (<xref ref-type="bibr" rid="b4">4</xref>).</p>
      </sec>
      <sec id="s3" sec-type="Hipertermična intraperitonealna kemoterapija">
         <label>3</label>
         <title>Hipertermična intraperitonealna kemoterapija</title>
         <p>CRS in HIPEC se kot ločeni metodi nista izkazali za učinkoviti, vendar sta v kombinaciji trenutno najučinkovitejši metodi zdravljenja bolnikov s peritonealnimi zasevki, ki so posledica RDČD, peritonealnega mezotelioma, karcinoma slepiča in karcinoma jajčnika (<xref ref-type="bibr" rid="b19">19</xref>,<xref ref-type="bibr" rid="b20">20</xref>). Prikaz uporabe HIPEC-a prikazuje <xref ref-type="fig" rid="fig1">Slika 1</xref>.</p>
         <fig position="anchor" id="fig1" orientation="portrait">
            <label>Slika 1:</label>
            <caption>
               <p> Shematski prikaz HIPEC-a.</p>
            </caption>
            <p>
               <graphic xlink:href="2836-web-resources/image/zdravvestn-2836-sl-01.png"
                        position="float"
                        orientation="portrait"/>
            </p>
            <p>Avtor: Corrado Bellini. Slika je s spleta in označena za »vnovično uporabo s spreminjanjem«.</p>
         </fig>
         <p>Prvi korak te metode zdravljenja je CRS, pri katerem se odstrani makroskopsko vidno tumorsko tkivo, nato se opravi HIPEC, ki uniči minimalne ostanke tumorskih celic. Raziskovalci so odkrili več dejavnikov, ki vplivajo na izid in uspešnos zdravljenja, nekaj ključnih je zbranih v <xref ref-type="table" rid="table1">Tabeli 1</xref> (<xref ref-type="bibr" rid="b21">21</xref>,<xref ref-type="bibr" rid="b22">22</xref>). Za dolgotrajno izboljšanje in čim manjšo možnost ponovitve bolezni je ključna odstranitev vseh vidnih tumorskih mas, cilj je torej t. i. popolna citoredukcija. Glede na razširjenost bolezni, se izvajajo različni kirurški posegi, peritonektomija zgornjega levega in desnega trebušnega kvadranta in medenice, omentektomija, resekcija rektosigmoidnega dela črevesa, desna hemikolektomija, splenektomija in delna gastrektomija (<xref ref-type="bibr" rid="b23">23</xref>).</p>
         <table-wrap position="anchor" id="table1" orientation="portrait">
            <label>Tabela 1:</label>
            <caption>
               <p> Dejavniki tveganja in ocenjevalni sistemi (povzeto po Sugarbaker in Van der Speeten, Benoit, Cotte et al. (<xref ref-type="bibr" rid="b8">8</xref>,<xref ref-type="bibr" rid="b28">28</xref>,<xref ref-type="bibr" rid="b59">59</xref>).</p>
            </caption>
            <table>
               <colgroup span="1">
                  <col span="1"/>
                  <col span="1"/>
                  <col span="1"/>
               </colgroup>
               <thead>
                  <tr>
                     <th colspan="3" rowspan="1">Dejavniki</th>
                  </tr>
               </thead>
               <tbody>
                  <tr>
                     <th content-type="table-subhead" rowspan="1" colspan="1">Primerni za poseg</th>
                     <th content-type="table-subhead" rowspan="1" colspan="1">Relativne kontraindikacije</th>
                     <th content-type="table-subhead" rowspan="1" colspan="1">Absolutne kontraindikacije</th>
                  </tr>
                  <tr>
                     <td rowspan="1" colspan="1">Dober splošen status.</td>
                     <td rowspan="1" colspan="1">Subokluzivni sindrom, zaradi več kot ene stenoze v GIT.</td>
                     <td rowspan="1" colspan="1">Slab splošni status.</td>
                  </tr>
                  <tr>
                     <td rowspan="1" colspan="1">Starost pod 65–70 let.</td>
                     <td rowspan="1" colspan="1">Napredovanje peritonealne bolezni ob sistemski KT.</td>
                     <td rowspan="1" colspan="1">Prisotnost več kot treh zasevkov (izjema so 3 dobro odstranljivi jetrni zasevki).</td>
                  </tr>
                  <tr>
                     <td rowspan="1" colspan="1">Odsotnost zunajtrebušnih zasevkov.</td>
                     <td rowspan="1" colspan="1">Prisotnost več kot 3 odstranljivih jetrnih zasevkov.</td>
                     <td rowspan="1" colspan="1">Veliki, difuzni peritonealni zasevki.</td>
                  </tr>
                  <tr>
                     <td rowspan="1" colspan="1">Odsotnost stenoze v GIT (prebavni cevi) in klinično ali radiološki preveliki zasevki v peritoneju.</td>
                     <td rowspan="1" colspan="1"/>
                     <td rowspan="1" colspan="1"/>
                  </tr>
                  <tr>
                     <th colspan="3" rowspan="1">Sugarbakerjev ocenjevalni sistem popolnosti opravljene CRC</th>
                  </tr>
                  <tr>
                     <th content-type="table-subhead" rowspan="1" colspan="1">Ocena</th>
                     <th content-type="table-subhead" colspan="2" rowspan="1">Definicija</th>
                  </tr>
                  <tr>
                     <td rowspan="1" colspan="1">CC-0</td>
                     <td colspan="2" rowspan="1">Brez vidne peritonealne karcinomatoze po CRC.</td>
                  </tr>
                  <tr>
                     <td rowspan="1" colspan="1">CC-1</td>
                     <td colspan="2" rowspan="1">Še vedno prisotni noduli velikosti &lt; 2,5 mm po CRC.</td>
                  </tr>
                  <tr>
                     <td rowspan="1" colspan="1">CC-2</td>
                     <td colspan="2" rowspan="1">Še vedno prisotni noduli velikosti med 2,5 mm in 2,5 cm.</td>
                  </tr>
                  <tr>
                     <td rowspan="1" colspan="1">CC-3</td>
                     <td colspan="2" rowspan="1">Še vedno prisotni noduli velikosti &gt; 2,5 cm.</td>
                  </tr>
                  <tr>
                     <th colspan="3" rowspan="1">STATUS ECOG</th>
                  </tr>
                  <tr>
                     <th content-type="table-subhead" rowspan="1" colspan="1">Število</th>
                     <th content-type="table-subhead" colspan="2" rowspan="1">Definicija</th>
                  </tr>
                  <tr>
                     <td rowspan="1" colspan="1">0</td>
                     <td colspan="2" rowspan="1">Popolna aktivnost in oseba sposobna vseh aktivnosti kot pred boleznijo.</td>
                  </tr>
                  <tr>
                     <td rowspan="1" colspan="1">1</td>
                     <td colspan="2" rowspan="1">Omejenost pri hujši telesni ejavnosti, ohranjena sposobnost hoje in opravljanje lažjih opravil.</td>
                  </tr>
                  <tr>
                     <td rowspan="1" colspan="1">2</td>
                     <td colspan="2" rowspan="1">Ohranjena sposobnost hoje in samooskrbe, vendar prisotna nezmožnost opravljanja delovnih aktivnosti, oseba budna &gt; 50 % dnevnih ur.</td>
                  </tr>
                  <tr>
                     <td rowspan="1" colspan="1">3</td>
                     <td colspan="2" rowspan="1">Oseba sposobna samo omejene samooskrbe, vezana na posteljo ali stol &gt; 50 % dnevnih ur.</td>
                  </tr>
                  <tr>
                     <td rowspan="1" colspan="1">4</td>
                     <td colspan="2" rowspan="1">Popolna invalidnost, oseba ni sposobna samooskrbe ter vezana na posteljo ali stol.</td>
                  </tr>
                  <tr>
                     <td rowspan="1" colspan="1">5</td>
                     <td colspan="2" rowspan="1">Smrt.</td>
                  </tr>
               </tbody>
            </table>
            <table-wrap-foot>
               <p>Legenda: GIT – prebavna cev, SKT – sistemska kemotrerapija, CRC – citoreduktivna operacija.</p>
            </table-wrap-foot>
         </table-wrap>
         <p>HIPEC je naslednji korak zdravljenja in se običajno izvede še pred rekonstrukcijo črevesja in pred zaprtjem trebušne votline, zato ker obstaja nevarnost, da se tumorske celice »ujamejo« v šive na mestih anastomoz. Gre za postopek, pri katerem se v peritonealno votlino preko dovodnega katetra vnese raztopina citostatika, ki je segreta na 41–44 °C (odvisno od vrste citostatika). Preko odvodnih katetrov se nato raztopina posrka iz peritonealne votline v hipertermično črpalko, ki ohranja temperaturo raztopine in omogoča njeno kroženje. Koncentracija citostatika v peritonealni votlini je sedemkrat večja, če jo apliciramo intraperitonealno, kot če jo apliciramo intravensko, vendar je prodiranje v tkivo omejeno le na nekaj milimetrov.  Izbira vrste citostatika, odmerjanje in temperatura raztopine je odvisna od vrste tumorja. Najpogosteje se uporabljajo doksorubicin, cisplatin, mitomicin C, melfalan, oksaliplatin, ifosfamid in gemcitabin (<xref ref-type="bibr" rid="b24">24</xref>) (<xref ref-type="table" rid="table2">Tabela 2</xref>). Hipertermija ima že sama po sebi protitumorski učinek, saj povzroči razgradnjo proteinov, aktiviranje lizosomov in apoptozo. Če segrejemo raztopino citostatika, se sprožijo zapletene kemične reakcije, ki dodatno povečajo učinkovitost in povečajo globino prodiranja citostatika v tumorsko tkivo (<xref ref-type="bibr" rid="b25">25</xref>).</p>
         <table-wrap position="anchor" id="table2" orientation="portrait">
            <label>Tabela 2:</label>
            <caption>
               <p> Nekatere značilnosti odprtega in zaprtega pristopa (povzeto po Sugarbaker in Van der Speeten) (<xref ref-type="bibr" rid="b8">8</xref>).</p>
            </caption>
            <table>
               <colgroup span="1">
                  <col span="1"/>
                  <col span="1"/>
                  <col span="1"/>
               </colgroup>
               <thead>
                  <tr>
                     <th rowspan="1" colspan="1">Značilnost</th>
                     <th rowspan="1" colspan="1">Odprti pristop</th>
                     <th rowspan="1" colspan="1">Zaprti pristop</th>
                  </tr>
               </thead>
               <tbody>
                  <tr>
                     <td rowspan="1" colspan="1">Učinkovitost</td>
                     <td rowspan="1" colspan="1">Omogoča kontinuirano citoredukcijo črevesja in mezenterija.</td>
                     <td rowspan="1" colspan="1">Kirurški postopki niso možni med kemoterapijo.</td>
                  </tr>
                  <tr>
                     <td rowspan="1" colspan="1">Nevarnost za okolico</td>
                     <td rowspan="1" colspan="1">Ni ugotavljanja aerosola.</td>
                     <td rowspan="1" colspan="1">Občutek večje varnosti.</td>
                  </tr>
                  <tr>
                     <td rowspan="1" colspan="1">Distribucija</td>
                     <td rowspan="1" colspan="1">Enakomerna porazdelitev temperature in citostatika, saj tkiva tik ob robu kože niso zajeta.</td>
                     <td rowspan="1" colspan="1">Morebitna slabša distribucija do pomembnejših in izoliranih področjih.</td>
                  </tr>
                  <tr>
                     <td rowspan="1" colspan="1">Tlak</td>
                     <td rowspan="1" colspan="1">Brez povišanega znotrajtrebušnega tlaka.</td>
                     <td rowspan="1" colspan="1">Povišani tlak v trebuhu lahko poveča prodiranje kemoterapevtika v tkiva.</td>
                  </tr>
                  <tr>
                     <td rowspan="1" colspan="1">Farmakokinetika</td>
                     <td rowspan="1" colspan="1">Omogoča farmakokinetično spremljanje tumorja in običajnega tkiva.</td>
                     <td rowspan="1" colspan="1">Tkivna absorpcija citostatika se ne more spremljati.</td>
                  </tr>
                  <tr>
                     <td rowspan="1" colspan="1">Trebušna incizijska rana in šivi</td>
                     <td rowspan="1" colspan="1">Se razreši pred končnim šivanjem.</td>
                     <td rowspan="1" colspan="1">Možnost ponovitve bolezni v trebušni incizijski in šivni rani.</td>
                  </tr>
                  <tr>
                     <td rowspan="1" colspan="1">Predrtje prepone ob peritonektomiji</td>
                     <td rowspan="1" colspan="1">Zdravljenje plevralnega prostora s HIPEC-om lahko prepreči razvoj nadaljnjih zasevkov.</td>
                     <td rowspan="1" colspan="1">Diafragma je zaprta pred začetkom postopka, zato se plevralni prostor ne zdravi.</td>
                  </tr>
                  <tr>
                     <td rowspan="1" colspan="1">Predrtje črevesja</td>
                     <td rowspan="1" colspan="1">Opazna ob potopitvi črevesja v tekočino.</td>
                     <td rowspan="1" colspan="1">Neopazna.</td>
                  </tr>
                  <tr>
                     <td rowspan="1" colspan="1">Hipertermija</td>
                     <td rowspan="1" colspan="1">Potrebne več toplote za vzdrževanje na 42 °C.</td>
                     <td rowspan="1" colspan="1">Manj toplote, potrebne za vzdrževanje 42 °C.</td>
                  </tr>
               </tbody>
            </table>
         </table-wrap>
         <p>Pri izvajanju tega postopka ločimo »zaprto in odprto« tehniko HIPEC-a (<xref ref-type="table" rid="table3">Tabela 3</xref>). Pri odprti tehniki je trebušna votlina še odprta ali prekrita s plastično prevleko, zato je problem aerosolizacija citostatika. Ta problem se skuša razrešiti s pregradami proti izhlapevanju in z odstranjevalci hlapov. Pri zaprti tehniki pa se najprej zapre kožni pokrov z vodotesnim šivom, nato pa se preko nastavljenih katetrov izpira peritonealna votlina. Po opravljenem postopku se trebušna votlina ponovno odpre, opravi se rekonstrukcija z anastomozami, šele nato pride na vrsto dokončno zaprtje trebušne votline (<xref ref-type="bibr" rid="b26">26</xref>). Uporablja se tudi laparoskopska tehnika HIPEC s paliativno indikacijo (močno zmanjša ascites) predvsem pri bolnikih z rakom, ki ga ni mogoče kirurško zdraviti. Trajanje izvajanja HIPEC-a, je odvisno od vrste citostatika, in sicer od 30 min (oksaliplatin) do 3 ur (pegilirani liposomalni doksirubicin) (<xref ref-type="bibr" rid="b24">24</xref>). Izbira zdravila za kemoterapijo je ključna za uspeh. Zdravilo ne sme povzročati lokalne toksičnosti, prav tako ne sme biti vezano na presnovo (pretvorba v aktivno obliko). Ob tem mora imeti neposreden citotoksičen učinek ter farmakokinetične prednosti ob IP vnosu (omejena sistemska toksičnost in dobra loko-regionalna prodornost). Prav tako je prednost, če ima zdravilo sinergistični učinek s toploto. Prednost te oblike zdravljenja je maksimalni lokalni in minimalni sistemski učinek, slabost pa predvsem to, da gre za tehnično zapleten poseg, ki je povezan z mnogimi tveganji. Na <xref ref-type="fig" rid="fig2">Sliki 2</xref> so prikazane nekatere spremenljivke, ki jih je potrebno imeti v mislih, preden se odločimo za opisano metodo zdravljenja (<xref ref-type="bibr" rid="b8">8</xref>,<xref ref-type="bibr" rid="b27">27</xref>).</p>
         <table-wrap position="anchor" id="table3" orientation="portrait">
            <label>Tabela 3:</label>
            <caption>
               <p>Seznam citostatikov za HIPEC (povzeto po Sugarbaker in Van der Speeten) (<xref ref-type="bibr" rid="b8">8</xref>).</p>
            </caption>
            <table>
               <colgroup span="1">
                  <col span="1"/>
                  <col span="1"/>
                  <col span="1"/>
                  <col span="1"/>
                  <col span="1"/>
                  <col span="1"/>
                  <col span="1"/>
                  <col span="1"/>
                  <col span="1"/>
                  <col span="1"/>
                  <col span="1"/>
                  <col span="1"/>
               </colgroup>
               <thead>
                  <tr>
                     <th rowspan="1" colspan="1">Zdravilo</th>
                     <th rowspan="1" colspan="1">Molekulska masa</th>
                     <th rowspan="1" colspan="1">Vrsta</th>
                     <th rowspan="1" colspan="1">AUC razmerje</th>
                     <th rowspan="1" colspan="1">T1/2 (min)</th>
                     <th rowspan="1" colspan="1">T80 % (min)</th>
                     <th rowspan="1" colspan="1">Odmerek</th>
                     <th rowspan="1" colspan="1">NT</th>
                     <th rowspan="1" colspan="1">Nezdružljivost v NT</th>
                     <th rowspan="1" colspan="1">Toplotna sinergija</th>
                     <th rowspan="1" colspan="1">Toplotna stabilnost</th>
                     <th rowspan="1" colspan="1">Globina učinka</th>
                  </tr>
               </thead>
               <tbody>
                  <tr>
                     <td rowspan="1" colspan="1">5-fluorouracil</td>
                     <td align="right" rowspan="1" colspan="1">130.08</td>
                     <td rowspan="1" colspan="1">Anti-metabolit</td>
                     <td align="right" rowspan="1" colspan="1">280</td>
                     <td align="right" rowspan="1" colspan="1">30</td>
                     <td align="right" rowspan="1" colspan="1">75</td>
                     <td rowspan="1" colspan="1">650 mg/m<sup>2</sup> (× 5 dni)</td>
                     <td rowspan="1" colspan="1">
                        <p>0.9 % NaCl;</p>
                        <p>1.5 % dekstrozna dializna tekočina; Icodextrin</p>
                     </td>
                     <td rowspan="1" colspan="1">Doksorubicin, Daunorubicin, Idaurubicin, Cisplatin, Diazepam, Icitarabin</td>
                     <td rowspan="1" colspan="1">MIN</td>
                     <td rowspan="1" colspan="1">43 °C</td>
                     <td rowspan="1" colspan="1">0.2 mm</td>
                  </tr>
                  <tr>
                     <td rowspan="1" colspan="1">Cisplatin</td>
                     <td align="right" rowspan="1" colspan="1">300.1</td>
                     <td rowspan="1" colspan="1">Alkilator</td>
                     <td align="right" rowspan="1" colspan="1">10</td>
                     <td align="right" rowspan="1" colspan="1">30</td>
                     <td align="right" rowspan="1" colspan="1">90</td>
                     <td align="right" rowspan="1" colspan="1">90 mg/m<sup>2</sup>
                     </td>
                     <td align="right" rowspan="1" colspan="1">0.9 % NaCl</td>
                     <td rowspan="1" colspan="1">NA</td>
                     <td rowspan="1" colspan="1">DA</td>
                     <td align="right" rowspan="1" colspan="1">41.5 °C</td>
                     <td rowspan="1" colspan="1">1–3 mm</td>
                  </tr>
                  <tr>
                     <td rowspan="1" colspan="1">Docetaksel</td>
                     <td align="right" rowspan="1" colspan="1">861.9</td>
                     <td rowspan="1" colspan="1">Antimitotik</td>
                     <td align="right" rowspan="1" colspan="1">552</td>
                     <td align="right" rowspan="1" colspan="1">NA</td>
                     <td align="right" rowspan="1" colspan="1">NA</td>
                     <td align="right" rowspan="1" colspan="1">45 mg/m<sup>2</sup>
                     </td>
                     <td align="right" rowspan="1" colspan="1">0.9 % NaCl</td>
                     <td rowspan="1" colspan="1">Plastični pripomočki in cevi</td>
                     <td rowspan="1" colspan="1">NE</td>
                     <td align="right" rowspan="1" colspan="1">NA</td>
                     <td rowspan="1" colspan="1">NA</td>
                  </tr>
                  <tr>
                     <td rowspan="1" colspan="1">Doksorubicin</td>
                     <td align="right" rowspan="1" colspan="1">579.99</td>
                     <td rowspan="1" colspan="1">Antitumor antibiotik</td>
                     <td align="right" rowspan="1" colspan="1">230</td>
                     <td align="right" rowspan="1" colspan="1">20</td>
                     <td align="right" rowspan="1" colspan="1">80</td>
                     <td align="right" rowspan="1" colspan="1">15 mg/m<sup>2</sup>
                     </td>
                     <td align="right" rowspan="1" colspan="1">1.5 % dekstrozna dializna tekočina</td>
                     <td rowspan="1" colspan="1">Heparin, fluorouracil</td>
                     <td rowspan="1" colspan="1">DA</td>
                     <td align="right" rowspan="1" colspan="1">42 °C</td>
                     <td rowspan="1" colspan="1">4–6 celičnih slojev</td>
                  </tr>
                  <tr>
                     <td rowspan="1" colspan="1">DOXIL (liposomalni doksorubicin)</td>
                     <td align="right" rowspan="1" colspan="1">579.99</td>
                     <td rowspan="1" colspan="1">Antitumor antibiotik</td>
                     <td align="right" rowspan="1" colspan="1">1,040</td>
                     <td align="right" rowspan="1" colspan="1">180</td>
                     <td align="right" rowspan="1" colspan="1">NA</td>
                     <td align="right" rowspan="1" colspan="1">100 mg/m<sup>2</sup>
                     </td>
                     <td align="right" rowspan="1" colspan="1">1.5 % dekstrozna dializna tekočina</td>
                     <td rowspan="1" colspan="1">Heparin, fluorouracil</td>
                     <td rowspan="1" colspan="1">DA</td>
                     <td align="right" rowspan="1" colspan="1">42 °C</td>
                     <td rowspan="1" colspan="1">4–6 celičnih slojev</td>
                  </tr>
                  <tr>
                     <td rowspan="1" colspan="1">Etopozid</td>
                     <td align="right" rowspan="1" colspan="1">588.58</td>
                     <td rowspan="1" colspan="1">Antitumor antibiotik</td>
                     <td align="right" rowspan="1" colspan="1">65</td>
                     <td align="right" rowspan="1" colspan="1">NA</td>
                     <td align="right" rowspan="1" colspan="1">NA</td>
                     <td align="right" rowspan="1" colspan="1">25–350 mg/m<sup>2</sup>
                     </td>
                     <td align="right" rowspan="1" colspan="1">5 % dekstroza</td>
                     <td rowspan="1" colspan="1">Pripomočki iz plastike; akril; antibiotiki</td>
                     <td rowspan="1" colspan="1">DA</td>
                     <td align="right" rowspan="1" colspan="1">42 °C</td>
                     <td rowspan="1" colspan="1">NA</td>
                  </tr>
                  <tr>
                     <td rowspan="1" colspan="1">Floksuridin (FUDR)</td>
                     <td align="right" rowspan="1" colspan="1">246.2</td>
                     <td rowspan="1" colspan="1">Anti-metabolit</td>
                     <td align="right" rowspan="1" colspan="1">75</td>
                     <td align="right" rowspan="1" colspan="1">NA</td>
                     <td align="right" rowspan="1" colspan="1">NA</td>
                     <td rowspan="1" colspan="1">
                        <p>500 mg/m<sup>2 </sup>/2x dan</p>
                        <p>(× 3 dneve)</p>
                     </td>
                     <td align="right" rowspan="1" colspan="1">0.9 % NaCl</td>
                     <td rowspan="1" colspan="1">NA</td>
                     <td rowspan="1" colspan="1">MIN</td>
                     <td align="right" rowspan="1" colspan="1">43 °C</td>
                     <td rowspan="1" colspan="1">NA</td>
                  </tr>
                  <tr>
                     <td rowspan="1" colspan="1">Gemcitabin</td>
                     <td align="right" rowspan="1" colspan="1">299.5</td>
                     <td rowspan="1" colspan="1">Pirimidinski antagonist</td>
                     <td align="right" rowspan="1" colspan="1">205</td>
                     <td align="right" rowspan="1" colspan="1">40</td>
                     <td align="right" rowspan="1" colspan="1">75</td>
                     <td align="right" rowspan="1" colspan="1">1,000 mg/m2</td>
                     <td align="right" rowspan="1" colspan="1">0.9 % NaCl</td>
                     <td rowspan="1" colspan="1">NA</td>
                     <td rowspan="1" colspan="1">V 48 h</td>
                     <td align="right" rowspan="1" colspan="1">42.5 °C</td>
                     <td rowspan="1" colspan="1">NA</td>
                  </tr>
                  <tr>
                     <td rowspan="1" colspan="1">Irinotekan</td>
                     <td align="right" rowspan="1" colspan="1">677.19</td>
                     <td rowspan="1" colspan="1">Antitumor antibiotik</td>
                     <td align="right" rowspan="1" colspan="1">NA</td>
                     <td align="right" rowspan="1" colspan="1">NA</td>
                     <td align="right" rowspan="1" colspan="1">NA</td>
                     <td align="right" rowspan="1" colspan="1">200 mg/m<sup>2</sup>
                     </td>
                     <td align="right" rowspan="1" colspan="1">1.5 % dekstrozna dializna tekočina</td>
                     <td rowspan="1" colspan="1">NA</td>
                     <td rowspan="1" colspan="1">NE</td>
                     <td align="right" rowspan="1" colspan="1">44 °C</td>
                     <td rowspan="1" colspan="1">NA</td>
                  </tr>
                  <tr>
                     <td rowspan="1" colspan="1">Karboplatin</td>
                     <td align="right" rowspan="1" colspan="1">371.25</td>
                     <td rowspan="1" colspan="1">Alkilator</td>
                     <td align="right" rowspan="1" colspan="1">10</td>
                     <td align="right" rowspan="1" colspan="1">NA</td>
                     <td align="right" rowspan="1" colspan="1">NA</td>
                     <td align="right" rowspan="1" colspan="1">300 mg/m<sup>2</sup>
                     </td>
                     <td align="right" rowspan="1" colspan="1">0.9 % NaCl</td>
                     <td rowspan="1" colspan="1">NA</td>
                     <td rowspan="1" colspan="1">DA</td>
                     <td align="right" rowspan="1" colspan="1">41.5 °C</td>
                     <td rowspan="1" colspan="1">0.5 mm</td>
                  </tr>
                  <tr>
                     <td rowspan="1" colspan="1">Melphalan</td>
                     <td align="right" rowspan="1" colspan="1">305.2</td>
                     <td rowspan="1" colspan="1">Alkilator</td>
                     <td align="right" rowspan="1" colspan="1">56</td>
                     <td align="right" rowspan="1" colspan="1">33</td>
                     <td align="right" rowspan="1" colspan="1">69</td>
                     <td align="right" rowspan="1" colspan="1">70 mg/m<sup>2</sup>
                     </td>
                     <td align="right" rowspan="1" colspan="1">0.9 % NaCl</td>
                     <td rowspan="1" colspan="1">NA</td>
                     <td rowspan="1" colspan="1">IZRAZITO</td>
                     <td align="right" rowspan="1" colspan="1">42 °C</td>
                     <td rowspan="1" colspan="1">NA</td>
                  </tr>
                  <tr>
                     <td rowspan="1" colspan="1">Mitoksantron</td>
                     <td align="right" rowspan="1" colspan="1">517.41</td>
                     <td rowspan="1" colspan="1">Antitumor antibiotik</td>
                     <td align="right" rowspan="1" colspan="1">115–255</td>
                     <td align="right" rowspan="1" colspan="1">NA</td>
                     <td align="right" rowspan="1" colspan="1">NA</td>
                     <td align="right" rowspan="1" colspan="1">28 mg/m<sup>2</sup>
                     </td>
                     <td align="right" rowspan="1" colspan="1">0.9 % NaCl; Ringerjev laktat</td>
                     <td rowspan="1" colspan="1">Heparin</td>
                     <td rowspan="1" colspan="1">DA</td>
                     <td align="right" rowspan="1" colspan="1">43 °C</td>
                     <td rowspan="1" colspan="1">5–6 celičnih slojev</td>
                  </tr>
                  <tr>
                     <td rowspan="1" colspan="1">Mitomicin C</td>
                     <td align="right" rowspan="1" colspan="1">334.3</td>
                     <td rowspan="1" colspan="1">Antitumor antibiotik</td>
                     <td align="right" rowspan="1" colspan="1">27</td>
                     <td align="right" rowspan="1" colspan="1">40</td>
                     <td align="right" rowspan="1" colspan="1">90</td>
                     <td align="right" rowspan="1" colspan="1">15 mg/m<sup>2</sup>
                     </td>
                     <td align="right" rowspan="1" colspan="1">1.5 % dekstrozna dializna tekočina</td>
                     <td rowspan="1" colspan="1">Bleomicin</td>
                     <td rowspan="1" colspan="1">DA</td>
                     <td align="right" rowspan="1" colspan="1">42.5 °C</td>
                     <td rowspan="1" colspan="1">2 mm</td>
                  </tr>
                  <tr>
                     <td rowspan="1" colspan="1">Oksaliplatin</td>
                     <td align="right" rowspan="1" colspan="1">397.3</td>
                     <td rowspan="1" colspan="1">Alkilator</td>
                     <td align="right" rowspan="1" colspan="1">16</td>
                     <td align="right" rowspan="1" colspan="1">40</td>
                     <td align="right" rowspan="1" colspan="1">60</td>
                     <td align="right" rowspan="1" colspan="1">460 mg/m<sup>2</sup>
                     </td>
                     <td align="right" rowspan="1" colspan="1">5 % dekstroza</td>
                     <td rowspan="1" colspan="1">Aluminijeve baze ali NaCl raztopine</td>
                     <td rowspan="1" colspan="1">DA</td>
                     <td align="right" rowspan="1" colspan="1">46 °C</td>
                     <td rowspan="1" colspan="1">1–2 mm</td>
                  </tr>
                  <tr>
                     <td rowspan="1" colspan="1">Paklitaksel</td>
                     <td align="right" rowspan="1" colspan="1">853.9</td>
                     <td rowspan="1" colspan="1">Antimitotik</td>
                     <td align="right" rowspan="1" colspan="1">1,000</td>
                     <td align="right" rowspan="1" colspan="1">NA</td>
                     <td align="right" rowspan="1" colspan="1">NA</td>
                     <td align="right" rowspan="1" colspan="1">120–180 mg (skupni odmerek)</td>
                     <td align="right" rowspan="1" colspan="1">1.5 % dekstrozna dializna tekočina; 6 % etoksiliran amilopektin</td>
                     <td rowspan="1" colspan="1">Plastični pripomočki in cevi</td>
                     <td rowspan="1" colspan="1">NE</td>
                     <td align="right" rowspan="1" colspan="1">42.5 °C</td>
                     <td rowspan="1" colspan="1">&gt;80 celičnih slojev</td>
                  </tr>
                  <tr>
                     <td rowspan="1" colspan="1">Pemetreksed</td>
                     <td align="right" rowspan="1" colspan="1">471.4</td>
                     <td rowspan="1" colspan="1">Večtarčni antifolat</td>
                     <td align="right" rowspan="1" colspan="1">70</td>
                     <td align="right" rowspan="1" colspan="1">90</td>
                     <td align="right" rowspan="1" colspan="1">260</td>
                     <td align="right" rowspan="1" colspan="1">500 mg/m<sup>2</sup>
                     </td>
                     <td align="right" rowspan="1" colspan="1">1.5 % dekstrozna dializna tekočina</td>
                     <td rowspan="1" colspan="1">NA</td>
                     <td rowspan="1" colspan="1">NA</td>
                     <td align="right" rowspan="1" colspan="1">NA</td>
                     <td rowspan="1" colspan="1">NA</td>
                  </tr>
               </tbody>
            </table>
            <table-wrap-foot>
               <p>Legenda: MIN – minimalno, NT – nosilna tekočina, NA – ni podatkov, AUC – area under the curve, tj. območje pod krivuljo; T80 % – čas, potreben za 80-odstotni očistek zdravila.</p>
            </table-wrap-foot>
         </table-wrap>
         <fig position="anchor" id="fig2" orientation="portrait">
            <label>Slika 2:</label>
            <caption>
               <p> Prikaz spremenljivk pri uporabi HIPEC-a (povzeto po Sugarbaker in Van der Speeten) (<xref ref-type="bibr" rid="b8">8</xref>).</p>
            </caption>
            <p>
               <graphic xlink:href="2836-web-resources/image/zdravvestn-2836-sl-02.png"
                        position="float"
                        orientation="portrait"/>
            </p>
         </fig>
         <sec id="s3.1" sec-type="Spremenljivke">
            <label>3.1</label>
            <title>Spremenljivke</title>
            <p>Priznani zdravstveni centri, ki obravnavajo zadostno število bolnikov s PC so v mednarodni literaturi objavili 8 kliničnih in radioloških spremenljivk, ki vplivajo na večjo verjetnost za kompletno CRS:</p>
            <list>
               <list-item>
                  <label>•</label>
                  <p>»Eastern Cooperative Oncology Group« (ECOG) »performance status“ 1 ali manj;</p>
               </list-item>
               <list-item>
                  <label>•</label>
                  <p>brez znakov širjenja bolezni izven trebušne votline;</p>
               </list-item>
               <list-item>
                  <label>•</label>
                  <p>do trije majhni resektabilni parenhimski jetrni zasevki;</p>
               </list-item>
               <list-item>
                  <label>•</label>
                  <p>brez znakov zapore žolčevodov;</p>
               </list-item>
               <list-item>
                  <label>•</label>
                  <p>brez znakov zapore sečevodov;</p>
               </list-item>
               <list-item>
                  <label>•</label>
                  <p>brez znakov več kot ene zapore prebavne cevi (GIT);</p>
               </list-item>
               <list-item>
                  <label>•</label>
                  <p>prehodnost tankega črevesa;</p>
               </list-item>
               <list-item>
                  <label>•</label>
                  <p>brez znakov makroskopske bolezni v mezenteriju s številnimi zaporami;</p>
               </list-item>
               <list-item>
                  <label>•</label>
                  <p>majhen tumor (<italic toggle="yes">angl.</italic> small volume disease) v gastro-hepatičnem ligamentu (<xref ref-type="bibr" rid="b28">28</xref>).</p>
               </list-item>
            </list>
            <p>Nekateri dejavniki predstavljajo absolutne, drugi relativne kontraindikacijea (<xref ref-type="table" rid="table1">Tabela 1</xref>) (<xref ref-type="bibr" rid="b28">28</xref>). Merila za vključitev bolnikov se nekoliko razlikujejo glede na vrsto rakaste bolezni, pri čemer se uporablja enaka skupina kvantitativnih napovednih meril za vse bolnike z zasevki v pertioneju. Mednje sodijo histopatološki izvid, peritonealni karcinomski indeks (<italic toggle="yes">angl.</italic> peritoneal cancer index – PCI, <xref ref-type="fig" rid="fig3">Slika 3</xref>), ocena popolnosti citoredukcijskega postopka (<italic toggle="yes">angl.</italic> completeness of cytoreduction score, (<xref ref-type="table" rid="table1">Tabela 1</xref>), slikovna diagnostika (CT) in Ž klasifikacija s peritonealno citologijo (<xref ref-type="bibr" rid="b1">1</xref>,<xref ref-type="bibr" rid="b29">29</xref>,<xref ref-type="bibr" rid="b30">30</xref>).</p>
            <fig position="anchor" id="fig3" orientation="portrait">
               <label>Slika 3:</label>
               <caption>
                  <p> Peritonealni karcinomski indeks (PCI) (povzeto po Cotte et al.) (<xref ref-type="bibr" rid="b59">59</xref>).</p>
               </caption>
               <p>
                  <graphic xlink:href="2836-web-resources/image/zdravvestn-2836-sl-03.png"
                           position="float"
                           orientation="portrait"/>
               </p>
            </fig>
            <sec id="s3.1.1" sec-type="Peritonealni karcinomski index">
               <label>3.1.1</label>
               <title>Peritonealni karcinomski index</title>
               <p>Peritonealni karcinomatozni index ali PCI je številčna vrednosti, ki služi kot ocena razširjenosti bolezni v trebušni in medenični regiji. Za izračun PCI je potrebno oceniti velikost spremembe (od 0 do 3) v trebušno medeničnih regijah (označene od 0 do 12). Izračun se naredi ob začetku operacije. Višja kot je končna vrednost PCI, manj učinkovit bo terapevtski režim CRS in HIPEC in manj verjetno je dolgoročno preživetje, zato obstajajo priporočene vrednosti PCI, do katerih je še smiselno opraviti poseg (pri psevdomiksomu ni zgornje meje, pri RDČD okoli 15) (<xref ref-type="bibr" rid="b30">30</xref>).</p>
            </sec>
            <sec id="s3.1.2" sec-type="Popolnost citoredukcijske kirurgije">
               <label>3.1.2</label>
               <title>Popolnost citoredukcijske kirurgije</title>
               <p>Eden ključnih dejavnikov je popolnost odstranitve ob CRS posegu. Njegova vrednost pomembeno vpliva na izid zdravljenja. V <xref ref-type="table" rid="table1">Tabeli 1</xref> so prikazane posamezne stopnje. Za boljši izid zdravljenja in boljšo kakovost življenja z manjšim številom zapletov je, večinoma, potrebna vrednost CC-0 ali CC-1 (<xref ref-type="bibr" rid="b30">30</xref>).</p>
            </sec>
            <sec id="s3.1.3"
                 sec-type="TNM klasifikacija, peritonealna citologija in klinične značilnosti primarnega karcinoma">
               <label>3.1.3</label>
               <title>TNM klasifikacija, peritonealna citologija in klinične značilnosti primarnega karcinoma</title>
               <p>Skrben pregled peritonealnih površin ob primarni resekciji raka prebavne cevi, hkrati s pravočasno in kakovostno histopatološko analizo reseciranega tkiva, lahko natančno napove pojavnost peritonealnih zasevkov, ki se pojavijo po operaciji. Ob tem pri napredovalih rakih prebavil peritonealna citologija prav tako nudi pomembne napovedne podatke (<xref ref-type="bibr" rid="b31">31</xref>,<xref ref-type="bibr" rid="b32">32</xref>). S pravilno oceno teh informacij se lahko zdravnik odloči za proaktivno zdravljenje s CRS in HIPEC. Dokazano je bilo, da se lahko pri bolnikih z visokim tveganjem na takšen način prepreči nastanek peritonealnih zasevkov ter bolnike z že prisotnimi zasevki zdravi s pristopom »drugega pogleda« (<italic toggle="yes">angl.</italic> second look) (<xref ref-type="bibr" rid="b30">30</xref>,<xref ref-type="bibr" rid="b32">32</xref>).</p>
            </sec>
            <sec id="s3.1.4" sec-type="Slikovna diagnostika pred posegom">
               <label>3.1.4</label>
               <title>Slikovna diagnostika pred posegom</title>
               <p>CT prsnega koša, trebuha in medenice so nujni pri izbiri primernih bolnikov za CRS in HIPEC. Namen slikovne diagnostike je oceniti razširjenost bolezni ter ugotoviti, ali so zasevki prisotni že na plevralnih površinah. Mesto in količina mucinoznega karcinoma v peritonealni votlini se lahko natančno določi. Prav nasprotno pa se nemucinozni peritonealni zasevki slabo prepoznajo na CT, zato se pogosto podcenijo. Če tanko črevo in njegov del mezenterija prekriva tumor ali je tumor v predelu žličke, je možnost uspešne CRS majhna. Priporoča se CT z maksimalnim odmerkom kontrasta v žilo ali skozi usta, da se ugotovi morebitna prizadetost tankega črevesa na posameznih mestih ali difuzno (<xref ref-type="bibr" rid="b31">31</xref>–<xref ref-type="bibr" rid="b33">33</xref>).</p>
            </sec>
            <sec id="s3.1.5" sec-type="Krivulja učenja">
               <label>3.1.5</label>
               <title>Krivulja učenja</title>
               <p>Izvedba CRS s HIPEC-om je zapleten postopek. Kot zanimivost navajamo, da je po študiji Smeeka s sod., onkološki kirurg dosegel primerno usposobljenost po 130 ponovitvah/posegih. Ključna vsebina učenja je pridobitev kirurških spretnosti, seveda pa so bolniku prilagojeni terapevtski pristopi in izkušnje celotne ekipe z obvladovanjem zapletov tudi pripomogli k zmanjšani umrljivosti (<xref ref-type="bibr" rid="b34">34</xref>).</p>
            </sec>
         </sec>
      </sec>
      <sec id="s4" sec-type="Maligni ascites">
         <label>4</label>
         <title>Maligni ascites</title>
         <p>Maligni ascites je nabiranje tekočine v peritonealni votlini zaradi napredovale oblike raka. Nastane zaradi zapore limfnih vodov s tumorskimi celicami, povečane prepustnosti žil, hormonskih vzrokov in povečane aktivnosti metaloproteinaz. Pogosto je povezan z napredovalimi stadiji raka rodil, prebavil in malignimi tumorji dojke. Med malignomi rodil prevladuje rak jajčnika, prebavil pa RDČD, trebušne slinavke in želodca (RŽ). Retrospektivna študija vzrokov malignega ascitesa je pokazala, da se najverjetneje pojavi pri raku jajčnika (37,7 %). Približno 10 % vseh ascitesov je malignih in 20 % bolnikov z malignim ascitesom ima tumorje neznanega izvora (<xref ref-type="bibr" rid="b35">35</xref>). Maligni ascites je slab napovedni dejavnik.</p>
         <sec id="s4.1" sec-type="Zdravljenje">
            <label>4.1</label>
            <title>Zdravljenje</title>
            <p>Zdravimo ga predvsem z zdravljenjem primarnega tumorja in z diuretiki, paracentezo, biološkimi zdravili in HIPEC-om, ki je trenutno najobetavnejša metoda zdravljenja. Vrsta citostatika, ki se uporabi pri HIPEC-u, je odvisna od primarnega tumorja, ki je povzročil maligni ascites. Pri karcinomu jajčnika je najprimernejše zdravilo cisplatin (50 mg/m<sup>2</sup>) ali doksorubicin (15 mg/m<sup>2</sup>), pri RDČD ali RŽ pa mitomicin C (12,5 mg/m<sup>2</sup>), pri bolnikih z drugimi vrstami tumorjev pa se uporabi dosksorubicin (12,5 mg/m<sup>2</sup>). V študiji, ki jo je izvedel Valle s sod. in je vključila 52 bolnikov z malignim ascitesom, so poročali o popolnem izginotju ascitesa v 94 % in povprečnempreživetju bolnikov 98 dni (21–796 dni) (<xref ref-type="bibr" rid="b36">36</xref>).</p>
         </sec>
      </sec>
      <sec id="s5" sec-type="Rak slepiča">
         <label>5</label>
         <title>Rak slepiča</title>
         <p>Patohistološko gledano lahko uvrstimo rak slepiča v skupino nevroendokrinih tumorjev in epitelnih tumorjev. Rak epitelnega izvora se lahko dalje deli v posamezne skupine: mukozne hiperplazije, retencijske ciste, mucinozni cistadenomi in adenokarcinomi (mucinozni, intestinalni, pečatnocelični). Mucinozne neoplazme slepiča so heterogena skupina tumorjev, ki se jih glede na gradus klasificira na nizko- in visokostopenjske histološke podtipe. Stanja, ki so v povezavi z zasevanjem raka slepiča, lahko delimo v tri skupine: razsejana peritonealna adenomucinoza (DPAM), peritonealna mucinozna karcinomatoza (PMCA) in PMCA z dobro diferenciacijo (<xref ref-type="bibr" rid="b4">4</xref>,<xref ref-type="bibr" rid="b37">37</xref>). Druga vrsta raka je karcinom čašastih celic, ki je kombinacija adenokarcinoma in karcinoida. Posebna oblika je peritonealni psevdomiksom (PMP), ki nastane iz mucinoznega adenoma (<xref ref-type="bibr" rid="b37">37</xref>). Zanj je značilno razpršeno nabiranje želatinastega materiala v trebušni votlini, medenici in mucinozni vrastki na površini peritoneja. PMP raste, ob tem se začne nabirati mukus, kar privede do razpoka in razsoja bolezni. V peritonealni votlini se začne nabirati mukus, kar privede do značilne slike »želejastega trebuha« (<italic toggle="yes">angl.</italic> jelly belly) in zapore prebavne cevi (<xref ref-type="bibr" rid="b9">9</xref>,<xref ref-type="bibr" rid="b37">37</xref>,<xref ref-type="bibr" rid="b38">38</xref>). Zaradi nepravilnega poimenovanja in poenostavljanja se je v zadnjih letih izraz začel enačiti tudi za peritonealno zasevanje mucinoznih adenokarcinomov slepiča, debelega črevesa, tankega črevesa, pljuč, dojk, trebušne slinavke, želodca, žolčnika, jajcevodov in jajčnikov. PMP in adenokarcinom sta zaradi narave zasevanja tudi najbolj primerna za zdravljenje s HIPEC-om (<xref ref-type="bibr" rid="b4">4</xref>).</p>
         <p>Patohistološki izvid zasevkov primarnega tumorja ima velik vpliv na izid zdravljenja CRS in HIPEC-a. Zasevki, ki so vsebovali več kot 90 % mukoznih, ploščatih epitelnih celic, brez atipije in mitoz, so imeli dobro napoved izida kljub visoki vrednosti PCI. Zasevki z močno atipijo celic, številčnimi mitozami in manj kot 50 % mukoznih epitelnih celic pa so imeli slabo (<xref ref-type="bibr" rid="b1">1</xref>). Bolniki z adenomucinozo imajo najboljši izid, pri čemer imajo bolniki z mucinoznim karcinomom podobno preživetje kot bolniki s peritonealnimi zasevki RDČD. Čeprav sta si rak črevesa in rak slepiča podobna, obstajajo pomembne razlike. Najpomembnejša razlika je v premeru svetline prizadetega organa. RDČD raste v svetlini in se širi skozi steno navzven, v napredovalih stadijih se razširi vse do seroze. Pri raku slepiča, ki ima majhno svetlino, pride zaradi rasti prej do preraščanja stene in zato širjenja tumorskih celic v trebušno votlino in medenični predel (<xref ref-type="bibr" rid="b1">1</xref>,<xref ref-type="bibr" rid="b34">34</xref>).</p>
         <sec id="s5.1" sec-type="Zdravljenje">
            <label>5.1</label>
            <title>Zdravljenje</title>
            <p>Začetnik takšnega pristopa zdravljenja je bil Sugarbaker, ki je leta 1987 poročal o prvi uporabi IPC po CRS pri bolnikih s PMP (<xref ref-type="bibr" rid="b4">4</xref>). Leta 2001 je poročal o 108 bolnikih, ki so jih spremljali 10 let, zdravljeni pa so bili s CRS in HIPEC-com z mitomicinom. Kemoterapevtski režim je vseboval 5-fluorouracil (5-FU) od prvega do šestega pooperativnega dne in nato tri cikluse adjuvantnega zdravljenja z mitomicinom (i. v.) ter IPKT s 5-FU. Vključena skupina bolnikov je bila zelo heterogena. V njihovem primeru je bila histologija izrednega pomena za preživetje, kajti bolniki z DPAM so imeli pomembno boljši izid zdravljenja kot druge skupine, z mucinoznim in intermediarnim karcinomom (<xref ref-type="bibr" rid="b38">38</xref>).</p>
            <p>Sistematski pregled bolnikov, ki so imeli histološko dokazan DPAM in opravljen CRS in HIPEC, je pokazal 70–86 % petletnega in 60–68 % desetletnega preživetja (<xref ref-type="bibr" rid="b39">39</xref>). V multicentrični študiji so poročali o 81 % petletnega ter 70 % desetletnega preživetja za bolnike z DPAM; za bolnike s PMCA je bilo 59 % petletnega ter 49 % desetletnega preživetja; za mešan tip pa 78 % petletnega in 63 % desetletnega preživetja. Povprečno preživetje je bilo 16,3 leta. Dokazali so, da je popolna citoredukcija najpomembnejši dejavnik povezan z boljšim preživetjem (<xref ref-type="bibr" rid="b40">40</xref>). Ob CRS se ne priporoča rutinska odstrantev bezgavk (<xref ref-type="bibr" rid="b4">4</xref>).</p>
         </sec>
      </sec>
      <sec id="s6" sec-type="Rak debelega črevesa in danke">
         <label>6</label>
         <title>Rak debelega črevesa in danke</title>
         <p>RDČD je tretji najpogostejši rak na svetu pri moških (746.000 primerov letno) in drugi najpogostejši pri ženskah (614.000 primerov letno) (<xref ref-type="bibr" rid="b41">41</xref>). Leta 2012 je bilo odkritih skoraj 1,4 milijona novih bolnikov. Predvidena pojavnost leta 2035 bo 2,4 milijona bolnikov. Incidenčne mere so višje v razvitih (737.000 primerov) kot v manj razvitih državah (624.000 primerov), umrljivost pa je večja v manj razvitih državah (<xref ref-type="bibr" rid="b42">42</xref>,<xref ref-type="bibr" rid="b43">43</xref>).</p>
         <p>Sluznica črevesa je prekrita z žleznim epitelom, zato je najpogostejši rak v tem področju adenokarcinom (90–95 %). Ob postavitvi diagnoze ima več kot 60 % bolnikov lokalno ali področno napredovalo bolezen, 15 % bolnikov pa tudi že oddaljene zasevke. RDČD zaseva limfo- in hematogeno, najpogosteje v jetra, pljuča in kosti (<xref ref-type="bibr" rid="b43">43</xref>).</p>
         <p>Peritonej je po jetrih drugo najpogostejše mesto za zasevke RDČD. V preteklosti objavljene študije trdijo, da je peritonej v do 25 % primerov edino mesto zasevkov. Novejše raziskave navajajo 10 %, pri čemer je do 20 % bolnikov, ki imajo zasevke v peritoneju in hkrati tudi v drugem organu (<xref ref-type="bibr" rid="b44">44</xref>). Stanje napredovale bolezni ima slabo napoved izida. Brez zdravljenja je povprečna doba preživetja do 9 mesecev (<xref ref-type="bibr" rid="b44">44</xref>). Žal v IV. stadiju bolezni kljub resekciji R0 bolezen napreduje v 50 % (<xref ref-type="bibr" rid="b1">1</xref>). V 10–35 % teh bolnikov se bolezen ponovi v peritoneju. Z modernimi SKT, ki vsebuje okasaliplatin in irinotekan z dodatkom 5-FU ter tarčnih zdravil, kot sta bevacizumab ter cetuksimab, se lahko povprečno preživetje bolnikov v stadiju IV podaljša za do več kot 15 mesecev (<xref ref-type="bibr" rid="b42">42</xref>). Kakovost življenja je pogosto slabša zaradi spremljajočega ascitesa in pogostih zaprtij (sub-, ileus). Pri treh četrtinah bolnikov s PC (vzrok je RDČD) je ob postavitvi diagnoze primerna samo še paliativna sistemska kemoterapija. Za preostalo četrtino bolnikov, ki je brez oddaljenih zasevkov in ima omejen tumor v peritoneju, je, kot metoda zdravljenja primerna CRS v kombinaciji s HIPEC-om (<xref ref-type="bibr" rid="b31">31</xref>).</p>
         <sec id="s6.1" sec-type="Zdravljenje">
            <label>6.1</label>
            <title>Zdravljenje</title>
            <p>Operacija igra osrednjo vlogo pri zdravljenju RDČD. Dopolnilno zdravljenje pa se pri obeh vrstah razlikuje. Standardno zdravljenje lokalno ali področno napredovalega raka danke je radioterapija ali radiokemoterapija s 5-FU v neprekinjeni infuziji ali s kapecitabinom pred operacijo. Z modernimi kombinacijami oksaliplatina in irinotekana z dodatkom 5-FU in tarčnimi učinkovinami, kot sta bevacizumab ter cetuksimab, je povprečno preživetje bolnikov s IV. stadijem bolezni danes tudi od 7 do več kot 24 mesecev (<xref ref-type="bibr" rid="b1">1</xref>). V primeru omejenosti zasevkov na peritonej in izpolnitvi prej omenjenih pogojev se lahko uporabi CRS in HIPEC.</p>
            <p>Relativna kontraindikacija za CRS in HIPEC je slabo diferenciran primarni tumor. Ko so vključeni bolniki z dobro in srednje diferenciranim tumorjem, je preživetje bistveno boljše. Pri zdravljenju teh bolnikov se uporabljata trenutno dva protokola HIPEC. Pri prvem se uporabi mitomicin C (60–90 min), ogret na 41 °C z zaprto tehniko. Pri drugem pa se uporabi oksaliplatin (460 mg/m<sup>2</sup> oksaliplatin v 2 L/m<sup>2</sup> izoosmotske 5-odstotne dekstroze) v 30 min (točno 30 min od trenutka, ko je v trebušni votlini dosežena minimalna temperatura 42 °C, plus 5–8 min, preden se infuzija segreje z 38 ° na 42 °C, in sicer na 43 °C (meja: 42–44 °C) z uporabo odprte tehnike (<xref ref-type="bibr" rid="b11">11</xref>). Dvosmerna, sistemska in intraperitonealna kemoterapija med operacijo, ki kombinira intraperitonealni oksaliplatin in i.v. infuzijo 5-FU (400 mg/m<sup>2</sup>) z levkovorinom (20 mg/m<sup>2</sup>) se predvsem uporablja za PC RDČD. Mitomicin ima prednost zaradi velike molekulske mase, dobre tkivne prehodnosti (do 5 mm) in ugodnega farmakokinetičnega profila, ki omogoča povečano intraperitonealno koncentracijo, ne da bi ob tem prišlo do hujših stranskih učinkov. V literaturi poročajo o primerljivi učinkovitosti obeh citostatikov za prej opisani režim. Kljub temu zagovarjajo nekateri raziskovalci uporabo oksaliplatina, ker ne povzroča nevtropenije in ima krajši perfuzijski čas (30 min vs 90 min) v primerjavi z mitomicinom-C (<xref ref-type="bibr" rid="b11">11</xref>,<xref ref-type="bibr" rid="b28">28</xref>).</p>
            <p>Randomizirana študija 105 bolnikov je primerjala skupini bolnikov, ki so imeli opravljen CRS + HIPEC + SKT ali zgolj SKT. Kljub vključitvenim težavam so v študiji poročali o 22 mesečni povprečni dobi preživetja za prvo skupino in 13 mescev za drugo skupino (<xref ref-type="bibr" rid="b45">45</xref>). Po osmih letih je bilo razmerje enako (<xref ref-type="bibr" rid="b46">46</xref>). V drugi študiji je Association Francaise de Chirurgie poročala o 30-odstotnem preživetju, ki je eno od najnižjih v literaturi (<xref ref-type="bibr" rid="b47">47</xref>). Centri, ki se pogosto ukvarjajo s takšnimi pristopi, so poročali o približno 40 %. Glehen s sod. je objavil rezultate uporabe HIPEC-a in pristopov EPIC pri bolnikih s to boleznijo. Vključenih je bilo 506 bolnikov iz 28 institucij; HIPEC (54 %), EPIC (24 %) in kombinacija (22 %). Za bolnike s CCR0 (kompletna resekcija) so bila 1-, 3- in 5-letna preživetja 87 %, 47 % in 31 % ter 32,4 mesecev povprečno preživetje. Splošno preživetje (OS) je bilo 72 %, 39 %, in 19 % za 1-, 3- in 5-letne intervale. Mediano splošno preživetje je bilo 19,2 meseca (<xref ref-type="bibr" rid="b48">48</xref>). Elias s sod. je v študiji primerjal HIPEC in EPIC pristop. V študijo je bilo vključenih 523 bolnikov, morebitnih razlik v preživetju pa žal niso bile navedli (<xref ref-type="bibr" rid="b47">47</xref>).</p>
            <p>Nekatere študije navajajo visoko umrljivost in obolevnost v povezavi s CRS in HIPEC-om za RDČD (<xref ref-type="bibr" rid="b7">7</xref>,<xref ref-type="bibr" rid="b28">28</xref>,<xref ref-type="bibr" rid="b49">49</xref>). Sugarbaker je leta 2014 predstavil podatke operacij bolnikov z zasevki raka črevesa, pri katerih je bila umrljivost 0,6 % in pogostost stranskih učinkov stopnje IV 12 %. Sklepal je, da je kombinirano zdravljenje s CRS in HIPEC-om za izbrane bolnike najboljši način zdravljenja (<xref ref-type="bibr" rid="b7">7</xref>). Prav tako je bil mnenja, da trenutno ni dokazov, ki bi, za bolnike z rakom črevesa in boleznijo, omejeno na peritonealno površino, podpirali uporabo izključno SKT (<xref ref-type="bibr" rid="b7">7</xref>). Pri tem sklepu je potrebno poudariti, da je istega leta Sugarbaker v drugem prispevku poudaril, da je napredek v razvoju citostatikov vodil do izboljšanja stanja bolnikov ter ob napredku KT (oksaliplatin, irinotekan, biološka zdravila) CRS in HIPEC nista nujno najboljša izbira pri zdravljenju, vendar imata še vedno svoje mesto pri zdravljenju izbranih bolnikov (<xref ref-type="bibr" rid="b31">31</xref>). Poudaril je, da se mora bolniku v vsakem primeru omogočiti multidisciplinarni pristop z naborom različnih možnosti zdravljenja.</p>
         </sec>
      </sec>
      <sec id="s7" sec-type="Rak želodca">
         <label>7</label>
         <title>Rak želodca</title>
         <p>Izid zdravljenja RŽ z zasevki v peritoneju je eden izmed najslabših s povprečnim preživetjem 3–7 mesecev in 0 % petletnim preživetjem (<xref ref-type="bibr" rid="b50">50</xref>). Čeprav so se adjuvantna KT, neoadjuvantna KT in adjuvantna KRT izkazale za uporabne in minmalno izboljšale preživetje bolnikov, ni nobena naštetih oblik zdravljenja značilno prispevala k zmanjšanju števila ponovitev. Bolniki z RŽ (ob uporabi HIPEC-a) in peritonealnimi zasevki imajo značilno slabšo odzivnost na kemoterapijo. Povprečno preživetje zdravljenih bolnikov z RŽ in PC je 9,5–12 mesecev. Zaradi zahtevnosti zdravljenja in nezadovoljivih rezultatih KT se je povečalo zanimanje za HIPEC s CRS (<xref ref-type="bibr" rid="b50">50</xref>).</p>
         <p>V preteklosti so nekateri nasprotovali postopku zaradi visoke stopnje umrljivosti in obolevnosti. Glede na dostopne vire se umrljivost za bolnike z RŽ verjetno giblje okoli 3,6–6,5 % (<xref ref-type="bibr" rid="b18">18</xref>). V primerjavi z rakom jajčnikov je umrljivost nekoliko višja zaradi gastrektomije, kajti pri raku jajčnikov se izvaja povprečno manj visceralnih resekcij. Glavni zapleti po operaciji so nevtropenija, fistula prebavne cevi, pljučnica, krvavitev, trebušni ognojek, sepsa, okužba rane in odpoved ledvic (<xref ref-type="bibr" rid="b18">18</xref>).</p>
         <p>HIPEC ima tri potencialne možnosti uporabe pri zdravljenju RŽ: profilaktično, za preprečitev recidiva po »ozdravitveni« (kurativni) gastrektomiji pri bolnikih z visokim tveganjem; terapevtsko pri bolnikih s PC po CRS in tretjič kot paliativno zdravljenje pri bolnikih s težko obvladljivim ascitesom zaradi hude razširitve PC, ki ni primerna za CRS (<xref ref-type="bibr" rid="b18">18</xref>). V prospektivni študiji z več kot 1.000 bolniki z adenokarcinomom želodca, ki so potem razvili metahrone PC, je bilo povprečno preživetje kljub prvotni R0 D2 resekciji samo 3 mesece. Čeprav je standardna sistemska terapija za bolnike s karcinomom želodca in PC to obdobje podaljšala na 7–10 mesecev, se RŽ slabo odziva na SKT (<xref ref-type="bibr" rid="b4">4</xref>). V drugi študiji se je to obdobje podaljšalo ob uporabi CRS in HIPEC metode, pri izbranih bolnikih, na povprečnih 9,2 meseca in 13 % petletnega preživetja (<xref ref-type="bibr" rid="b51">51</xref>). V prospektivni randomizirani študiji so primerjali sistemsko kemoterapijo s CRS in HIPEC-om. Sistemska kemoterapija je bila po shemi FOLFOXIRI (irinotekan, leukovorin, oksaliplatin in 5-FU) v režimu irinotekan 165 mg/m<sup>2</sup> za 90 min, nato levkovorin 200 mg/m<sup>2</sup> in oksaliplatin 85 mg/m<sup>2</sup> za 2 uri prvi dan ter ob tem s kontinuirano infuzijo 3.200 mg/m<sup>2</sup> 5-FU 48 ur. Drugi skupini bolnikov so po gastrektomiji odstranili zasevke iz jeter in pljuč, CRS in HIPEC (oksaliplatin 460 mg/ m<sup>2</sup> na 41 °C za 30 minut). Druga skupina je čez 8 mesecev prav tako pričela s KT po shemi FOLFOXIRI. Bolniki v prvi skupini so imeli povprečno preživetje 4,3 mesecev, v drugi skupini bolnikov pa je bilo preživetje 11,3 mesecev (<xref ref-type="bibr" rid="b52">52</xref>).</p>
         <p>Kot zanimivost navajamo, da so opisali tudi strategijo neoadjuvantne IP in SKT (NIPS), CRS in HIPEC-a in IP KT (EPIC) po operaciji. Osnovna ideja je bilo zmanjšanje tumorskega bremena pred operacijo in hkrati uporaba NIPS pri bolnikih s pozitivno peritonealno citologijo kot oblika kemoterapije, ki deluje terapevtsko na peritonealno bolezen v peritoneju in subperitonealno, v ožilju. Temu sledi CRS in HIPEC. Režim odmerjanja NIPS je bil 60 mg/m<sup>2</sup> oralno S-1 za 21 dni, čemur sledi enotedenski premor. Na prvi, osmi in petnajsti dan prejmejo v trebuh 30 mg/m<sup>2</sup> taksotera in 30 mg/m<sup>2</sup> CIS v 500 mL fiziološke raztopine (<xref ref-type="bibr" rid="b53">53</xref>).</p>
      </sec>
      <sec id="s8" sec-type="Rak jajčnika">
         <label>8</label>
         <title>Rak jajčnika</title>
         <p>Rak jajčnika je eden izmed vodilnih vzrokov smrti žensk z maligno boleznijo. Incidenčna stopnja v Sloveniji za leto 2015 je 14,7/100.000 prebivalcev. Predstavlja osmi (v svetovnem merilu) in deseti (Slovenija) najpogostejši rak pri ženskah, po podatkih iz leta 2014 letno zboli 166 žensk, večina med 55. in 65. letom. Najpogostejši tip raka jajčnika je maligni epitelni tumor podtipa serozni adenokarcinom (40–45 %), za njim pa endometroidni podtip. Običajno se diagnosticira v FIGO stadiju III in IV, ko je že prisoten razsoj po peritoneju v 75 %. Standardno zdravljenje predstavlja CRS in sistemska kemoterapija, klub temu pride do ponovitve bolezni pri 75 % bolnic (<xref ref-type="bibr" rid="b54">54</xref>). O rekurentnem raku jajčnika govorimo, ko se ponovno pojavi po že zaključenem zdravljenju, če se pojavi v roku do 6 mesecev, je to na platino odporen rak jajčnika, če se pojavi po več kot 6 mesecih po začetku zdravljenja, pa je to na platino občutljiv rak jajčnika.</p>
         <sec id="s8.1" sec-type="Zdravljenje">
            <label>8.1</label>
            <title>Zdravljenje</title>
            <p>Kombinacija CRS in HIPEC-a se je pri teh bolnicah izkazala kot učinkovit način zdravljenja. Optimalnega režima zdravljenja še niso opredelili. V različnih študijah so uporabili cisplatin, oksaliplatin, mitomicin in doksorubicin. V eni od študij so kot najustreznejši protokol potrdili 70 mg/m<sup>2</sup> cisplatina in izvajanje HIPEC-a eno uro pri 42 °C (<xref ref-type="bibr" rid="b28">28</xref>). Pred nedavnim so objavili prvo randomizirano študijo, ki je preučevala HIPEC za zdravljenje raka jajčnika. V klinično študijo so uvrstili 120 bolnic s ponavljajočo se boleznijo, ki so bile prvotno zdravljene z CRS in sistemsko kemoterapijo. Tiste bolnice, ki so bile poleg CRS in sistemske kemoterapije zdravljene še s HIPEC-om, so imele bistveno boljše srednje preživetje od ostalih (26,7 meseca proti 13,4 meseca, p &lt; 0,006) in 3- letno preživetje (75 % proti 18 %, p &lt; 0.01). Preživetje je bilo, ob takšni terapiji, boljše pri bolnicah z na platino občutljivim kot tudi neobčutljivim rakom jajčnika (<xref ref-type="bibr" rid="b55">55</xref>).</p>
         </sec>
      </sec>
      <sec id="s9" sec-type="Mezoteliom">
         <label>9</label>
         <title>Mezoteliom</title>
         <p>Mezoteliomi so skupina malignih tumorjev, ki nastanejo iz seroznih membran (plevra, peritonej, perikard, tunica vaginalis testis). Difuzni maligni peritonealni mezoteliom (DMPM) je lokalno agresivni primarni maligni tumor serozne površine peritoneja in predstavlja 7–10 % vseh diagnosticiranih mezoteliomov.</p>
         <sec id="s9.1" sec-type="Zdravljenje">
            <label>9.1</label>
            <title>Zdravljenje</title>
            <p>Bolniki, zdravljeni s paliativno kirurgijo s kemoterapijo ali brez nje so dosegali povprečno preživetje eno leto. Napredovanje na področju zdravljenja je pripeljalo do kombinacije CRS in HIPEC, ki trenutno velja za najprimernejše zdravljenje. V študiji, v kateri so primerjali citostatika cisplatin in karboplatin za izvedbo HIPEC-a, so ugotovili daljše povprečno preživetje pri bolnikih, zdravljenih s karboplatinom (<xref ref-type="bibr" rid="b56">56</xref>). V študiji, ki je zajela 240 bolnikov z DMPM, ki so bili zdravljeni s kombinacijo CRS in HIPEC, je bilo srednje preživetje 53 mesecev, 3-letno preživetje 60 % in 5-letno preživetje 47 % (<xref ref-type="bibr" rid="b57">57</xref>).</p>
            <p>Deraco je predlagal nov sistem določanja stadija bolnikov z DMPM, ki temelji samo na določanju PCI: stadij I (do 10), stadij II (11–20, stadij III (21–30), stadij IV (&gt; 30). Bolniki s stadijem III ali IV niso kandidati za CRS in HIPEC. Petletna preživetja za stopnje I, II in III so 87 %, 53 % in 29 % (<xref ref-type="bibr" rid="b58">58</xref>).</p>
         </sec>
      </sec>
      <sec id="s10" sec-type="Zaključek">
         <label>10</label>
         <title>Zaključek</title>
         <p>Kombinacija CRS in HIPEC-a je ena učinkovitih možnosti na področju zdravljenja peritonealnih zasevkov, ki so posledica različnih tumorjev. V prispevku smo predstavili posamezne pristope k zdravljenju nekaterih vrst raka. Kot najpomembnejši napovedni dejavniki uspešnosti tega pristopa so vrsta raka, bolezenski stadij in možnost popolne citoredukcije. Ključnega pomena je tudi ustrezna izbira bolnikov, saj prinaša poseg veliko tveganje. Priporočljivo je, da se izvaja v centrih s primerno izobraženim in izkušenim osebjem.</p>
         <p>Na tem onkološkem področju je potrebnih še mnogo raziskav, preden bodo dokončno sprejeta priporočila za zdravljenje posameznih tipov tumorjev, izbiro najprimernejšega citostatika in režim dovajanja pri HIPEC-u. Že zdaj pa je moč zaključiti, da so v številnih mutinacionalnih študijah dokazali, da zdravljenje s CRS in HIPEC-om podaljša preživetje izbranih bolnikov, obenem pa je njihova umrljivost med samim posegom ali tik po njem primerljiva z umrljivostjo pri ostalih velikih kirurških posegih v trebušni votlini.</p>
      </sec>
   </body>
   <back>
      <ref-list>
         <ref id="b1">
            <mixed-citation publication-type="unknown" specific-use="parsed">
               <person-group person-group-type="author">
                  <collab>VIRI IN LITERATURA</collab>
               </person-group>
            </mixed-citation>
         </ref>
         <ref id="b2">
            <label>1. </label>
            <mixed-citation publication-type="book-chapter" specific-use="restruct">
               <person-group person-group-type="author">
                  <string-name name-style="western">
                     <surname>DeVita</surname> 
                     <given-names>VT</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Lawrence</surname> 
                     <given-names>TS</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Rosenberg</surname> 
                     <given-names>SA</given-names>
                  </string-name>
               </person-group>. <chapter-title>Peritoneal Metastases and Peritoneal Mesothelioma</chapter-title>. In: <person-group person-group-type="editor">
                  <string-name name-style="western">
                     <surname>Deraco</surname> 
                     <given-names>M</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Elias</surname> 
                     <given-names>DM</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Glehen</surname> 
                     <given-names>O</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Helm</surname> 
                     <given-names>CW</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Sugarbaker</surname> 
                     <given-names>PH</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Verwaal</surname> 
                     <given-names>VJ</given-names>
                  </string-name>, <role>editors</role>
               </person-group>. <source>DeVita, Hellman, and Rosenberg’s cancer: principles &amp; practice of oncology</source>. <edition>10th ed.</edition> 
               <year>2015</year>. p. <fpage>2234</fpage>. [<comment>Internet</comment>], Available from <ext-link ext-link-type="uri"
                         xlink:href="https://www.lww.co.uk/devita-hellman-and-rosenbergs-cancer-principles-practice-of-oncology-10-edition">https://www.lww.co.uk/devita-hellman-and-rosenbergs-cancer-principles-practice-of-oncology-10-edition</ext-link>
               <annotation>
                  <p content-type="warning">Could not find a publisher location in this book chapter reference. (Ref. 1 "DeVita, Lawrence, Rosenberg, 2015")</p>
                  <p content-type="warning">Could not find a publisher name in this book chapter reference. (Ref. 1 "DeVita, Lawrence, Rosenberg, 2015")</p>
               </annotation>
            </mixed-citation>
         </ref>
         <ref id="b3">
            <label>2.	</label>
            <mixed-citation publication-type="journal" specific-use="restruct">
               <person-group person-group-type="author">
                  <string-name name-style="western">
                     <surname>Lambert</surname> 
                     <given-names>LA</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Harris</surname> 
                     <given-names>A</given-names>
                  </string-name>
               </person-group>. <article-title>Palliative cytoreductive surgery and hyperthermic intraperitoneal chemoperfusion: current clinical practice or misnomer?</article-title> 
               <source>J Gastrointest Oncol</source>. <year>2016</year> 
               <month>Feb</month>;<volume>7</volume>(<issue>1</issue>):<fpage>112</fpage>–<lpage>21</lpage>.<pub-id pub-id-type="pmid">26941989</pub-id>
               <issn>2078-6891</issn>
            </mixed-citation>
         </ref>
         <ref id="b4">
            <label>3.	</label>
            <mixed-citation publication-type="journal" specific-use="restruct">
               <person-group person-group-type="author">
                  <string-name name-style="western">
                     <surname>Canbay</surname> 
                     <given-names>E</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Yonemura</surname> 
                     <given-names>Y</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Brucher</surname> 
                     <given-names>B</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Baik</surname> 
                     <given-names>SH</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Sugarbaker</surname> 
                     <given-names>PH</given-names>
                  </string-name>
               </person-group>. <article-title>Intraperitoneal chemotherapy and its evolving role in management of gastric cancer with peritoneal metastases</article-title>. <source>Chin J Cancer Res</source>. <year>2014</year> 
               <month>Feb</month>;<volume>26</volume>(<issue>1</issue>):<fpage>1</fpage>–<lpage>3</lpage>.<pub-id pub-id-type="pmid">24653620</pub-id>
               <issn>1000-9604</issn>
            </mixed-citation>
         </ref>
         <ref id="b5">
            <label>4.	</label>
            <mixed-citation publication-type="journal" specific-use="restruct">
               <person-group person-group-type="author">
                  <string-name name-style="western">
                     <surname>Dehal</surname> 
                     <given-names>A</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Smith</surname> 
                     <given-names>JJ</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Nash</surname> 
                     <given-names>GM</given-names>
                  </string-name>
               </person-group>. <article-title>Cytoreductive surgery and intraperitoneal chemotherapy: an evidence-based review-past, present and future</article-title>. <source>J Gastrointest Oncol</source>. <year>2016</year> 
               <month>Feb</month>;<volume>7</volume>(<issue>1</issue>):<fpage>143</fpage>–<lpage>57</lpage>.<pub-id pub-id-type="pmid">26941992</pub-id>
               <issn>2078-6891</issn>
            </mixed-citation>
         </ref>
         <ref id="b6">
            <label>5.	</label>
            <mixed-citation publication-type="journal" specific-use="restruct">
               <person-group person-group-type="author">
                  <string-name name-style="western">
                     <surname>Arjona-Sánchez</surname> 
                     <given-names>A</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Medina-Fernández</surname> 
                     <given-names>FJ</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Muñoz-Casares</surname> 
                     <given-names>FC</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Casado-Adam</surname> 
                     <given-names>A</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Sánchez-Hidalgo</surname> 
                     <given-names>JM</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Rufián-Peña</surname> 
                     <given-names>S</given-names>
                  </string-name>
               </person-group>. <article-title>Peritoneal metastases of colorectal origin treated by cytoreduction and HIPEC: an overview</article-title>. <source>World J Gastrointest Oncol</source>. <year>2014</year> 
               <month>Oct</month>;<volume>6</volume>(<issue>10</issue>):<fpage>407</fpage>–<lpage>12</lpage>. <pub-id pub-id-type="doi">10.4251/wjgo.v6.i10.407</pub-id>
               <pub-id pub-id-type="pmid">25320657</pub-id>
               <issn>1948-5204</issn>
            </mixed-citation>
         </ref>
         <ref id="b7">
            <label>6.	</label>
            <mixed-citation publication-type="journal" specific-use="restruct">
               <person-group person-group-type="author">
                  <string-name name-style="western">
                     <surname>Brücher</surname> 
                     <given-names>BL</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Piso</surname> 
                     <given-names>P</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Verwaal</surname> 
                     <given-names>V</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Esquivel</surname> 
                     <given-names>J</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Derraco</surname> 
                     <given-names>M</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Yonemura</surname> 
                     <given-names>Y</given-names>
                  </string-name>, <etal>et al.</etal>
               </person-group> 
               <article-title>Peritoneal carcinomatosis: cytoreductive surgery and HIPEC—overview and basics</article-title>. <source>Cancer Invest</source>. <year>2012</year> 
               <month>Mar</month>;<volume>30</volume>(<issue>3</issue>):<fpage>209</fpage>–<lpage>24</lpage>. <pub-id pub-id-type="doi">10.3109/07357907.2012.654871</pub-id>
               <pub-id pub-id-type="pmid">22360361</pub-id>
               <issn>0735-7907</issn>
            </mixed-citation>
         </ref>
         <ref id="b8">
            <label>7.	</label>
            <mixed-citation publication-type="journal" specific-use="restruct">
               <person-group person-group-type="author">
                  <string-name name-style="western">
                     <surname>Poskus</surname> 
                     <given-names>E</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Strupas</surname> 
                     <given-names>K</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Gushchin</surname> 
                     <given-names>V</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Sugarbaker</surname> 
                     <given-names>PH</given-names>
                  </string-name>
               </person-group>. <article-title>Cytoreductive Surgery and HIPEC in the Baltic States: An International Scientific Workshop with Live Surgery</article-title>. <source>Viszeralmedizin</source>. <year>2014</year> 
               <month>Oct</month>;<volume>30</volume>(<issue>5</issue>):<fpage>353</fpage>–<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1159/000368685</pub-id>
               <pub-id pub-id-type="pmid">26535046</pub-id>
               <issn>1662-6664</issn>
            </mixed-citation>
         </ref>
         <ref id="b9">
            <label>8.	</label>
            <mixed-citation publication-type="journal" specific-use="restruct">
               <person-group person-group-type="author">
                  <string-name name-style="western">
                     <surname>Sugarbaker</surname> 
                     <given-names>PH</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Van der Speeten</surname> 
                     <given-names>K</given-names>
                  </string-name>
               </person-group>. <article-title>Surgical technology and pharmacology of hyperthermic perioperative chemotherapy</article-title>. <source>J Gastrointest Oncol</source>. <year>2016</year> 
               <month>Feb</month>;<volume>7</volume>(<issue>1</issue>):<fpage>29</fpage>–<lpage>44</lpage>.<pub-id pub-id-type="pmid">26941982</pub-id>
               <issn>2078-6891</issn>
            </mixed-citation>
         </ref>
         <ref id="b10">
            <label>9.	</label>
            <mixed-citation publication-type="journal" specific-use="restruct">
               <person-group person-group-type="author">
                  <string-name name-style="western">
                     <surname>Carmignani</surname> 
                     <given-names>CP</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Sugarbaker</surname> 
                     <given-names>TA</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Bromley</surname> 
                     <given-names>CM</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Sugarbaker</surname> 
                     <given-names>PH</given-names>
                  </string-name>
               </person-group>. <article-title>Intraperitoneal cancer dissemination: mechanisms of the patterns of spread</article-title>. <source>Cancer Metastasis Rev</source>. <year>2003</year> 
               <month>Dec</month>;<volume>22</volume>(<issue>4</issue>):<fpage>465</fpage>–<lpage>72</lpage>. <pub-id pub-id-type="doi">10.1023/A:1023791229361</pub-id>
               <pub-id pub-id-type="pmid">12884919</pub-id>
               <issn>0167-7659</issn>
            </mixed-citation>
         </ref>
         <ref id="b11">
            <label>10.	</label>
            <mixed-citation publication-type="journal" specific-use="restruct">
               <person-group person-group-type="author">
                  <string-name name-style="western">
                     <surname>Dubé</surname> 
                     <given-names>P</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Sideris</surname> 
                     <given-names>L</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Law</surname> 
                     <given-names>C</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Mack</surname> 
                     <given-names>L</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Haase</surname> 
                     <given-names>E</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Giacomantonio</surname> 
                     <given-names>C</given-names>
                  </string-name>, <etal>et al.</etal>
               </person-group> 
               <article-title>Guidelines on the use of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in patients with peritoneal surface malignancy arising from colorectal or appendiceal neoplasms</article-title>. <source>Curr Oncol</source>. <year>2015</year> 
               <month>Apr</month>;<volume>22</volume>(<issue>2</issue>):<fpage>e100</fpage>–<lpage>12</lpage>. <pub-id pub-id-type="doi">10.3747/co.22.2058</pub-id>
               <pub-id pub-id-type="pmid">25908915</pub-id>
               <issn>1198-0052</issn>
            </mixed-citation>
         </ref>
         <ref id="b12">
            <label>11.	</label>
            <mixed-citation publication-type="journal" specific-use="restruct">
               <person-group person-group-type="author">
                  <string-name name-style="western">
                     <surname>Bhatt</surname> 
                     <given-names>A</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Goéré</surname> 
                     <given-names>D</given-names>
                  </string-name>
               </person-group>. <article-title>Cytoreductive Surgery plus HIPEC for Peritoneal Metastases from Colorectal Cancer</article-title>. <source>Indian J Surg Oncol</source>. <year>2016</year> 
               <month>Jun</month>;<volume>7</volume>(<issue>2</issue>):<fpage>177</fpage>–<lpage>87</lpage>. <pub-id pub-id-type="doi">10.1007/s13193-016-0499-z</pub-id>
               <pub-id pub-id-type="pmid">27065708</pub-id>
               <issn>0975-7651</issn>
            </mixed-citation>
         </ref>
         <ref id="b13">
            <label>12.	</label>
            <mixed-citation publication-type="journal" specific-use="restruct">
               <person-group person-group-type="author">
                  <string-name name-style="western">
                     <surname>Seshadri</surname> 
                     <given-names>RA</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Glehen</surname> 
                     <given-names>O</given-names>
                  </string-name>
               </person-group>. <article-title>The Role of Hyperthermic Intraperitoneal Chemotherapy in Gastric Cancer</article-title>. <source>Indian J Surg Oncol</source>. <year>2016</year> 
               <month>Jun</month>;<volume>7</volume>(<issue>2</issue>):<fpage>198</fpage>–<lpage>207</lpage>. <pub-id pub-id-type="doi">10.1007/s13193-016-0502-8</pub-id>
               <pub-id pub-id-type="pmid">27065710</pub-id>
               <issn>0975-7651</issn>
            </mixed-citation>
         </ref>
         <ref id="b14">
            <label>13.	</label>
            <mixed-citation publication-type="journal" specific-use="restruct">
               <person-group person-group-type="author">
                  <string-name name-style="western">
                     <surname>Hayes-Jordan</surname> 
                     <given-names>A</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Green</surname> 
                     <given-names>H</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Prieto</surname> 
                     <given-names>V</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Wolff</surname> 
                     <given-names>JE</given-names>
                  </string-name>
               </person-group>. <article-title>Unusual cases: melanomatosis and nephroblastomatosis treated with hyperthermic intraperitoneal chemotherapy</article-title>. <source>J Pediatr Surg</source>. <year>2012</year> 
               <month>Apr</month>;<volume>47</volume>(<issue>4</issue>):<fpage>782</fpage>–<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1016/j.jpedsurg.2011.12.018</pub-id>
               <pub-id pub-id-type="pmid">22498396</pub-id>
               <issn>0022-3468</issn>
            </mixed-citation>
         </ref>
         <ref id="b15">
            <label>14.	</label>
            <mixed-citation publication-type="journal" specific-use="restruct">
               <person-group person-group-type="author">
                  <string-name name-style="western">
                     <surname>Cardi</surname> 
                     <given-names>M</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Sammartino</surname> 
                     <given-names>P</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Framarino</surname> 
                     <given-names>ML</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Biacchi</surname> 
                     <given-names>D</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Cortesi</surname> 
                     <given-names>E</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Sibio</surname> 
                     <given-names>S</given-names>
                  </string-name>, <etal>et al.</etal>
               </person-group> 
               <article-title>Treatment of peritoneal carcinomatosis from breast cancer by maximal cytoreduction and HIPEC: a preliminary report on 5 cases</article-title>. <source>Breast</source>. <year>2013</year> 
               <month>Oct</month>;<volume>22</volume>(<issue>5</issue>):<fpage>845</fpage>–<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1016/j.breast.2013.02.020</pub-id>
               <pub-id pub-id-type="pmid">23523180</pub-id>
               <issn>0960-9776</issn>
            </mixed-citation>
         </ref>
         <ref id="b16">
            <label>15.	</label>
            <mixed-citation publication-type="journal" specific-use="restruct">
               <person-group person-group-type="author">
                  <string-name name-style="western">
                     <surname>Honore</surname> 
                     <given-names>C</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Goere</surname> 
                     <given-names>D</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Dartigues</surname> 
                     <given-names>P</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Burtin</surname> 
                     <given-names>P</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Dumont</surname> 
                     <given-names>F</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Elias</surname> 
                     <given-names>D</given-names>
                  </string-name>
               </person-group>. <article-title>Peritoneal carcinomatosis from solid pseudopapillary neoplasm (Frantz’s tumour) of the pancreas treated with HIPEC</article-title>. <source>Anticancer Res</source>. <year>2012</year> 
               <month>Mar</month>;<volume>32</volume>(<issue>3</issue>):<fpage>1069</fpage>–<lpage>73</lpage>.<pub-id pub-id-type="pmid">22399634</pub-id>
               <issn>1791-7530</issn>
            </mixed-citation>
         </ref>
         <ref id="b17">
            <label>16.	</label>
            <mixed-citation publication-type="journal" specific-use="restruct">
               <person-group person-group-type="author">
                  <string-name name-style="western">
                     <surname>Salti</surname> 
                     <given-names>GI</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Ailabouni</surname> 
                     <given-names>L</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Undevia</surname> 
                     <given-names>S</given-names>
                  </string-name>
               </person-group>. <article-title>Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for the treatment of peritoneal sarcomatosis</article-title>. <source>Ann Surg Oncol</source>. <year>2012</year> 
               <month>May</month>;<volume>19</volume>(<issue>5</issue>):<fpage>1410</fpage>–<lpage>5</lpage>. <pub-id pub-id-type="doi">10.1245/s10434-012-2240-7</pub-id>
               <pub-id pub-id-type="pmid">22302269</pub-id>
               <issn>1068-9265</issn>
            </mixed-citation>
         </ref>
         <ref id="b18">
            <label>17.	</label>
            <mixed-citation publication-type="journal" specific-use="restruct">
               <person-group person-group-type="author">
                  <string-name name-style="western">
                     <surname>Randle</surname> 
                     <given-names>RW</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Swett</surname> 
                     <given-names>KR</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Shen</surname> 
                     <given-names>P</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Stewart</surname> 
                     <given-names>JH</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Levine</surname> 
                     <given-names>EA</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Votanopoulos</surname> 
                     <given-names>KI</given-names>
                  </string-name>
               </person-group>. <article-title>Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy in peritoneal sarcomatosis</article-title>. <source>Am Surg</source>. <year>2013</year> 
               <month>Jun</month>;<volume>79</volume>(<issue>6</issue>):<fpage>620</fpage>–<lpage>4</lpage>.<pub-id pub-id-type="pmid">23711273</pub-id>
               <issn>1555-9823</issn>
            </mixed-citation>
         </ref>
         <ref id="b19">
            <label>18.	</label>
            <mixed-citation publication-type="journal" specific-use="restruct">
               <person-group person-group-type="author">
                  <string-name name-style="western">
                     <surname>Beeharry</surname> 
                     <given-names>MK</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Liu</surname> 
                     <given-names>WT</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Yao</surname> 
                     <given-names>XX</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Yan</surname> 
                     <given-names>M</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Zhu</surname> 
                     <given-names>ZG</given-names>
                  </string-name>
               </person-group>. <article-title>A critical analysis of the cytoreductive surgery with hyperthermic intraperitoneal chemotherapy combo in the clinical management of advanced gastric cancer: an effective multimodality approach with scope for improvement</article-title>. <source>Transl Gastroenterol Hepatol</source>. <year>2016</year> 
               <month>Oct</month>;<volume>1</volume>:<fpage>77</fpage>. <pub-id pub-id-type="doi">10.21037/tgh.2016.08.05</pub-id>
               <pub-id pub-id-type="pmid">28138643</pub-id>
               <issn>2415-1289</issn>
               <annotation>
                  <p content-type="warning">Edifix has not found an issue number in the journal reference. Please check the volume/issue information. (Ref. 18 "Beeharry, Liu, Yao, Yan, Zhu, 2016")</p>
               </annotation>
            </mixed-citation>
         </ref>
         <ref id="b20">
            <label>19.    </label>
            <mixed-citation publication-type="unknown" specific-use="unparsed">H. Sugarbaker P. Pseudomyxoma peritonei and peritoneal metastases from appendiceal malignancy. In: H. Sugarbaker P, ed. Cytoreductive Surgery &amp; Perioperative Chemotherapy for Peritoneal Surface Malignancy. Woodbury: Cine-Med Publishing; <year>2012</year>. p. 57–78.</mixed-citation>
         </ref>
         <ref id="b21">
            <label>20.	</label>
            <mixed-citation publication-type="journal" specific-use="restruct">
               <person-group person-group-type="author">
                  <string-name name-style="western">
                     <surname>Glehen</surname> 
                     <given-names>O</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Gilly</surname> 
                     <given-names>FN</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Boutitie</surname> 
                     <given-names>F</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Bereder</surname> 
                     <given-names>JM</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Quenet</surname> 
                     <given-names>F</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Sideris</surname> 
                     <given-names>L</given-names>
                  </string-name>, <etal>et al.</etal>; <collab>French Surgical Association</collab>
               </person-group>. <article-title>Toward curative treatment of peritoneal carcinomatosis from nonovarian origin by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy: a multi-institutional study of 1,290 patients</article-title>. <source>Cancer</source>. <year>2010</year> 
               <month>Dec</month>;<volume>116</volume>(<issue>24</issue>):<fpage>5608</fpage>–<lpage>18</lpage>. <pub-id pub-id-type="doi">10.1002/cncr.25356</pub-id>
               <pub-id pub-id-type="pmid">20737573</pub-id>
               <issn>0008-543X</issn>
            </mixed-citation>
         </ref>
         <ref id="b22">
            <label>21.	</label>
            <mixed-citation publication-type="journal" specific-use="restruct">
               <person-group person-group-type="author">
                  <string-name name-style="western">
                     <surname>Elias</surname> 
                     <given-names>D</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Goéré</surname> 
                     <given-names>D</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Dumont</surname> 
                     <given-names>F</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Honoré</surname> 
                     <given-names>C</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Dartigues</surname> 
                     <given-names>P</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Stoclin</surname> 
                     <given-names>A</given-names>
                  </string-name>, <etal>et al.</etal>
               </person-group> 
               <article-title>Role of hyperthermic intraoperative peritoneal chemotherapy in the management of peritoneal metastases</article-title>. <source>Eur J Cancer</source>. <year>2014</year> 
               <month>Jan</month>;<volume>50</volume>(<issue>2</issue>):<fpage>332</fpage>–<lpage>40</lpage>. <pub-id pub-id-type="doi">10.1016/j.ejca.2013.09.024</pub-id>
               <pub-id pub-id-type="pmid">24157254</pub-id>
               <issn>0959-8049</issn>
            </mixed-citation>
         </ref>
         <ref id="b23">
            <label>22.	</label>
            <mixed-citation publication-type="journal" specific-use="restruct">
               <person-group person-group-type="author">
                  <string-name name-style="western">
                     <surname>Newton</surname> 
                     <given-names>AD</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Bartlett</surname> 
                     <given-names>EK</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Karakousis</surname> 
                     <given-names>GC</given-names>
                  </string-name>
               </person-group>. <article-title>Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: a review of factors contributing to morbidity and mortality</article-title>. <source>J Gastrointest Oncol</source>. <year>2016</year> 
               <month>Feb</month>;<volume>7</volume>(<issue>1</issue>):<fpage>99</fpage>–<lpage>111</lpage>.<pub-id pub-id-type="pmid">26941988</pub-id>
               <issn>2078-6891</issn>
            </mixed-citation>
         </ref>
         <ref id="b24">
            <label>23.	</label>
            <mixed-citation publication-type="journal" specific-use="restruct">
               <person-group person-group-type="author">
                  <string-name name-style="western">
                     <surname>Sugarbaker</surname> 
                     <given-names>PH</given-names>
                  </string-name>
               </person-group>. <article-title>Peritonectomy procedures</article-title>. <source>Ann Surg</source>. <year>1995</year> 
               <month>Jan</month>;<volume>221</volume>(<issue>1</issue>):<fpage>29</fpage>–<lpage>42</lpage>. <pub-id pub-id-type="doi">10.1097/00000658-199501000-00004</pub-id>
               <pub-id pub-id-type="pmid">7826158</pub-id>
               <issn>0003-4932</issn>
            </mixed-citation>
         </ref>
         <ref id="b25">
            <label>24.	</label>
            <mixed-citation publication-type="journal" specific-use="restruct">
               <person-group person-group-type="author">
                  <string-name name-style="western">
                     <surname>Ceelen</surname> 
                     <given-names>WP</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Påhlman</surname> 
                     <given-names>L</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Mahteme</surname> 
                     <given-names>H</given-names>
                  </string-name>
               </person-group>. <article-title>Pharmacodynamic aspects of intraperitoneal cytotoxic therapy</article-title>. <source>Cancer Treat Res</source>. <year>2007</year>;<volume>134</volume>:<fpage>195</fpage>–<lpage>214</lpage>.<pub-id pub-id-type="pmid">17633055</pub-id>
               <issn>0927-3042</issn>
               <annotation>
                  <p content-type="warning">Edifix has not found an issue number in the journal reference. Please check the volume/issue information. (Ref. 24 "Ceelen, Påhlman, Mahteme, 2007")</p>
               </annotation>
            </mixed-citation>
         </ref>
         <ref id="b26">
            <label>25.	</label>
            <mixed-citation publication-type="journal" specific-use="restruct">
               <person-group person-group-type="author">
                  <string-name name-style="western">
                     <surname>Sticca</surname> 
                     <given-names>RP</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Dach</surname> 
                     <given-names>BW</given-names>
                  </string-name>
               </person-group>. <article-title>Rationale for hyperthermia with intraoperative intraperitoneal chemotherapy agents</article-title>. <source>Surg Oncol Clin N Am</source>. <year>2003</year> 
               <month>Jul</month>;<volume>12</volume>(<issue>3</issue>):<fpage>689</fpage>–<lpage>701</lpage>. <pub-id pub-id-type="doi">10.1016/S1055-3207(03)00029-2</pub-id>
               <pub-id pub-id-type="pmid">14567025</pub-id>
               <issn>1055-3207</issn>
            </mixed-citation>
         </ref>
         <ref id="b27">
            <label>26.    </label>
            <mixed-citation publication-type="unknown" specific-use="linked">
               <person-group person-group-type="author">
                  <string-name name-style="western">
                     <surname>Benoit</surname> 
                     <given-names>L</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Cheynel</surname> 
                     <given-names>N</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Ortega-Deballon</surname> 
                     <given-names>P</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Giacomo</surname> 
                     <given-names>G</given-names> 
                     <surname>Di</surname>
                  </string-name>, <string-name name-style="western">
                     <surname>Chauffert</surname> 
                     <given-names>B</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Rat</surname> 
                     <given-names>P.</given-names>
                  </string-name>
               </person-group> 
               <article-title>Closed hyperthermic intraperitoneal chemotherapy with open abdomen: a novel technique to reduce exposure of the surgical team to chemotherapy drugs.</article-title> Ann Surg Oncol. Springer; <year>2008</year> Feb 10;15(2):542–6. <pub-id pub-id-type="doi">10.1245/s10434-007-9635-x</pub-id>
               <annotation>
                  <p content-type="warning">Edifix has not updated the authors because of a name mismatch. Please compare "Di" with "Chauffert" and "Chauffert" with "Rat". The Crossref authors are <underline>Benoit L, Cheynel N, Ortega-Deballon P, Giacomo GD, Chauffert B, Rat P</underline>. (Ref. 26 "Benoit, Cheynel, Ortega-Deballon, Giacomo, Di, Chauffert, Rat, 2008")</p>
               </annotation>
            </mixed-citation>
         </ref>
         <ref id="b28">
            <label>27.	</label>
            <mixed-citation publication-type="journal" specific-use="restruct">
               <person-group person-group-type="author">
                  <string-name name-style="western">
                     <surname>Lemoine</surname> 
                     <given-names>L</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Sugarbaker</surname> 
                     <given-names>P</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Van der Speeten</surname> 
                     <given-names>K</given-names>
                  </string-name>
               </person-group>. <article-title>Pathophysiology of colorectal peritoneal carcinomatosis: role of the peritoneum</article-title>. <source>World J Gastroenterol</source>. <year>2016</year> 
               <month>Sep</month>;<volume>22</volume>(<issue>34</issue>):<fpage>7692</fpage>–<lpage>707</lpage>. <pub-id pub-id-type="doi">10.3748/wjg.v22.i34.7692</pub-id>
               <pub-id pub-id-type="pmid">27678351</pub-id>
               <issn>1007-9327</issn>
            </mixed-citation>
         </ref>
         <ref id="b29">
            <label>28.	</label>
            <mixed-citation publication-type="journal" specific-use="restruct">
               <person-group person-group-type="author">
                  <string-name name-style="western">
                     <surname>Bhatt</surname> 
                     <given-names>A</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Glehen</surname> 
                     <given-names>O</given-names>
                  </string-name>
               </person-group>. <article-title>The role of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Ovarian Cancer: A Review</article-title>. <source>Indian J Surg Oncol</source>. <year>2016</year> 
               <month>Jun</month>;<volume>7</volume>(<issue>2</issue>):<fpage>188</fpage>–<lpage>97</lpage>. <pub-id pub-id-type="doi">10.1007/s13193-016-0501-9</pub-id>
               <pub-id pub-id-type="pmid">27065709</pub-id>
               <issn>0975-7651</issn>
            </mixed-citation>
         </ref>
         <ref id="b30">
            <label>29.	</label>
            <mixed-citation publication-type="journal" specific-use="restruct">
               <person-group person-group-type="author">
                  <string-name name-style="western">
                     <surname>Gilly</surname> 
                     <given-names>FN</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Cotte</surname> 
                     <given-names>E</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Brigand</surname> 
                     <given-names>C</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Monneuse</surname> 
                     <given-names>O</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Beaujard</surname> 
                     <given-names>AC</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Freyer</surname> 
                     <given-names>G</given-names>
                  </string-name>, <etal>et al.</etal>
               </person-group> 
               <article-title>Quantitative prognostic indices in peritoneal carcinomatosis</article-title>. <source>Eur J Surg Oncol</source>. <year>2006</year> 
               <month>Aug</month>;<volume>32</volume>(<issue>6</issue>):<fpage>597</fpage>–<lpage>601</lpage>. <pub-id pub-id-type="doi">10.1016/j.ejso.2006.03.002</pub-id>
               <pub-id pub-id-type="pmid">16617003</pub-id>
               <issn>0748-7983</issn>
            </mixed-citation>
         </ref>
         <ref id="b31">
            <label>30.	</label>
            <mixed-citation publication-type="journal" specific-use="restruct">
               <person-group person-group-type="author">
                  <string-name name-style="western">
                     <surname>Harmon</surname> 
                     <given-names>RL</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Sugarbaker</surname> 
                     <given-names>PH</given-names>
                  </string-name>
               </person-group>. <article-title>Prognostic indicators in peritoneal carcinomatosis from gastrointestinal cancer</article-title>. <source>Int Semin Surg Oncol</source>. <year>2005</year> 
               <month>Feb</month>;<volume>2</volume>(<issue>1</issue>):<fpage>3</fpage>. <pub-id pub-id-type="doi">10.1186/1477-7800-2-3</pub-id>
               <pub-id pub-id-type="pmid">15701175</pub-id>
               <issn>1477-7800</issn>
            </mixed-citation>
         </ref>
         <ref id="b32">
            <label>31.	</label>
            <mixed-citation publication-type="journal" specific-use="restruct">
               <person-group person-group-type="author">
                  <string-name name-style="western">
                     <surname>Sugarbaker</surname> 
                     <given-names>PH</given-names>
                  </string-name>
               </person-group>. <article-title>Colorectal cancer: prevention and management of metastatic disease</article-title>. <source>BioMed Res Int</source>. <year>2014</year>;<volume>2014</volume>:<fpage>782890</fpage>. <pub-id pub-id-type="doi">10.1155/2014/782890</pub-id>
               <pub-id pub-id-type="pmid">24783222</pub-id>
               <issn>2314-6133</issn>
               <annotation>
                  <p content-type="warning">Edifix has not found an issue number in the journal reference. Please check the volume/issue information. (Ref. 31 "Sugarbaker, 2014")</p>
               </annotation>
            </mixed-citation>
         </ref>
         <ref id="b33">
            <label>32.	</label>
            <mixed-citation publication-type="journal" specific-use="restruct">
               <person-group person-group-type="author">
                  <string-name name-style="western">
                     <surname>Sammartino</surname> 
                     <given-names>P</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Sibio</surname> 
                     <given-names>S</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Biacchi</surname> 
                     <given-names>D</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Cardi</surname> 
                     <given-names>M</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Accarpio</surname> 
                     <given-names>F</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Mingazzini</surname> 
                     <given-names>P</given-names>
                  </string-name>, <etal>et al.</etal>
               </person-group> 
               <article-title>Prevention of Peritoneal Metastases from Colon Cancer in High-Risk Patients: Preliminary Results of Surgery plus Prophylactic HIPEC</article-title>. <source>Gastroenterol Res Pract</source>. <year>2012</year>;<volume>2012</volume>:<fpage>141585</fpage>. <pub-id pub-id-type="doi">10.1155/2012/141585</pub-id>
               <pub-id pub-id-type="pmid">22645605</pub-id>
               <issn>1687-6121</issn>
               <annotation>
                  <p content-type="warning">Edifix has not found an issue number in the journal reference. Please check the volume/issue information. (Ref. 32 "Sammartino, Sibio, Biacchi, Cardi, Accarpio, Mingazzini, et al., 2012")</p>
               </annotation>
            </mixed-citation>
         </ref>
         <ref id="b34">
            <label>33.	</label>
            <mixed-citation publication-type="journal" specific-use="restruct">
               <person-group person-group-type="author">
                  <string-name name-style="western">
                     <surname>Lungoci</surname> 
                     <given-names>C</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Mironiuc</surname> 
                     <given-names>AI</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Muntean</surname> 
                     <given-names>V</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Oniu</surname> 
                     <given-names>T</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Leebmann</surname> 
                     <given-names>H</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Mayr</surname> 
                     <given-names>M</given-names>
                  </string-name>, <etal>et al.</etal>
               </person-group> 
               <article-title>Multimodality treatment strategies have changed prognosis of peritoneal metastases</article-title>. <source>World J Gastrointest Oncol</source>. <year>2016</year> 
               <month>Jan</month>;<volume>8</volume>(<issue>1</issue>):<fpage>67</fpage>–<lpage>82</lpage>. <pub-id pub-id-type="doi">10.4251/wjgo.v8.i1.67</pub-id>
               <pub-id pub-id-type="pmid">26798438</pub-id>
               <issn>1948-5204</issn>
            </mixed-citation>
         </ref>
         <ref id="b35">
            <label>34.	</label>
            <mixed-citation publication-type="journal" specific-use="restruct">
               <person-group person-group-type="author">
                  <string-name name-style="western">
                     <surname>Smeenk</surname> 
                     <given-names>RM</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>van Velthuysen</surname> 
                     <given-names>ML</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Verwaal</surname> 
                     <given-names>VJ</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Zoetmulder</surname> 
                     <given-names>FA</given-names>
                  </string-name>
               </person-group>. <article-title>Appendiceal neoplasms and pseudomyxoma peritonei: a population based study</article-title>. <source>Eur J Surg Oncol</source>. <year>2008</year> 
               <month>Feb</month>;<volume>34</volume>(<issue>2</issue>):<fpage>196</fpage>–<lpage>201</lpage>. <pub-id pub-id-type="doi">10.1016/j.ejso.2007.04.002</pub-id>
               <pub-id pub-id-type="pmid">17524597</pub-id>
               <issn>0748-7983</issn>
            </mixed-citation>
         </ref>
         <ref id="b36">
            <label>35.	</label>
            <mixed-citation publication-type="journal" specific-use="restruct">
               <person-group person-group-type="author">
                  <string-name name-style="western">
                     <surname>Ayantunde</surname> 
                     <given-names>AA</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Parsons</surname> 
                     <given-names>SL</given-names>
                  </string-name>
               </person-group>. <article-title>Pattern and prognostic factors in patients with malignant ascites: a retrospective study</article-title>. <source>Ann Oncol</source>. <year>2007</year> 
               <month>May</month>;<volume>18</volume>(<issue>5</issue>):<fpage>945</fpage>–<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1093/annonc/mdl499</pub-id>
               <pub-id pub-id-type="pmid">17298959</pub-id>
               <issn>0923-7534</issn>
            </mixed-citation>
         </ref>
         <ref id="b37">
            <label>36.	</label>
            <mixed-citation publication-type="journal" specific-use="restruct">
               <person-group person-group-type="author">
                  <string-name name-style="western">
                     <surname>Valle</surname> 
                     <given-names>M</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Van der Speeten</surname> 
                     <given-names>K</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Garofalo</surname> 
                     <given-names>A</given-names>
                  </string-name>
               </person-group>. <article-title>Laparoscopic hyperthermic intraperitoneal peroperative chemotherapy (HIPEC) in the management of refractory malignant ascites: A multi-institutional retrospective analysis in 52 patients</article-title>. <source>J Surg Oncol</source>. <year>2009</year> 
               <month>Sep</month>;<volume>100</volume>(<issue>4</issue>):<fpage>331</fpage>–<lpage>4</lpage>. <pub-id pub-id-type="doi">10.1002/jso.21321</pub-id>
               <pub-id pub-id-type="pmid">19697441</pub-id>
               <issn>0022-4790</issn>
            </mixed-citation>
         </ref>
         <ref id="b38">
            <label>37.	</label>
            <mixed-citation publication-type="journal" specific-use="restruct">
               <person-group person-group-type="author">
                  <string-name name-style="western">
                     <surname>Turaga</surname> 
                     <given-names>KK</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Pappas</surname> 
                     <given-names>SG</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Gamblin</surname> 
                     <given-names>T</given-names>
                  </string-name>
               </person-group>. <article-title>Importance of histologic subtype in the staging of appendiceal tumors</article-title>. <source>Ann Surg Oncol</source>. <year>2012</year> 
               <month>May</month>;<volume>19</volume>(<issue>5</issue>):<fpage>1379</fpage>–<lpage>85</lpage>. <pub-id pub-id-type="doi">10.1245/s10434-012-2238-1</pub-id>
               <pub-id pub-id-type="pmid">22302267</pub-id>
               <issn>1068-9265</issn>
            </mixed-citation>
         </ref>
         <ref id="b39">
            <label>38.	</label>
            <mixed-citation publication-type="journal" specific-use="restruct">
               <person-group person-group-type="author">
                  <string-name name-style="western">
                     <surname>Sugarbaker</surname> 
                     <given-names>PH</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Ronnett</surname> 
                     <given-names>BM</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Archer</surname> 
                     <given-names>A</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Averbach</surname> 
                     <given-names>AM</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Bland</surname> 
                     <given-names>R</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Chang</surname> 
                     <given-names>D</given-names>
                  </string-name>, <etal>et al.</etal>
               </person-group> 
               <article-title>Pseudomyxoma peritonei syndrome</article-title>. <source>Adv Surg</source>. <year>1996</year>;<volume>30</volume>:<fpage>233</fpage>–<lpage>80</lpage>.<pub-id pub-id-type="pmid">8960339</pub-id>
               <issn>0065-3411</issn>
               <annotation>
                  <p content-type="warning">Edifix has not found an issue number in the journal reference. Please check the volume/issue information. (Ref. 38 "Sugarbaker, Ronnett, Archer, Averbach, Bland, Chang, et al., 1996")</p>
               </annotation>
            </mixed-citation>
         </ref>
         <ref id="b40">
            <label>39.	</label>
            <mixed-citation publication-type="journal" specific-use="restruct">
               <person-group person-group-type="author">
                  <string-name name-style="western">
                     <surname>Bryant</surname> 
                     <given-names>J</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Clegg</surname> 
                     <given-names>AJ</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Sidhu</surname> 
                     <given-names>MK</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Brodin</surname> 
                     <given-names>H</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Royle</surname> 
                     <given-names>P</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Davidson</surname> 
                     <given-names>P</given-names>
                  </string-name>
               </person-group>. <article-title>Systematic review of the Sugarbaker procedure for pseudomyxoma peritonei</article-title>. <source>Br J Surg</source>. <year>2005</year> 
               <month>Feb</month>;<volume>92</volume>(<issue>2</issue>):<fpage>153</fpage>–<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1002/bjs.4862</pub-id>
               <pub-id pub-id-type="pmid">15685704</pub-id>
               <issn>0007-1323</issn>
            </mixed-citation>
         </ref>
         <ref id="b41">
            <label>40.	</label>
            <mixed-citation publication-type="journal" specific-use="restruct">
               <person-group person-group-type="author">
                  <string-name name-style="western">
                     <surname>Chua</surname> 
                     <given-names>TC</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Moran</surname> 
                     <given-names>BJ</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Sugarbaker</surname> 
                     <given-names>PH</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Levine</surname> 
                     <given-names>EA</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Glehen</surname> 
                     <given-names>O</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Gilly</surname> 
                     <given-names>FN</given-names>
                  </string-name>, <etal>et al.</etal>
               </person-group> 
               <article-title>Early- and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy</article-title>. <source>J Clin Oncol</source>. <year>2012</year> 
               <month>Jul</month>;<volume>30</volume>(<issue>20</issue>):<fpage>2449</fpage>–<lpage>56</lpage>. <pub-id pub-id-type="doi">10.1200/JCO.2011.39.7166</pub-id>
               <pub-id pub-id-type="pmid">22614976</pub-id>
               <issn>0732-183X</issn>
            </mixed-citation>
         </ref>
         <ref id="b42">
            <label>41.	</label>
            <mixed-citation publication-type="journal" specific-use="restruct">
               <person-group person-group-type="author">
                  <string-name name-style="western">
                     <surname>Ferlay</surname> 
                     <given-names>J</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Steliarova-Foucher</surname> 
                     <given-names>E</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Lortet-Tieulent</surname> 
                     <given-names>J</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Rosso</surname> 
                     <given-names>S</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Coebergh</surname> 
                     <given-names>JW</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Comber</surname> 
                     <given-names>H</given-names>
                  </string-name>, <etal>et al.</etal>
               </person-group> 
               <article-title>Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012</article-title>. <source>Eur J Cancer</source>. <year>2013</year> 
               <month>Apr</month>;<volume>49</volume>(<issue>6</issue>):<fpage>1374</fpage>–<lpage>403</lpage>. <pub-id pub-id-type="doi">10.1016/j.ejca.2012.12.027</pub-id>
               <pub-id pub-id-type="pmid">23485231</pub-id>
               <issn>0959-8049</issn>
            </mixed-citation>
         </ref>
         <ref id="b43">
            <label>42.	</label>
            <mixed-citation publication-type="journal" specific-use="restruct">
               <person-group person-group-type="author">
                  <string-name name-style="western">
                     <surname>Klaver</surname> 
                     <given-names>CE</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Musters</surname> 
                     <given-names>GD</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Bemelman</surname> 
                     <given-names>WA</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Punt</surname> 
                     <given-names>CJ</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Verwaal</surname> 
                     <given-names>VJ</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Dijkgraaf</surname> 
                     <given-names>MG</given-names>
                  </string-name>, <etal>et al.</etal>
               </person-group> 
               <article-title>Adjuvant hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with colon cancer at high risk of peritoneal carcinomatosis; the COLOPEC randomized multicentre trial</article-title>. <source>BMC Cancer</source>. <year>2015</year> 
               <month>May</month>;<volume>15</volume>(<issue>1</issue>):<fpage>428</fpage>. <pub-id pub-id-type="doi">10.1186/s12885-015-1430-7</pub-id>
               <pub-id pub-id-type="pmid">26003804</pub-id>
               <issn>1471-2407</issn>
            </mixed-citation>
         </ref>
         <ref id="b44">
            <label>43.	</label>
            <mixed-citation publication-type="journal" specific-use="restruct">
               <person-group person-group-type="author">
                  <string-name name-style="western">
                     <surname>Tariq</surname> 
                     <given-names>K</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Ghias</surname> 
                     <given-names>K</given-names>
                  </string-name>
               </person-group>. <article-title>Colorectal cancer carcinogenesis: a review of mechanisms. Cancer Biol Med. Tianjing China</article-title>. <source>Chinese Anti-Cancer Association</source>. <year>2016</year> 
               <month>Mar</month>;<volume>13</volume>(<issue>1</issue>):<fpage>120</fpage>–<lpage>35</lpage>.<annotation>
                  <p content-type="warning">Edifix does not recognize the journal "Chinese Anti-Cancer Association". If this is a valid journal title, please send this reference to journals@inera.com for addition to our journal database. (Ref. 43 "Tariq, Ghias, 2016")</p>
               </annotation>
            </mixed-citation>
         </ref>
         <ref id="b45">
            <label>44.    </label>
            <mixed-citation publication-type="unknown" specific-use="linked">
               <person-group person-group-type="author">
                  <string-name name-style="western">
                     <surname>März</surname> 
                     <given-names>L</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Piso</surname> 
                     <given-names>P</given-names>
                  </string-name>
               </person-group>. <article-title>Treatment of peritoneal metastases from colorectal cancer.</article-title> Gastroenterol Rep. Oxford University Press; <year>2015</year> Nov 30;3(4):298–302. <pub-id pub-id-type="doi">10.1093/gastro/gov044</pub-id>
            </mixed-citation>
         </ref>
         <ref id="b46">
            <label>45.	</label>
            <mixed-citation publication-type="journal" specific-use="restruct">
               <person-group person-group-type="author">
                  <string-name name-style="western">
                     <surname>Verwaal</surname> 
                     <given-names>VJ</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>van Ruth</surname> 
                     <given-names>S</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>de Bree</surname> 
                     <given-names>E</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>van Sloothen</surname> 
                     <given-names>GW</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>van Tinteren</surname> 
                     <given-names>H</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Boot</surname> 
                     <given-names>H</given-names>
                  </string-name>, <etal>et al.</etal>
               </person-group> 
               <article-title>Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer</article-title>. <source>J Clin Oncol</source>. <year>2003</year> 
               <month>Oct</month>;<volume>21</volume>(<issue>20</issue>):<fpage>3737</fpage>–<lpage>43</lpage>. <pub-id pub-id-type="doi">10.1200/JCO.2003.04.187</pub-id>
               <pub-id pub-id-type="pmid">14551293</pub-id>
               <issn>0732-183X</issn>
            </mixed-citation>
         </ref>
         <ref id="b47">
            <label>46.	</label>
            <mixed-citation publication-type="journal" specific-use="restruct">
               <person-group person-group-type="author">
                  <string-name name-style="western">
                     <surname>Verwaal</surname> 
                     <given-names>VJ</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Bruin</surname> 
                     <given-names>S</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Boot</surname> 
                     <given-names>H</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>van Slooten</surname> 
                     <given-names>G</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>van Tinteren</surname> 
                     <given-names>H</given-names>
                  </string-name>
               </person-group>. <article-title>8-year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer</article-title>. <source>Ann Surg Oncol</source>. <year>2008</year> 
               <month>Sep</month>;<volume>15</volume>(<issue>9</issue>):<fpage>2426</fpage>–<lpage>32</lpage>. <pub-id pub-id-type="doi">10.1245/s10434-008-9966-2</pub-id>
               <pub-id pub-id-type="pmid">18521686</pub-id>
               <issn>1068-9265</issn>
            </mixed-citation>
         </ref>
         <ref id="b48">
            <label>47.	</label>
            <mixed-citation publication-type="journal" specific-use="restruct">
               <person-group person-group-type="author">
                  <string-name name-style="western">
                     <surname>Elias</surname> 
                     <given-names>D</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Gilly</surname> 
                     <given-names>F</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Boutitie</surname> 
                     <given-names>F</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Quenet</surname> 
                     <given-names>F</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Bereder</surname> 
                     <given-names>JM</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Mansvelt</surname> 
                     <given-names>B</given-names>
                  </string-name>, <etal>et al.</etal>
               </person-group> 
               <article-title>Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: retrospective analysis of 523 patients from a multicentric French study</article-title>. <source>J Clin Oncol</source>. <year>2010</year> 
               <month>Jan</month>;<volume>28</volume>(<issue>1</issue>):<fpage>63</fpage>–<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1200/JCO.2009.23.9285</pub-id>
               <pub-id pub-id-type="pmid">19917863</pub-id>
               <issn>0732-183X</issn>
            </mixed-citation>
         </ref>
         <ref id="b49">
            <label>48.	</label>
            <mixed-citation publication-type="journal" specific-use="restruct">
               <person-group person-group-type="author">
                  <string-name name-style="western">
                     <surname>Glehen</surname> 
                     <given-names>O</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Kwiatkowski</surname> 
                     <given-names>F</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Sugarbaker</surname> 
                     <given-names>PH</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Elias</surname> 
                     <given-names>D</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Levine</surname> 
                     <given-names>EA</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>De Simone</surname> 
                     <given-names>M</given-names>
                  </string-name>, <etal>et al.</etal>
               </person-group> 
               <article-title>Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multi-institutional study</article-title>. <source>J Clin Oncol</source>. <year>2004</year> 
               <month>Aug</month>;<volume>22</volume>(<issue>16</issue>):<fpage>3284</fpage>–<lpage>92</lpage>. <pub-id pub-id-type="doi">10.1200/JCO.2004.10.012</pub-id>
               <pub-id pub-id-type="pmid">15310771</pub-id>
               <issn>0732-183X</issn>
            </mixed-citation>
         </ref>
         <ref id="b50">
            <label>49.	</label>
            <mixed-citation publication-type="journal" specific-use="restruct">
               <person-group person-group-type="author">
                  <string-name name-style="western">
                     <surname>Park</surname> 
                     <given-names>DG</given-names>
                  </string-name>
               </person-group>. <article-title>Is Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy a Safe and Effective Procedure for Treating Patients With a Peritoneal Surface Malignancy?</article-title> 
               <source>Ann Coloproctol</source>. <year>2017</year> 
               <month>Feb</month>;<volume>33</volume>(<issue>1</issue>):<fpage>3</fpage>–<lpage>4</lpage>. <pub-id pub-id-type="doi">10.3393/ac.2017.33.1.3</pub-id>
               <pub-id pub-id-type="pmid">28289655</pub-id>
               <issn>2287-9714</issn>
            </mixed-citation>
         </ref>
         <ref id="b51">
            <label>50.	</label>
            <mixed-citation publication-type="journal" specific-use="restruct">
               <person-group person-group-type="author">
                  <string-name name-style="western">
                     <surname>Seshadri</surname> 
                     <given-names>RA</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Glehen</surname> 
                     <given-names>O</given-names>
                  </string-name>
               </person-group>. <article-title>Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in gastric cancer</article-title>. <source>World J Gastroenterol</source>. <year>2016</year> 
               <month>Jan</month>;<volume>22</volume>(<issue>3</issue>):<fpage>1114</fpage>–<lpage>30</lpage>. <pub-id pub-id-type="doi">10.3748/wjg.v22.i3.1114</pub-id>
               <pub-id pub-id-type="pmid">26811651</pub-id>
               <issn>1007-9327</issn>
            </mixed-citation>
         </ref>
         <ref id="b52">
            <label>51.	</label>
            <mixed-citation publication-type="journal" specific-use="restruct">
               <person-group person-group-type="author">
                  <string-name name-style="western">
                     <surname>Glehen</surname> 
                     <given-names>O</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Gilly</surname> 
                     <given-names>FN</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Arvieux</surname> 
                     <given-names>C</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Cotte</surname> 
                     <given-names>E</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Boutitie</surname> 
                     <given-names>F</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Mansvelt</surname> 
                     <given-names>B</given-names>
                  </string-name>, <etal>et al.</etal>; <collab>Association Française de Chirurgie</collab>
               </person-group>. <article-title>Peritoneal carcinomatosis from gastric cancer: a multi-institutional study of 159 patients treated by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy</article-title>. <source>Ann Surg Oncol</source>. <year>2010</year> 
               <month>Sep</month>;<volume>17</volume>(<issue>9</issue>):<fpage>2370</fpage>–<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1245/s10434-010-1039-7</pub-id>
               <pub-id pub-id-type="pmid">20336386</pub-id>
               <issn>1068-9265</issn>
            </mixed-citation>
         </ref>
         <ref id="b53">
            <label>52.	</label>
            <mixed-citation publication-type="journal" specific-use="restruct">
               <person-group person-group-type="author">
                  <string-name name-style="western">
                     <surname>Rudloff</surname> 
                     <given-names>U</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Langan</surname> 
                     <given-names>RC</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Mullinax</surname> 
                     <given-names>JE</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Beane</surname> 
                     <given-names>JD</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Steinberg</surname> 
                     <given-names>SM</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Beresnev</surname> 
                     <given-names>T</given-names>
                  </string-name>, <etal>et al.</etal>
               </person-group> 
               <article-title>Impact of maximal cytoreductive surgery plus regional heated intraperitoneal chemotherapy (HIPEC) on outcome of patients with peritoneal carcinomatosis of gastric origin: results of the GYMSSA trial</article-title>. <source>J Surg Oncol</source>. <year>2014</year> 
               <month>Sep</month>;<volume>110</volume>(<issue>3</issue>):<fpage>275</fpage>–<lpage>84</lpage>. <pub-id pub-id-type="doi">10.1002/jso.23633</pub-id>
               <pub-id pub-id-type="pmid">25042700</pub-id>
               <issn>0022-4790</issn>
            </mixed-citation>
         </ref>
         <ref id="b54">
            <label>53.	</label>
            <mixed-citation publication-type="journal" specific-use="restruct">
               <person-group person-group-type="author">
                  <string-name name-style="western">
                     <surname>Yonemura</surname> 
                     <given-names>Y</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Elnemr</surname> 
                     <given-names>A</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Endou</surname> 
                     <given-names>Y</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Hirano</surname> 
                     <given-names>M</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Mizumoto</surname> 
                     <given-names>A</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Takao</surname> 
                     <given-names>N</given-names>
                  </string-name>, <etal>et al.</etal>
               </person-group> 
               <article-title>Multidisciplinary therapy for treatment of patients with peritoneal carcinomatosis from gastric cancer. World J Gastrointest Oncol. Baishideng Publishing Group Co</article-title>. <source>Limited</source>. <year>2010</year> 
               <month>Feb</month>;<volume>2</volume>(<issue>2</issue>):<fpage>85</fpage>–<lpage>97</lpage>.<annotation>
                  <p content-type="warning">Edifix does not recognize the journal "Limited". If this is a valid journal title, please send this reference to journals@inera.com for addition to our journal database. (Ref. 53 "Yonemura, Elnemr, Endou, Hirano, Mizumoto, Takao, et al., 2010")</p>
               </annotation>
            </mixed-citation>
         </ref>
         <ref id="b55">
            <label>54.	</label>
            <mixed-citation publication-type="journal" specific-use="restruct">
               <person-group person-group-type="author">
                  <string-name name-style="western">
                     <surname>Doubeni</surname> 
                     <given-names>CA</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Doubeni</surname> 
                     <given-names>AR</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Myers</surname> 
                     <given-names>AE</given-names>
                  </string-name>
               </person-group>. <article-title>Diagnosis and Management of Ovarian Cancer</article-title>. <source>Am Fam Physician</source>. <year>2016</year> 
               <month>Jun</month>;<volume>93</volume>(<issue>11</issue>):<fpage>937</fpage>–<lpage>44</lpage>.<pub-id pub-id-type="pmid">27281838</pub-id>
               <issn>1532-0650</issn>
            </mixed-citation>
         </ref>
         <ref id="b56">
            <label>55.	</label>
            <mixed-citation publication-type="journal" specific-use="restruct">
               <person-group person-group-type="author">
                  <string-name name-style="western">
                     <surname>Spiliotis</surname> 
                     <given-names>J</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Halkia</surname> 
                     <given-names>E</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>de Bree</surname> 
                     <given-names>E</given-names>
                  </string-name>
               </person-group>. <article-title>Treatment of peritoneal surface malignancies with hyperthermic intraperitoneal chemotherapy-current perspectives</article-title>. <source>Curr Oncol</source>. <year>2016</year> 
               <month>Jun</month>;<volume>23</volume>(<issue>3</issue>):<fpage>e266</fpage>–<lpage>75</lpage>. <pub-id pub-id-type="doi">10.3747/co.23.2831</pub-id>
               <pub-id pub-id-type="pmid">27330364</pub-id>
               <issn>1198-0052</issn>
            </mixed-citation>
         </ref>
         <ref id="b57">
            <label>56.	</label>
            <mixed-citation publication-type="journal" specific-use="restruct">
               <person-group person-group-type="author">
                  <string-name name-style="western">
                     <surname>Shetty</surname> 
                     <given-names>SJ</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Bathla</surname> 
                     <given-names>L</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Govindarajan</surname> 
                     <given-names>V</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Thomas</surname> 
                     <given-names>P</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Loggie</surname> 
                     <given-names>BW</given-names>
                  </string-name>
               </person-group>. <article-title>Comparison of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy with mitomycin or carboplatin for diffuse malignant peritoneal mesothelioma</article-title>. <source>Am Surg</source>. <year>2014</year> 
               <month>Apr</month>;<volume>80</volume>(<issue>4</issue>):<fpage>348</fpage>–<lpage>52</lpage>.<pub-id pub-id-type="pmid">24887664</pub-id>
               <issn>1555-9823</issn>
            </mixed-citation>
         </ref>
         <ref id="b58">
            <label>57.	</label>
            <mixed-citation publication-type="journal" specific-use="restruct">
               <person-group person-group-type="author">
                  <string-name name-style="western">
                     <surname>Yan</surname> 
                     <given-names>TD</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Deraco</surname> 
                     <given-names>M</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Baratti</surname> 
                     <given-names>D</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Kusamura</surname> 
                     <given-names>S</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Elias</surname> 
                     <given-names>D</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Glehen</surname> 
                     <given-names>O</given-names>
                  </string-name>, <etal>et al.</etal>
               </person-group> 
               <article-title>Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience</article-title>. <source>J Clin Oncol</source>. <year>2009</year> 
               <month>Dec</month>;<volume>27</volume>(<issue>36</issue>):<fpage>6237</fpage>–<lpage>42</lpage>. <pub-id pub-id-type="doi">10.1200/JCO.2009.23.9640</pub-id>
               <pub-id pub-id-type="pmid">19917862</pub-id>
               <issn>0732-183X</issn>
            </mixed-citation>
         </ref>
         <ref id="b59">
            <label>58.	</label>
            <mixed-citation publication-type="journal" specific-use="restruct">
               <person-group person-group-type="author">
                  <string-name name-style="western">
                     <surname>Yan</surname> 
                     <given-names>TD</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Deraco</surname> 
                     <given-names>M</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Elias</surname> 
                     <given-names>D</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Glehen</surname> 
                     <given-names>O</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Levine</surname> 
                     <given-names>EA</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Moran</surname> 
                     <given-names>BJ</given-names>
                  </string-name>, <etal>et al.</etal>; <collab>Peritoneal Surface Oncology Group</collab>
               </person-group>. <article-title>A novel tumor-node-metastasis (TNM) staging system of diffuse malignant peritoneal mesothelioma using outcome analysis of a multi-institutional database*</article-title>. <source>Cancer</source>. <year>2011</year> 
               <month>May</month>;<volume>117</volume>(<issue>9</issue>):<fpage>1855</fpage>–<lpage>63</lpage>. <pub-id pub-id-type="doi">10.1002/cncr.25640</pub-id>
               <pub-id pub-id-type="pmid">21509762</pub-id>
               <issn>0008-543X</issn>
            </mixed-citation>
         </ref>
         <ref id="b60">
            <label>59.	</label>
            <mixed-citation publication-type="journal" specific-use="restruct">
               <person-group person-group-type="author">
                  <string-name name-style="western">
                     <surname>Cotte</surname> 
                     <given-names>E</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Passot</surname> 
                     <given-names>G</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Gilly</surname> 
                     <given-names>FN</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Glehen</surname> 
                     <given-names>O</given-names>
                  </string-name>
               </person-group>. <article-title>Selection of patients and staging of peritoneal surface malignancies. World J Gastrointest Oncol. Baishideng Publishing Group Co</article-title>. <source>Limited</source>. <year>2010</year> 
               <month>Jan</month>;<volume>2</volume>(<issue>1</issue>):<fpage>31</fpage>–<lpage>5</lpage>.<annotation>
                  <p content-type="warning">The reference title appears to be set in title case rather than sentence case. (Ref. 59 "Cotte, Passot, Gilly, Glehen, 2010")</p>
                  <p content-type="warning">Edifix does not recognize the journal "Limited". If this is a valid journal title, please send this reference to journals@inera.com for addition to our journal database. (Ref. 59 "Cotte, Passot, Gilly, Glehen, 2010")</p>
               </annotation>
            </mixed-citation>
         </ref>
      </ref-list>
   </back>
   <sub-article id="article-en" xml:lang="en" article-type="other">
      <front>
         <journal-meta>
            <journal-id journal-id-type="publisher-id">Zdrav Vestn</journal-id>
            <journal-id journal-id-type="nlm-ta">Zdrav Vestn</journal-id>
            <journal-id journal-id-type="doi">Zdrav Vestn</journal-id>
            <journal-title-group>
               <journal-title>Slovenian Medical Journal</journal-title>
               <!--<trans-title-group xml:lang="sl"><trans-title>Zdravniški vestnik</trans-title></trans-title-group>-->
               <abbrev-journal-title>Zdrav Vestn</abbrev-journal-title>
            </journal-title-group>
            <issn publication-format="ppub" pub-type="ppub">1318-0347</issn>
            <issn publication-format="epub" pub-type="epub">1581-0224</issn>
            <issn-l>0350-0063</issn-l>
            <publisher>
               <publisher-name xml:lang="sl">Slovensko zdravniško društvo</publisher-name>
               <publisher-name xml:lang="en">Slovenian Medical Association</publisher-name>
               <publisher-loc xml:lang="sl">Ljubljana, Slovenia</publisher-loc>
            </publisher>
         </journal-meta>
         <article-meta>
            <article-id pub-id-type="doi">10.6016/ZdravVestn.2836</article-id>
            <article-id pub-id-type="publisher-id">2836</article-id>
            <article-categories>
               <subj-group subj-group-type="discipline" xml:lang="en">
                  <subject>Medicine and health sciences</subject>
                  <subj-group>
                     <subject>Oncology</subject>
                  </subj-group>
               </subj-group>
               <subj-group subj-group-type="article-type" xml:lang="en">
                  <subject>Review article</subject>
               </subj-group>
               <subj-group subj-group-type="heading" xml:lang="en">
                  <subject>Oncology</subject>
               </subj-group>
            </article-categories>
            <title-group>
               <article-title xml:lang="en">Hyperthermic intraperitoneal chemotherapy</article-title>
               <alt-title alt-title-type="running-head" xml:lang="en">Hyperthermic intraperitoneal chemotherapy</alt-title>
            </title-group>
            <contrib-group>
               <contrib contrib-type="author" xlink:type="simple">
                  <name name-style="western">
                     <surname>Skok</surname>
                     <given-names>Kristijan</given-names>
                  </name>
                  <xref ref-type="aff" rid="en-aff1">1</xref>
               </contrib>
               <contrib contrib-type="author" xlink:type="simple">
                  <name name-style="western">
                     <surname>Skornšek</surname>
                     <given-names>Nina</given-names>
                  </name>
                  <xref ref-type="aff" rid="en-aff1">1</xref>
               </contrib>
               <contrib contrib-type="author" xlink:type="simple">
                  <name name-style="western">
                     <surname>Hočevar</surname>
                     <given-names>Marko</given-names>
                  </name>
                  <xref ref-type="aff" rid="en-aff2">2</xref>
                  <xref ref-type="aff" rid="en-aff3">3</xref>
               </contrib>
               <contrib contrib-type="author" xlink:type="simple">
                  <name name-style="western">
                     <surname>Skok</surname>
                     <given-names>Pavel</given-names>
                  </name>
                  <xref ref-type="aff" rid="en-aff4">4</xref>
                  <xref ref-type="corresp" rid="en-corr"/>
               </contrib>
            </contrib-group>
            <aff id="en-aff1" xml:lang="en">
               <label>1</label>
               <institution>Faculty of medicine, University of Maribor, Maribor, Slovenia</institution>
            </aff>
            <aff id="en-aff2" xml:lang="en">
               <label>2</label>
               <institution>Medicinska fakulteta, Univerza v Ljubljani, Ljubljana, Slovenija</institution>
            </aff>
            <aff id="en-aff3" xml:lang="en">
               <label>3</label>
               <institution>Division of surgery, Institute of Oncology Ljubljana, Ljubljana, Slovenia</institution>
            </aff>
            <aff id="en-aff4" xml:lang="en">
               <label>4</label>
               <institution>Medical research department, University Medical Centre Maribor, Maribor, Slovenia</institution>
            </aff>
            <author-notes>
               <fn fn-type="conflict" xml:lang="en">
                  <p>The authors have declared that no competing interests exist.</p>
               </fn>
               <fn fn-type="conflict" xml:lang="sl">
                  <p>Avtorji so izjavili, da ne obstajajo nobeni konkurenčni interesi.</p>
               </fn>
               <corresp id="en-corr">Pavel Skok, e-mail: <email xlink:type="simple"/>
               </corresp>
            </author-notes>
            <pub-date pub-type="ppub">
               <month>2</month>
               <year>2019</year>
            </pub-date>
            <pub-date pub-type="epub">
               <month>2</month>
               <year>2019</year>
            </pub-date>
            <volume>88</volume>
            <issue>1–2</issue>
            <fpage>21</fpage>
            <lpage>38</lpage>
            <history>
               <date date-type="received">
                  <day/>
                  <month/>
                  <year/>
               </date>
               <date date-type="accepted">
                  <day/>
                  <month/>
                  <year/>
               </date>
            </history>
            <permissions>
               <copyright-statement xml:lang="en">Copyright © 2019, Slovenian Medical Association (SZD)</copyright-statement>
               <copyright-statement xml:lang="sl">© 2019, Slovensko zdravniško društvo (SZD)</copyright-statement>
               <copyright-year>2019</copyright-year>
               <copyright-holder xml:lang="en">Slovenian Medical Association (SZD)</copyright-holder>
               <copyright-holder xml:lang="sl">Slovensko zdravniško društvo (SZD)</copyright-holder>
               <license xlink:href="https://creativecommons.org/licenses/by-nc/4.0/"
                        xlink:type="simple"
                        xml:lang="en">
                  <license-p>This is an open access article distributed under the terms of the
          <ext-link ext-link-type="uri"
                               xlink:href="https://creativecommons.org/licenses/by-nc/4.0/"
                               xlink:type="simple">Creative Commons Attribution-NonCommercial
            License</ext-link>, which permits unrestricted use, distribution, and
          reproduction in any medium, provided the original author and source are
          credited and only for non-commercial purposes. </license-p>
               </license>
               <license xlink:href="https://creativecommons.org/licenses/by-nc/4.0/"
                        xlink:type="simple"
                        xml:lang="sl">
                  <license-p>To je članek z odprtim dostopom, ki ga lahko uporabite pod pogoji iz
          <ext-link ext-link-type="uri"
                               xlink:href="https://creativecommons.org/licenses/by-nc/4.0/"
                               xlink:type="simple">Creative Commons Priznanje avtorstva-Nekomercialno
            licence</ext-link>. ki dovoljuje distribucijo, predelavo ali
          prilagoditev, ter gradijo na njem, v nekomercialne namene, z navedbo avtorja
          in izvirnega dela.</license-p>
               </license>
            </permissions>
            <abstract xml:lang="en">
               <title>Abstract</title>
               <p>In the past, patients with peritoneal metastases have been treated only with palliative therapy. Their state was deemed to be incurable. The median survival time was approximately two months. The therapeutic approach started to change in the nineties. Some researchers were of the opinion that peritoneal metastases were, in certain cases, only a locoregional disease and consequently, the patient could not only be treated, but cured. One of the main supporters of this theory and new treatment approach was Paul Sugarbaker. The proposed treatment consisted of cytoreductive surgery in combination with intraperitoneal chemotherapy. The purpose of the surgical procedure is macroscopic elimination of the tumour and removal of its microscopic remains via intraperitoneal chemotherapy. The procedure in which we apply a heated chemotherapeutic agent is known as hyperthermic intraperitoneal chemotherapy. Heat on its own has some direct anti-tumour effects. It causes protein denaturation, lysosomal activation and increased apoptotic cell death. If the chemotherapeutic agent is heated, complex chemical reactions take place, which promote its effectiveness and increase the depth of penetration. The best results achieved by this method have been reported in colorectal carcinoma, appendiceal malignancies, ovarian carcinoma and peritoneal mesothelioma. In the paper, the authors present this complex procedure, indications, criteria of patient selection and contemporary knowledge on the effectiveness of this method of treatment for certain types of cancer.</p>
            </abstract>
            <kwd-group xml:lang="en">
               <kwd>hyperthermic intraperitoneal chemotherapy</kwd>
               <kwd>cytoreductive surgery</kwd>
               <kwd>colorectal cancer</kwd>
               <kwd>peritoneal carcinosis</kwd>
               <kwd>metastases</kwd>
            </kwd-group>
            <custom-meta-group>
               <custom-meta>
                  <meta-name>TotalReferences</meta-name>
                  <meta-value>60</meta-value>
               </custom-meta>
               <custom-meta>
                  <meta-name>ReferencesParsed</meta-name>
                  <meta-value>57</meta-value>
               </custom-meta>
               <custom-meta>
                  <meta-name>ReferencesBillable</meta-name>
                  <meta-value>58</meta-value>
               </custom-meta>
               <custom-meta>
                  <meta-name>LinkServices</meta-name>
                  <meta-value>pubmed-crossref</meta-value>
               </custom-meta>
               <custom-meta>
                  <meta-name>ReferencesLinked</meta-name>
                  <meta-value>54</meta-value>
               </custom-meta>
               <custom-meta>
                  <meta-name>ReferencesLinkedDOI</meta-name>
                  <meta-value>43</meta-value>
               </custom-meta>
               <custom-meta>
                  <meta-name>ReferencesLinkedPMID</meta-name>
                  <meta-value>52</meta-value>
               </custom-meta>
               <custom-meta>
                  <meta-name>JournalReferences</meta-name>
                  <meta-value>55</meta-value>
               </custom-meta>
               <custom-meta>
                  <meta-name>BookReferences</meta-name>
                  <meta-value>0</meta-value>
               </custom-meta>
               <custom-meta>
                  <meta-name>BookChapterReferences</meta-name>
                  <meta-value>1</meta-value>
               </custom-meta>
               <custom-meta>
                  <meta-name>ConferenceReferences</meta-name>
                  <meta-value>0</meta-value>
               </custom-meta>
               <custom-meta>
                  <meta-name>ElectronicReferences</meta-name>
                  <meta-value>0</meta-value>
               </custom-meta>
               <custom-meta>
                  <meta-name>DissertationReferences</meta-name>
                  <meta-value>0</meta-value>
               </custom-meta>
               <custom-meta>
                  <meta-name>LegalReferences</meta-name>
                  <meta-value>0</meta-value>
               </custom-meta>
               <custom-meta>
                  <meta-name>StandardReferences</meta-name>
                  <meta-value>0</meta-value>
               </custom-meta>
               <custom-meta>
                  <meta-name>OtherReferences</meta-name>
                  <meta-value>0</meta-value>
               </custom-meta>
               <custom-meta>
                  <meta-name>UnknownReferences</meta-name>
                  <meta-value>4</meta-value>
               </custom-meta>
               <custom-meta>
                  <meta-name>ReferencesSemiParsed</meta-name>
                  <meta-value>0</meta-value>
               </custom-meta>
               <custom-meta>
                  <meta-name>ReferencesBookUnparsed</meta-name>
                  <meta-value>0</meta-value>
               </custom-meta>
               <custom-meta>
                  <meta-name>EditorialStyle</meta-name>
                  <meta-value>ICMJE-WHO</meta-value>
               </custom-meta>
            </custom-meta-group>
         </article-meta>
      </front>
      <body>
         <sec id="en-s1" sec-type="Introduction">
            <label>1</label>
            <title>Introduction</title>
            <p>Peritoneal carcinomatosis (PC) is intraperitoneal dissemination of a malignant tumour (<xref ref-type="bibr" rid="en-b1">1</xref>). It can be due to a primary peritoneal malignoma (e.g. peritoneal mesothelioma), dissemination of gastrointestinal cancers (appendiceal, colorectal or gastric cancer), pseudomixoma of the peritoneum and gynaecological cancers (ovarian cancer) (<xref ref-type="bibr" rid="en-b2">2</xref>,<xref ref-type="bibr" rid="en-b3">3</xref>). In the past, peritoneal metastases were deemed to be the incurable and terminal stage of cancer, and accordingly, patients received only palliative therapy (<xref ref-type="bibr" rid="en-b3">3</xref>). With such an approach, the average survival of patients was only two months (<xref ref-type="bibr" rid="en-b4">4</xref>). In the 1990’s, the therapeutic approach started to change considerably (<xref ref-type="bibr" rid="en-b5">5</xref>). Namely, some researchers believed that in certain cases peritoneal metastases are but a type of locoregional diseases, and thus the patient has a fair chance of being cured (<xref ref-type="bibr" rid="en-b6">6</xref>). One of the main proponents of this theory and new treatment approach was Paul Sugarbaker (<xref ref-type="bibr" rid="en-b7">7</xref>).</p>
            <p>Thus, cytoreductive surgery (CRS) in combination with intraperitoneal chemotherapy (IPCT) has become part of cancer treatment. The purpose of CRS is to eliminate the macroscopic tumour. To this purpose, surgical peritonectomy with visceral resection has come into use for the removal or peritoneal metastases. The next significant step in the treatment of these diseases has been the locoregional chemotherapy, which is used during surgery or in the early postoperative period (<xref ref-type="bibr" rid="en-b4">4</xref>). The procedure in which a cytotoxic drug is heated and administered during surgery is called hyperthermic intraperitoneal chemotherapy (HIPEC). Chemotherapy (CT) that is used in the early postoperative period is called EPIC. Both are intended to remove any microscopic residual disease (<xref ref-type="bibr" rid="en-b8">8</xref>).</p>
            <p>The special feature of the combined treatment with CRS and HIPEC is in that the whole therapy is performed during or along with the surgery (<xref ref-type="bibr" rid="en-b8">8</xref>,<xref ref-type="bibr" rid="en-b9">9</xref>). The usefulness of this therapeutic approach is based on the pathophysiological mechanism of the disease and the hypothesised tumour cell entrapment (<xref ref-type="bibr" rid="en-b8">8</xref>). According to this hypothesis, at the time of surgery, cancerous cells are still released from severed lymph vessels or from venous blood left after surgery. Furthermore, it is known that cancer dissemination may take form of low-density seeding and results in a peritoneal metastasis or a nodular implant at a distance from the primary cancer site. Another form of dissemination is high-density seeding where several cancer cells are entrapped on the surface of the resection site. This creates a layer of cancerous tissue that adapts to the adjoining anatomical structures (<xref ref-type="bibr" rid="en-b8">8</xref>). The basic eligibility criteria for surgery are 1) the absence of systemic or hepatic metastases (with the exception of up to 3 well-delineated focal lesions), and 2) exclusively locoregional progression of the disease in the peritoneum or peritoneal surfaces (<xref ref-type="bibr" rid="en-b10">10</xref>).</p>
            <p>A multidisciplinary approach is required in patients with peritoneal cancer. The best results obtained by such treatment approach have been reported in peritoneal pseudomixoma, colorectal cancer (CRCA), appendiceal cancer, ovarian cancer and in peritoneal mesothelioma (<xref ref-type="bibr" rid="en-b7">7</xref>,<xref ref-type="bibr" rid="en-b11">11</xref>,<xref ref-type="bibr" rid="en-b12">12</xref>). However, peritoneal metastases may also occur in histological subtypes of tumours that are typically not associated with metastatic spread in the peritoneal cavity. Among these are breast cancer, malignant melanoma, neuroendocrine tumours (NET) and sarcomas (<xref ref-type="bibr" rid="en-b13">13</xref>-<xref ref-type="bibr" rid="en-b15">15</xref>). Recently, several studies have been published that reported the effective use of CRS in peritoneal metastases of NET and sarcoma (<xref ref-type="bibr" rid="en-b16">16</xref>,<xref ref-type="bibr" rid="en-b17">17</xref>). The use of IPCT in NET, gastrointestinal stromal tumours (GIST) and sarcomas did not prove to be effective as it failed to result in a significant prolongation of survival (<xref ref-type="bibr" rid="en-b4">4</xref>). Guidelines for using CRS with or without IPCT in pancreatic cancer, primary hepatic cancer, breast cancer and malignant melanoma are not yet available (<xref ref-type="bibr" rid="en-b4">4</xref>).</p>
            <p>In their article, the authors present some historical facts regarding HIPEC, treatment procedures used in this challenging method, and current reports on the encouraging results achieved in individual cancer types.</p>
         </sec>
         <sec id="en-s2" sec-type="History">
            <label>2</label>
            <title>History</title>
            <p>In 1955, Weissberger was the first to present the concept of IPCT for the treatment of localised peritoneal tumours (<xref ref-type="bibr" rid="en-b18">18</xref>). The concept was then adopted and spread in the U.S.A., and in the 1980’s new treatment modalities were introduced for the treatment of patients with peritoneal metastases. In 1979, Dedrick developed an experimental model for IPCT pharmacokinetics, and in 1988, Fujimoto described the use of hyperthermia to enhance the potential of antitumour agents. Combined use of CRS and IPCT as an aggressive locoregional therapy was first reported by Dr Paul Sugarbaker in the 1990’s (<xref ref-type="bibr" rid="en-b3">3</xref>). The use of this approach indicated the possibility of a more effective treatment resulting in a potentially longer survival. Despite certain scepticism and contradictory views, this approach proved to be the only one that prolonged the average survival of selective patients for even up to 46 months (<xref ref-type="bibr" rid="en-b4">4</xref>).</p>
         </sec>
         <sec id="en-s3" sec-type="Hyperthermic intraperitoneal chemotherapy">
            <label>3</label>
            <title>Hyperthermic intraperitoneal chemotherapy</title>
            <p>CRS and HIPEC have not been found effective as separate methods, but their combination is currently considered the most effective treatment in patients with peritoneal metastases from colorectal cancer, peritoneal mesothelioma, appendiceal carcinoma and ovarian cancer (<xref ref-type="bibr" rid="en-b19">19</xref>,<xref ref-type="bibr" rid="en-b20">20</xref>). <xref ref-type="fig" rid="en-fig1">Figure 1</xref> shows the use of HIPEC.</p>
            <fig position="anchor" id="en-fig1" orientation="portrait">
               <label>Figure 1:</label>
               <caption>
                  <p> Schematic presentation of HIPEC</p>
               </caption>
               <p>
                  <graphic xlink:href="2836-en-web-resources/image/zdravvestn-2836-en-01.png"
                           position="float"
                           orientation="portrait"/>
               </p>
               <p>Author: Corrado Bellini. The figure is from the web and marked as »reusable by changing«.</p>
            </fig>
            <p>In the first step, all the macroscopically visible tumour tissue is removed by CRS, and afterwards HIPEC is used in order to eliminate any minimal residual disease. The researchers have found several factors that influence the outcome and success of treatment, and some of the key findings are summarised in <xref ref-type="table" rid="en-table1">Table 1</xref> (<xref ref-type="bibr" rid="en-b21">21</xref>,<xref ref-type="bibr" rid="en-b22">22</xref>). To achieve a long term improvement and minimise the possibility of recurrence, it is crucial to remove all the macroscopically visible tumour masses, i.e. to achieve complete cytoreduction. Depending on the extent of the disease, various surgical approaches are used, such as peritonectomy of the upper left and right abdominal quadrants and the pelvis, omentectomy, resection of the rectosigmoid segment of the colon, right hemicolectomy, splenectomy and partial gastrectomy (<xref ref-type="bibr" rid="en-b23">23</xref>).</p>
            <table-wrap position="anchor" id="en-table1" orientation="portrait">
               <label>Table 1:</label>
               <caption>
                  <p> Risk variables and grading systems.</p>
               </caption>
               <table>
                  <colgroup span="1">
                     <col span="1"/>
                     <col span="1"/>
                     <col span="1"/>
                  </colgroup>
                  <thead>
                     <tr>
                        <th colspan="3" rowspan="1">Variables</th>
                     </tr>
                  </thead>
                  <tbody>
                     <tr>
                        <th content-type="table-subhead" rowspan="1" colspan="1">Eligible for procedure</th>
                        <th content-type="table-subhead" rowspan="1" colspan="1">Relative contraindications</th>
                        <th content-type="table-subhead" rowspan="1" colspan="1">Absolute contraindications</th>
                     </tr>
                     <tr>
                        <td rowspan="1" colspan="1">Good general status.</td>
                        <td rowspan="1" colspan="1">A sub occlusive syndrome due to more than one stenosis of the GIT.</td>
                        <td rowspan="1" colspan="1">Poor general status.</td>
                     </tr>
                     <tr>
                        <td rowspan="1" colspan="1">Age below 65–70 years.</td>
                        <td rowspan="1" colspan="1">Peritoneal disease progressing under systemic chemotherapy.</td>
                        <td rowspan="1" colspan="1">The presence of extra peritoneal metastases (except 3 liver metastases easily resectable).</td>
                     </tr>
                     <tr>
                        <td rowspan="1" colspan="1">Lack of extra-abdominal metastases.</td>
                        <td rowspan="1" colspan="1">Presence of more than 3 resectable liver metastases.</td>
                        <td rowspan="1" colspan="1">Huge and diffuse peritoneal metastases.</td>
                     </tr>
                     <tr>
                        <td rowspan="1" colspan="1">No occlusive disorders and no bulky clinical or radiological peritoneal metastases.</td>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                     </tr>
                     <tr>
                        <th colspan="3" rowspan="1">Sugarbaker’s completeness of CRS</th>
                     </tr>
                     <tr>
                        <th content-type="table-subhead" rowspan="1" colspan="1">Grade</th>
                        <th content-type="table-subhead" colspan="2" rowspan="1">Definition</th>
                     </tr>
                     <tr>
                        <td rowspan="1" colspan="1">CC-0</td>
                        <td colspan="2" rowspan="1">No visible peritoneal carcinomatosis after CRS</td>
                     </tr>
                     <tr>
                        <td rowspan="1" colspan="1">CC-1</td>
                        <td colspan="2" rowspan="1">Nodules persisting &lt; 2.5 mm after CRS</td>
                     </tr>
                     <tr>
                        <td rowspan="1" colspan="1">CC-2</td>
                        <td colspan="2" rowspan="1">Nodules persisting between 2.5 mm and 2.5 cm</td>
                     </tr>
                     <tr>
                        <td rowspan="1" colspan="1">CC-3</td>
                        <td colspan="2" rowspan="1">Nodules persisting &gt; 2.5 cm</td>
                     </tr>
                     <tr>
                        <th colspan="3" rowspan="1">STATUS ECOG</th>
                     </tr>
                     <tr>
                        <th content-type="table-subhead" rowspan="1" colspan="1">Grade</th>
                        <th content-type="table-subhead" colspan="2" rowspan="1">Definition</th>
                     </tr>
                     <tr>
                        <td rowspan="1" colspan="1">0</td>
                        <td colspan="2" rowspan="1">Fully active, able to carry on all pre-disease performance without restriction.</td>
                     </tr>
                     <tr>
                        <td rowspan="1" colspan="1">1</td>
                        <td colspan="2" rowspan="1">Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light house work, office work.</td>
                     </tr>
                     <tr>
                        <td rowspan="1" colspan="1">2</td>
                        <td colspan="2" rowspan="1">Ambulatory and capable of all selfcare but unable to carry out any work activities. Up and about more than 50 % of waking hours.</td>
                     </tr>
                     <tr>
                        <td rowspan="1" colspan="1">3</td>
                        <td colspan="2" rowspan="1">Capable of only limited selfcare, confined to bed or chair more than 50 % of waking hours.</td>
                     </tr>
                     <tr>
                        <td rowspan="1" colspan="1">4</td>
                        <td colspan="2" rowspan="1">Completely disabled. Cannot carry on any selfcare. Totally confined to bed or chair.</td>
                     </tr>
                     <tr>
                        <td rowspan="1" colspan="1">5</td>
                        <td colspan="2" rowspan="1">Dead.</td>
                     </tr>
                  </tbody>
               </table>
               <table-wrap-foot>
                  <p>Summarized after (<xref ref-type="bibr" rid="en-b8">8</xref>,<xref ref-type="bibr" rid="en-b28">28</xref>,<xref ref-type="bibr" rid="en-b59">59</xref>).</p>
                  <p>Legend: GIT – gastrointestinal tract, SCT – systemic chemotherapy, CRS – cytoreductive surgery.</p>
               </table-wrap-foot>
            </table-wrap>
            <p>HIPEC, the next step in the treatment, is generally performed before bowel reconstruction and before abdominal cavity closure in order to prevent the risk of tumour cell entrapment in the sutures at the site of anastomoses. In this procedure, a cytostatic solution heated to 41–44 °C (depending on the type of cytostatic agent) is inserted into the peritoneal cavity via inlet catheters. Then, using drainage catheters, the solution is drained from the peritoneal cavity into a hyperthermal pump, which maintains the temperature of the solution and allows its circulation. While the cytostatic’s concentration in the peritoneal cavity is 7-fold higher than with (standard) intraperitoneal or intravenous application, its tissue penetration is limited to only a few millimetres. The choice of cytostatic type, the dosage and the temperature of the solution depend on the tumour type. The most frequently used are doxorubicin, cisplatin, mitomycin C, melphalan, oxaliplatin, ifosfamide and gemcitabine (<xref ref-type="bibr" rid="en-b24">24</xref>) (<xref ref-type="table" rid="en-table2">Table 2</xref>). Hyperthermia alone already has an antitumour effect by causing protein degradation, lysosome activation and apoptosis. Heating a cytostatic solution triggers complex chemical reactions that further increase the effectiveness and the depth of cytostatic penetration into the tumour tissue (<xref ref-type="bibr" rid="en-b25">25</xref>).</p>
            <table-wrap position="anchor" id="en-table2" orientation="portrait">
               <label>Table 2:</label>
               <caption>
                  <p> Properties of a closed and open HIPEC approach.</p>
               </caption>
               <table>
                  <colgroup span="1">
                     <col span="1"/>
                     <col span="1"/>
                     <col span="1"/>
                  </colgroup>
                  <thead>
                     <tr>
                        <th rowspan="1" colspan="1">Features</th>
                        <th rowspan="1" colspan="1">Open approach</th>
                        <th rowspan="1" colspan="1">Closed approach</th>
                     </tr>
                  </thead>
                  <tbody>
                     <tr>
                        <td rowspan="1" colspan="1">Efficiency</td>
                        <td rowspan="1" colspan="1">Allows continued cytoreduction of bowel and mesenteric surfaces.</td>
                        <td rowspan="1" colspan="1">No surgery possible during chemotherapy.</td>
                     </tr>
                     <tr>
                        <td rowspan="1" colspan="1">Environmental hazard</td>
                        <td rowspan="1" colspan="1">No aerosols detected.</td>
                        <td rowspan="1" colspan="1">Perception of increased safety.</td>
                     </tr>
                     <tr>
                        <td rowspan="1" colspan="1">Distribution</td>
                        <td rowspan="1" colspan="1">Uniform distribution of heat and chemotherapy solutions, tissues close to skin edge not immersed.</td>
                        <td rowspan="1" colspan="1">Possible poor distribution to dependent sites and closed spaces.</td>
                     </tr>
                     <tr>
                        <td rowspan="1" colspan="1">Pressure</td>
                        <td rowspan="1" colspan="1">No increased intraabdominal pressure.</td>
                        <td rowspan="1" colspan="1">Increased intraabdominal pressure may increase chemotherapy penetration into tissue.</td>
                     </tr>
                     <tr>
                        <td rowspan="1" colspan="1">Pharmacology</td>
                        <td rowspan="1" colspan="1">Allows pharmacokinetic monitoring of tumor and normal tissue</td>
                        <td rowspan="1" colspan="1">Tissue uptake of chemotherapy cannot be determined.</td>
                     </tr>
                     <tr>
                        <td rowspan="1" colspan="1">Abdominal incision and suture lines</td>
                        <td rowspan="1" colspan="1">Treated prior to performing the suturing.</td>
                        <td rowspan="1" colspan="1">Risk of recurrence in abdominal incision and suture lines.</td>
                     </tr>
                     <tr>
                        <td rowspan="1" colspan="1">Diaphragm perforation with peritonectomy</td>
                        <td rowspan="1" colspan="1">Pleural space treated by hyperthermic chemotherapy may prevent seeding of pleural space</td>
                        <td rowspan="1" colspan="1">Diaphragm closed prior to hyperthermic intraperitoneal chemotherapy so pleural space is not treated</td>
                     </tr>
                     <tr>
                        <td rowspan="1" colspan="1">Intestinal perforation</td>
                        <td rowspan="1" colspan="1">Detected by observing immersed bowel loops.</td>
                        <td rowspan="1" colspan="1">Not detected.</td>
                     </tr>
                     <tr>
                        <td rowspan="1" colspan="1">Hyperthermia</td>
                        <td rowspan="1" colspan="1">Increased heat necessary to maintain 42 °C.</td>
                        <td rowspan="1" colspan="1">Less heat required to maintain 42 °C.</td>
                     </tr>
                  </tbody>
               </table>
               <table-wrap-foot>
                  <p>Summarized after Sugarbaker and Van der Speeten (<xref ref-type="bibr" rid="en-b8">8</xref>).</p>
               </table-wrap-foot>
            </table-wrap>
            <p>This procedure can be carried out using either closed or open HIPEC technique (<xref ref-type="table" rid="en-table3">Table 3</xref>). In the open technique, the abdominal cavity is still open or covered with a plastic foil, and therefore there is a problem of cytostatic aerosolization. This problem is supposed to be solved by using anti-evaporation barriers and evaporators. In the closed technique, first the skin cover is sealed with a waterproof seam, and then the peritoneal cavity is perfused via the installed catheters. After the perfusion procedure is completed, the abdominal cavity is reopened, and only after the reconstruction with anastomoses is done, the abdominal cavity is closed permanently (<xref ref-type="bibr" rid="en-b26">26</xref>). Laparoscopic HIPEC technique for palliative indication (considerably reduced ascites) is used mainly in patients with cancer that cannot be treated surgically. The duration of HIPEC treatment depends on the type of cytostatic agent, and may range from 30 min (oxaliplatin) to 3 hrs (pegylated liposomal doxorubicin) (<xref ref-type="bibr" rid="en-b24">24</xref>). The choice of chemotherapeutic agent is crucial for treatment success. The cytostatic agent should neither cause local toxicity, and nor be dependent on metabolism (conversion into the active form). In addition, it must have a direct cytotoxic effect and pharmacokinetic advantages with i.p. administration (limited systemic toxicity and good locoregional penetration). It is also advantageous if the agent has a synergistic effect with heat. The advantage of this type of treatment is in its maximal local and minimal systemic effects, but the drawback is the technical complexity of the procedure which is associated with several risks. <xref ref-type="fig" rid="en-fig2">Figure 2</xref> shows some variables that should be taken into account before deciding to use the method of treatment in question (<xref ref-type="bibr" rid="en-b8">8</xref>,<xref ref-type="bibr" rid="en-b27">27</xref>).</p>
            <table-wrap position="anchor" id="en-table3" orientation="portrait">
               <label>Tabela 3:</label>
               <caption>
                  <p> List of chemotherapy agents used for HIPEC.</p>
               </caption>
               <table>
                  <colgroup span="1">
                     <col span="1"/>
                     <col span="1"/>
                     <col span="1"/>
                     <col span="1"/>
                     <col span="1"/>
                     <col span="1"/>
                     <col span="1"/>
                     <col span="1"/>
                     <col span="1"/>
                     <col span="1"/>
                     <col span="1"/>
                     <col span="1"/>
                  </colgroup>
                  <thead>
                     <tr>
                        <th rowspan="1" colspan="1">Drug</th>
                        <th rowspan="1" colspan="1">Molecular weight</th>
                        <th rowspan="1" colspan="1">Type</th>
                        <th rowspan="1" colspan="1">AUC ratio</th>
                        <th rowspan="1" colspan="1">T<sup>1/2</sup> (min)</th>
                        <th rowspan="1" colspan="1">T<sup>80 %</sup> (min)</th>
                        <th rowspan="1" colspan="1">Dose</th>
                        <th rowspan="1" colspan="1">Carrier solution</th>
                        <th rowspan="1" colspan="1">
                           <p>Incompatibility</p>
                           <p>in solution</p>
                        </th>
                        <th rowspan="1" colspan="1">Heat synergya</th>
                        <th rowspan="1" colspan="1">Heat stability</th>
                        <th rowspan="1" colspan="1">Depth of penetration</th>
                     </tr>
                  </thead>
                  <tbody>
                     <tr>
                        <td rowspan="1" colspan="1">5-fluorouracil</td>
                        <td rowspan="1" colspan="1">130.08</td>
                        <td rowspan="1" colspan="1">Anti-metabolite</td>
                        <td rowspan="1" colspan="1">280</td>
                        <td rowspan="1" colspan="1">30</td>
                        <td rowspan="1" colspan="1">75</td>
                        <td rowspan="1" colspan="1">650 mg/m<sup>2</sup> (× 5 days)</td>
                        <td rowspan="1" colspan="1">
                           <p>0.9 % NaCl;</p>
                           <p>1.5 % dexstrose dialysis solution; Icodextrin</p>
                        </td>
                        <td rowspan="1" colspan="1">Doxorubicin, Daunorubicin, Idaurubicin, Cisplatin, Diazepam, Icytarabine</td>
                        <td rowspan="1" colspan="1">MIN</td>
                        <td rowspan="1" colspan="1">43 °C</td>
                        <td rowspan="1" colspan="1">0.2 mm</td>
                     </tr>
                     <tr>
                        <td rowspan="1" colspan="1">Cisplatin</td>
                        <td rowspan="1" colspan="1">300.1</td>
                        <td rowspan="1" colspan="1">Alkylator</td>
                        <td rowspan="1" colspan="1">10</td>
                        <td rowspan="1" colspan="1">30</td>
                        <td rowspan="1" colspan="1">90</td>
                        <td rowspan="1" colspan="1">90 mg/m<sup>2</sup>
                        </td>
                        <td rowspan="1" colspan="1">0.9 % NaCl</td>
                        <td rowspan="1" colspan="1">NA</td>
                        <td rowspan="1" colspan="1">YES</td>
                        <td rowspan="1" colspan="1">41.5 °C</td>
                        <td rowspan="1" colspan="1">1–3 mm</td>
                     </tr>
                     <tr>
                        <td rowspan="1" colspan="1">Docetaxel</td>
                        <td rowspan="1" colspan="1">861.9</td>
                        <td rowspan="1" colspan="1">Antimitotic</td>
                        <td rowspan="1" colspan="1">552</td>
                        <td rowspan="1" colspan="1">NA</td>
                        <td rowspan="1" colspan="1">NA</td>
                        <td rowspan="1" colspan="1">45 mg/m<sup>2</sup>
                        </td>
                        <td rowspan="1" colspan="1">0.9 % NaCl</td>
                        <td rowspan="1" colspan="1">Plastic containers and tubes</td>
                        <td rowspan="1" colspan="1">NO</td>
                        <td rowspan="1" colspan="1">NA</td>
                        <td rowspan="1" colspan="1">NA</td>
                     </tr>
                     <tr>
                        <td rowspan="1" colspan="1">Doxorubicin</td>
                        <td rowspan="1" colspan="1">579.99</td>
                        <td rowspan="1" colspan="1">Antitumour antibiotic</td>
                        <td rowspan="1" colspan="1">230</td>
                        <td rowspan="1" colspan="1">20</td>
                        <td rowspan="1" colspan="1">80</td>
                        <td rowspan="1" colspan="1">15 mg/m<sup>2</sup>
                        </td>
                        <td rowspan="1" colspan="1">1.5 % dextrose dialysis solution</td>
                        <td rowspan="1" colspan="1">Heparin, fluorouracil</td>
                        <td rowspan="1" colspan="1">YES</td>
                        <td rowspan="1" colspan="1">42 °C</td>
                        <td rowspan="1" colspan="1">4–6 cell layers</td>
                     </tr>
                     <tr>
                        <td rowspan="1" colspan="1">DOXIL (liposomal doxorubicin)</td>
                        <td rowspan="1" colspan="1">579.99</td>
                        <td rowspan="1" colspan="1">Antitumour antibiotic</td>
                        <td rowspan="1" colspan="1">1.040</td>
                        <td rowspan="1" colspan="1">180</td>
                        <td rowspan="1" colspan="1">NA</td>
                        <td rowspan="1" colspan="1">100 mg/m<sup>2</sup>
                        </td>
                        <td rowspan="1" colspan="1">1.5 % dextrose dialysis solution</td>
                        <td rowspan="1" colspan="1">Heparin, fluorouracil</td>
                        <td rowspan="1" colspan="1">YES</td>
                        <td rowspan="1" colspan="1">42 °C</td>
                        <td rowspan="1" colspan="1">4–6 cell layers</td>
                     </tr>
                     <tr>
                        <td rowspan="1" colspan="1">Etoposide</td>
                        <td rowspan="1" colspan="1">588.58</td>
                        <td rowspan="1" colspan="1">Antitumour antibiotic</td>
                        <td rowspan="1" colspan="1">65</td>
                        <td rowspan="1" colspan="1">NA</td>
                        <td rowspan="1" colspan="1">NA</td>
                        <td rowspan="1" colspan="1">25–350 mg/m<sup>2</sup>
                        </td>
                        <td rowspan="1" colspan="1">5 % dextrose</td>
                        <td rowspan="1" colspan="1">Plastic containers and tubes; acryl; antibiotics</td>
                        <td rowspan="1" colspan="1">YES</td>
                        <td rowspan="1" colspan="1">42 °C</td>
                        <td rowspan="1" colspan="1">NA</td>
                     </tr>
                     <tr>
                        <td rowspan="1" colspan="1">Floxuridine (FUDR)</td>
                        <td rowspan="1" colspan="1">246.2</td>
                        <td rowspan="1" colspan="1">Anti-metabolite</td>
                        <td rowspan="1" colspan="1">75</td>
                        <td rowspan="1" colspan="1">NA</td>
                        <td rowspan="1" colspan="1">NA</td>
                        <td rowspan="1" colspan="1">
                           <p>500 mg/m<sup>2</sup>/2x day</p>
                           <p>(× 3 days)</p>
                        </td>
                        <td rowspan="1" colspan="1">0.9 % NaCl</td>
                        <td rowspan="1" colspan="1">NA</td>
                        <td rowspan="1" colspan="1">MIN</td>
                        <td rowspan="1" colspan="1">43 °C</td>
                        <td rowspan="1" colspan="1">NA</td>
                     </tr>
                     <tr>
                        <td rowspan="1" colspan="1">Gemcitabine</td>
                        <td rowspan="1" colspan="1">299.5</td>
                        <td rowspan="1" colspan="1">Pyrimidine antagonist</td>
                        <td rowspan="1" colspan="1">205</td>
                        <td rowspan="1" colspan="1">40</td>
                        <td rowspan="1" colspan="1">75</td>
                        <td rowspan="1" colspan="1">1,000 mg/m<sup>2</sup>
                        </td>
                        <td rowspan="1" colspan="1">0.9 % NaCl</td>
                        <td rowspan="1" colspan="1">NA</td>
                        <td rowspan="1" colspan="1">In 48 h</td>
                        <td rowspan="1" colspan="1">42.5 °C</td>
                        <td rowspan="1" colspan="1">NA</td>
                     </tr>
                     <tr>
                        <td rowspan="1" colspan="1">Irinotecan</td>
                        <td rowspan="1" colspan="1">677.19</td>
                        <td rowspan="1" colspan="1">Antitumour antibiotic</td>
                        <td rowspan="1" colspan="1">NA</td>
                        <td rowspan="1" colspan="1">NA</td>
                        <td rowspan="1" colspan="1">NA</td>
                        <td rowspan="1" colspan="1">200 mg/m<sup>2</sup>
                        </td>
                        <td rowspan="1" colspan="1">1.5 % dextrose dialysis solution</td>
                        <td rowspan="1" colspan="1">NA</td>
                        <td rowspan="1" colspan="1">NO</td>
                        <td rowspan="1" colspan="1">44 °C</td>
                        <td rowspan="1" colspan="1">NA</td>
                     </tr>
                     <tr>
                        <td rowspan="1" colspan="1">Carboplatin</td>
                        <td rowspan="1" colspan="1">371.25</td>
                        <td rowspan="1" colspan="1">Alkylator</td>
                        <td rowspan="1" colspan="1">10</td>
                        <td rowspan="1" colspan="1">NA</td>
                        <td rowspan="1" colspan="1">NA</td>
                        <td rowspan="1" colspan="1">300 mg/m<sup>2</sup>
                        </td>
                        <td rowspan="1" colspan="1">0.9 % NaCl</td>
                        <td rowspan="1" colspan="1">NA</td>
                        <td rowspan="1" colspan="1">YES</td>
                        <td rowspan="1" colspan="1">41.5 °C</td>
                        <td rowspan="1" colspan="1">0.5 mm</td>
                     </tr>
                     <tr>
                        <td rowspan="1" colspan="1">Melphalan</td>
                        <td rowspan="1" colspan="1">305.2</td>
                        <td rowspan="1" colspan="1">Alkylator</td>
                        <td rowspan="1" colspan="1">56</td>
                        <td rowspan="1" colspan="1">33</td>
                        <td rowspan="1" colspan="1">69</td>
                        <td rowspan="1" colspan="1">70 mg/m<sup>2</sup>
                        </td>
                        <td rowspan="1" colspan="1">0.9 % NaCl</td>
                        <td rowspan="1" colspan="1">NA</td>
                        <td rowspan="1" colspan="1">MAXIMAL</td>
                        <td rowspan="1" colspan="1">42 °C</td>
                        <td rowspan="1" colspan="1">NA</td>
                     </tr>
                     <tr>
                        <td rowspan="1" colspan="1">Mitoxantrone</td>
                        <td rowspan="1" colspan="1">517.41</td>
                        <td rowspan="1" colspan="1">Antitumour antibiotic</td>
                        <td rowspan="1" colspan="1">115–255</td>
                        <td rowspan="1" colspan="1">NA</td>
                        <td rowspan="1" colspan="1">NA</td>
                        <td rowspan="1" colspan="1">28 mg/m<sup>2</sup>
                        </td>
                        <td rowspan="1" colspan="1">0.9 % NaCl; Ringer’s lactate</td>
                        <td rowspan="1" colspan="1">Heparin</td>
                        <td rowspan="1" colspan="1">YES</td>
                        <td rowspan="1" colspan="1">43 °C</td>
                        <td rowspan="1" colspan="1">5–6 cell layers</td>
                     </tr>
                     <tr>
                        <td rowspan="1" colspan="1">Mitomycin C</td>
                        <td rowspan="1" colspan="1">334.3</td>
                        <td rowspan="1" colspan="1">Antitumour antibiotic</td>
                        <td rowspan="1" colspan="1">27</td>
                        <td rowspan="1" colspan="1">40</td>
                        <td rowspan="1" colspan="1">90</td>
                        <td rowspan="1" colspan="1">15 mg/m<sup>2</sup>
                        </td>
                        <td rowspan="1" colspan="1">1.5 % dextrose dialysis solution</td>
                        <td rowspan="1" colspan="1">Bleomycin</td>
                        <td rowspan="1" colspan="1">YES</td>
                        <td rowspan="1" colspan="1">42.5 °C</td>
                        <td rowspan="1" colspan="1">2,000 µm</td>
                     </tr>
                     <tr>
                        <td rowspan="1" colspan="1">Oxaliplatin</td>
                        <td rowspan="1" colspan="1">397.3</td>
                        <td rowspan="1" colspan="1">Alkylator</td>
                        <td rowspan="1" colspan="1">16</td>
                        <td rowspan="1" colspan="1">40</td>
                        <td rowspan="1" colspan="1">60</td>
                        <td rowspan="1" colspan="1">460 mg/m<sup>2</sup>
                        </td>
                        <td rowspan="1" colspan="1">5 % dextrose</td>
                        <td rowspan="1" colspan="1">Aluminum alkaline or NaCl solutions</td>
                        <td rowspan="1" colspan="1">YES</td>
                        <td rowspan="1" colspan="1">46 °C</td>
                        <td rowspan="1" colspan="1">1–2 mm</td>
                     </tr>
                     <tr>
                        <td rowspan="1" colspan="1">Paklitaxel</td>
                        <td rowspan="1" colspan="1">853.9</td>
                        <td rowspan="1" colspan="1">Antimitotic</td>
                        <td rowspan="1" colspan="1">1,000</td>
                        <td rowspan="1" colspan="1">NA</td>
                        <td rowspan="1" colspan="1">NA</td>
                        <td rowspan="1" colspan="1">120–180 mg (total dose)</td>
                        <td rowspan="1" colspan="1">1.5 % dextrose dialysis solution; 6 % ethoxylated amylopectin</td>
                        <td rowspan="1" colspan="1">Plastic containers and tubes</td>
                        <td rowspan="1" colspan="1">NO</td>
                        <td rowspan="1" colspan="1">42.5 °C</td>
                        <td rowspan="1" colspan="1">&gt;80 cell layers</td>
                     </tr>
                     <tr>
                        <td rowspan="1" colspan="1">Pemetrexed</td>
                        <td rowspan="1" colspan="1">471.4</td>
                        <td rowspan="1" colspan="1">Multitargeted antifolate</td>
                        <td rowspan="1" colspan="1">70</td>
                        <td rowspan="1" colspan="1">90</td>
                        <td rowspan="1" colspan="1">260</td>
                        <td rowspan="1" colspan="1">500 mg/m<sup>2</sup>
                        </td>
                        <td rowspan="1" colspan="1">1.5 % dextrose dialysis solution</td>
                        <td rowspan="1" colspan="1">NA</td>
                        <td rowspan="1" colspan="1">NA</td>
                        <td rowspan="1" colspan="1">NA</td>
                        <td rowspan="1" colspan="1">NA</td>
                     </tr>
                  </tbody>
               </table>
               <table-wrap-foot>
                  <p>Summarized after Sugarbaker and Van der Speeten (<xref ref-type="bibr" rid="en-b8">8</xref>).</p>
               </table-wrap-foot>
            </table-wrap>
            <fig position="anchor" id="en-fig2" orientation="portrait">
               <label>Figure 2:</label>
               <caption>
                  <p> Variables in the use of HIPEC</p>
               </caption>
               <p>
                  <graphic xlink:href="2836-en-web-resources/image/zdravvestn-2836-en-02.png"
                           position="float"
                           orientation="portrait"/>
               </p>
               <p>Summarized after Sugarbaker and Van der Speeten (<xref ref-type="bibr" rid="en-b8">8</xref>).</p>
            </fig>
            <sec id="en-s3.1" sec-type="Variables">
               <label>3.1</label>
               <title>Variables</title>
               <p>Recognised cancer centres with a sufficient volume of patients with peritoneal carcinomatosis (PC) have published 8 clinical and radiological factors that are deemed to be associated with a greater probability of a complete CRS:</p>
               <list>
                  <list-item>
                     <label>•</label>
                     <p>»Eastern Cooperative Oncology Group« (ECOG) »performance status» 1 or less;</p>
                  </list-item>
                  <list-item>
                     <label>•</label>
                     <p>no evidence of spread outside the abdominal cavity;</p>
                  </list-item>
                  <list-item>
                     <label>•</label>
                     <p>up to three small, resectable parenchymal liver metastases;</p>
                  </list-item>
                  <list-item>
                     <label>•</label>
                     <p>no evidence of bile duct obstruction;</p>
                  </list-item>
                  <list-item>
                     <label>•</label>
                     <p>no evidence of ureteral obstruction;</p>
                  </list-item>
                  <list-item>
                     <label>•</label>
                     <p>no evidence of gastrointestinal (GIT) obstruction at more than one site;</p>
                  </list-item>
                  <list-item>
                     <label>•</label>
                     <p>patency of the small bowel;</p>
                  </list-item>
                  <list-item>
                     <label>•</label>
                     <p>no macroscopic evidence of disease in the mesentery with several obstructions;</p>
                  </list-item>
                  <list-item>
                     <label>•</label>
                     <p>small volume disease in the gastrohepatic ligament (<xref ref-type="bibr" rid="en-b28">28</xref>).</p>
                  </list-item>
               </list>
               <p>Some factors are absolute while others are relative contraindications (<xref ref-type="table" rid="en-table1">Table 1</xref>) (<xref ref-type="bibr" rid="en-b28">28</xref>). The patient inclusion criteria vary slightly with regard to the type of cancer, while using the same quantitative predictive criteria for all patients with peritoneal metastases. These include histopathological findings, peritoneal cancer index – PCI (<xref ref-type="fig" rid="en-fig3">Figure 3</xref>), completeness of cytoreduction score (<xref ref-type="table" rid="en-table1">Table 1</xref>), diagnostic imaging (CT), and classification with peritoneal cytology (<xref ref-type="bibr" rid="en-b1">1</xref>,<xref ref-type="bibr" rid="en-b29">29</xref>,<xref ref-type="bibr" rid="en-b30">30</xref>).</p>
               <fig position="anchor" id="en-fig3" orientation="portrait">
                  <label>Figure 3:</label>
                  <caption>
                     <p> Peritoneal cancer indeks (PCI)</p>
                  </caption>
                  <p>
                     <graphic xlink:href="2836-en-web-resources/image/zdravvestn-2836-en-03.png"
                              position="float"
                              orientation="portrait"/>
                  </p>
                  <p>Summarized after Cotte et al. (<xref ref-type="bibr" rid="en-b59">59</xref>).</p>
               </fig>
               <sec id="en-s3.1.1" sec-type="Peritoneal cancer index">
                  <label>3.1.1</label>
                  <title>Peritoneal cancer index</title>
                  <p>Peritoneal cancer index (PCI) is a numerical value that serves as an estimate of the spread of disease in the abdominal and pelvic regions. To calculate the PCI score, it is necessary to evaluate the size of the change (<xref ref-type="bibr" rid="en-b3">3</xref>) in the abdominal and pelvic regions (indicated from 0 to 12). The calculation is made at the beginning of surgery. The higher the PCI score, the less effective will be the CRS and HIPEC treatment and thus less probable long-term survival. Therefore, there are recommended PCI scores up to which it is still reasonable to perform this therapeutic procedure (in pseudomixoma there is no upper limit, while in colorectal cancer the score should be ~ 15) (<xref ref-type="bibr" rid="en-b30">30</xref>).</p>
               </sec>
               <sec id="en-s3.1.2" sec-type="The completeness of cytoreductive surgery">
                  <label>3.1.2</label>
                  <title>The completeness of cytoreductive surgery</title>
                  <p>One of the key factors is a complete tumour removal at the time of CRS intervention. The PCI score significantly influences the outcome of treatment. <xref ref-type="table" rid="en-table1">Table 1</xref> shows individual scores. A score of CC-0 or CC-1 is generally required in order to achieve a better treatment outcome and a better quality of life with fewer complications (<xref ref-type="bibr" rid="en-b30">30</xref>).</p>
               </sec>
               <sec id="en-s3.1.3"
                    sec-type="TNM classification, peritoneal cytology, and clinical features of primary cancer">
                  <label>3.1.3</label>
                  <title>TNM classification, peritoneal cytology, and clinical features of primary cancer</title>
                  <p>A careful examination of the peritoneal surfaces at the primary GIT cancer resection, along with timely and high-quality histopathological analysis of the resected tissue may accurately predict the occurrence of peritoneal metastases after surgery. However, in advanced GIT cancers, peritoneal cytology also provides relevant predictive data (<xref ref-type="bibr" rid="en-b31">31</xref>,<xref ref-type="bibr" rid="en-b32">32</xref>). By accurately evaluating this information, the physician may decide to carry out proactive treatment with CRS and HIPEC. It has been demonstrated that in high-risk patients this way may prevent the onset of peritoneal metastases, and patients with already present metastases are treated by second-look approach (<xref ref-type="bibr" rid="en-b30">30</xref>,<xref ref-type="bibr" rid="en-b32">32</xref>).</p>
               </sec>
               <sec id="en-s3.1.4" sec-type="Pretreatment diagnostic imaging">
                  <label>3.1.4</label>
                  <title>Pretreatment diagnostic imaging</title>
                  <p>In selecting patients suitable for CRS and HIPEC, a CT scan of the chest, abdomen and pelvis is essential. The aim of <italic toggle="yes">diagnostic imaging </italic>is to evaluate the extent of the disease and to check for possible presence of metastases on the pleural surfaces. The site and amount of mucinous carcinoma in the peritoneal cavity can be determined accurately. On the contrary, non-mucinous peritoneal metastases are poorly recognisable on a CT scan, and are therefore often underdiagnosed. If the small intestine and its mesenterial part are covered by tumour or the tumour is situated behind the xiphoid bone, the possibility of CRS success is low. In this situation, CT should be performed with a maximum dose of the contrast medium applied intravenously or <italic toggle="yes">per os</italic>, to detect possible small-bowel involvement either in individual sites or diffuse (<xref ref-type="bibr" rid="en-b31">31</xref>-<xref ref-type="bibr" rid="en-b33">33</xref>).</p>
               </sec>
               <sec id="en-s3.1.5" sec-type="Learning curve">
                  <label>3.1.5</label>
                  <title>Learning curve</title>
                  <p>CRS with HIPEC is a complex procedure. It is interesting to note that, according to the study of Smeeka et al., a surgical oncologist has achieved an appropriate level of competence after 130 performed procedures. The key competence of training is the acquisition of surgical skills. However, patient-oriented therapeutic approaches and the entire team’s experience in managing complications also contribute to a lower mortality rate (<xref ref-type="bibr" rid="en-b34">34</xref>).</p>
               </sec>
            </sec>
         </sec>
         <sec id="en-s4" sec-type="Malignant ascites">
            <label>4</label>
            <title>Malignant ascites</title>
            <p>Malignant ascites is the accumulation of fluid in the peritoneal cavity due to advanced forms of cancer. It occurs as a result of lymph ducts’ blockage by tumour cells, increased permeability of blood vessels, hormonal causes and increased metalloproteinases activity. It is often associated with advanced stages of gynaecological, gastrointestinal and breast cancers. Predominant among the gynaecological cancers is ovarian cancer, while in the gastrointestinal tract the most prevalent are colorectal, pancreatic and gastric cancers. A retrospective study of the causes of malignant ascites has shown that it occurs most likely in ovarian cancer (37.7 %). Approximately 10 % of all ascites are malignant, and 20 % of patients with malignant ascites have tumours of unknown origin (<xref ref-type="bibr" rid="en-b35">35</xref>). Malignant ascites is a poor prognostic factor.</p>
            <sec id="en-s4.1" sec-type="Treatment">
               <label>4.1</label>
               <title>Treatment</title>
               <p>Ascites is treated primarily by primary tumour treatment, diuretics, paracentesis, biological agents and HIPEC, the latter being currently the most promising treatment modality. The type of cytostatic used in HIPEC depends on the primary tumour that caused malignant ascites. In ovarian cancer, the most appropriate agent is cisplatin (50 mg/ m<sup>2</sup>) or doxorubicin (15 mg/m<sup>2</sup>), in colorectal or gastric cancer it is mitomycin C (12.5 mg/m<sup>2</sup>), while in patients with other tumour types doxorubicin (12.5 mg/m<sup>2</sup>) is used. The study by Valle et al., which included 52 patients with malignant ascites, a total disappearance of ascites was reported in 94 %, and the average survival of patients was 98 days (range 21–796 days) (<xref ref-type="bibr" rid="en-b36">36</xref>).</p>
            </sec>
         </sec>
         <sec id="en-s5" sec-type="Appendiceal cancer">
            <label>5</label>
            <title>Appendiceal cancer</title>
            <p>In terms of its pathohistological features, appendiceal cancer can be classified as neuroendocrine or epithelial tumours. The cancer of epithelial origin can further be classified into individual subgroups: mucous hyperplasias, retention cysts, mucinous cystadenomas and adenocarcinomas (mucinous, intestinal, signet-ring cell). Mucinous neoplasms of the appendix are a heterogeneous group of tumours, classified with respect to their grade of malignancy into low- and high-grade histological subtypes. Conditions associated with appendiceal cancer dissemination can be divided into three groups: Disseminated peritoneal adenomucinosis (DPAM), peritoneal mucinous carcinomatosis (PMCA) and well differentiated PMCA (<xref ref-type="bibr" rid="en-b4">4</xref>,<xref ref-type="bibr" rid="en-b37">37</xref>). Another type of (appendiceal) cancer is goblet-cell carcinoma, which is a combination of adenocarcinoma and carcinoid. A special form is peritoneal pseudomyxoma (PMP), which originates from mucinous adenoma (<xref ref-type="bibr" rid="en-b37">37</xref>). It is characterised by a disperse accumulation of gelatinous material in the abdominal cavity and pelvis, and mucinous ingrowths on the peritoneal surface. As PMP grows, mucus begins to accumulate, leading to a burst and dissemination of the disease. Mucus starts to accumulate in the peritoneal cavity, leading to a characteristic “jelly belly” appearance and GIT obstruction. Due to incorrect denomination and simplification, in recent years the term has also been used for peritoneal dissemination of mucinous adenocarcinomas of the appendix, large and small intestine, lung, breast, pancreas, stomach, gallbladder, fallopian tubes and the ovaries. The nature of their dissemination renders PMP and adenocarcinoma most suitable for treatment with HIPEC (<xref ref-type="bibr" rid="en-b4">4</xref>).</p>
            <p>The pathohistological findings of metastases from the primary tumour largely influence the outcome of CRS and HIPEC treatment. Metastases containing more than 90 % of mucous, squamous epithelial cells, without atypia and mitoses, were predictive of a favourable outcome despite a high PCI score. Metastases with a high cell atypia, numerous mitoses and less than 50 % of mucous epithelial cells were associated with poor outcome (<xref ref-type="bibr" rid="en-b1">1</xref>). Patients with adenomucinosis have the best prognosis; the survival of patients with mucinous carcinoma is comparable to the survival of patients with peritoneal metastases from colorectal cancer. Although colorectal cancer and cancer of the appendix are similar, there are still significant differences between the two. The most relevant difference is in the diameter of the lumen of the affected organ. Colorectal cancer (CRCA) grows in the lumen and spreads outward through the wall, in its advanced stages spreading all the way to serosis. Because of the appedix’s small lumen, cancer invades the wall sooner and spreads tumour cells further into the abdominal cavity and the pelvic area (<xref ref-type="bibr" rid="en-b1">1</xref>,<xref ref-type="bibr" rid="en-b34">34</xref>).</p>
            <sec id="en-s5.1" sec-type="Treatment">
               <label>5.1</label>
               <title>Treatment</title>
               <p>The pioneer of such treatment approach was Sugarbaker who in 1987 reported on the first use of IPC after CRS in patients with PMP (<xref ref-type="bibr" rid="en-b4">4</xref>). In 2001, he reported on a 10-year follow up of 108 patients treated with CRS and HIPEC with mitomycin. The chemotherapeutic schedule included 5-fluorouracil (5-FU) from postoperative Days 1 to 6, followed by three cycles of adjuvant therapy with mitomycin (i.v.) and IPCT with 5-FU. The group of patients under study was very heterogeneous. In their study, the histology was of outstanding importance for patients survival, since the patients with DPAM had significantly better survival than patients in other groups, who had mucinous and intermediary cancers (<xref ref-type="bibr" rid="en-b38">38</xref>).</p>
               <p>A systematic review of patients with histologically verified DPAM who underwent CRS and HIPEC showed 70–86 % five-year survival and 60–68 % ten-year survival (<xref ref-type="bibr" rid="en-b39">39</xref>). In a multicentric study, the authors reported on 81 % 5-year and 70 % 10-year survival for patients with DPAM, 95 % 5-year and 49 % 10-year for patients with PMCA, and 78 % 5-year and 63 % 10-year survival for those with mixed type cancer. The average survival was 16.3 years. It has been proven that complete cytoreduction is the most important factor associated with longer survival (<xref ref-type="bibr" rid="en-b40">40</xref>). With CRS, a routine lymphadenectomy is not recommended (<xref ref-type="bibr" rid="en-b4">4</xref>).</p>
            </sec>
         </sec>
         <sec id="en-s6" sec-type="Colorectal cancer">
            <label>6</label>
            <title>Colorectal cancer</title>
            <p>Colorectal cancer (CRC) is the third most common cancer in men worldwide (746,000 cases per year) and the second most common in women (614,000 cases per year). In 2012, there were almost 1.4 million new patients detected. The predicted incidence in 2035 will be 2.4 million patients. Incidence rates are higher in the developed (737,000 cases) than in less developed countries (624,000 cases), while mortality is higher in less developed countries (<xref ref-type="bibr" rid="en-b42">42</xref>,<xref ref-type="bibr" rid="en-b43">43</xref>).</p>
            <p>The intestinal mucous membrane is covered with the glandular epithelium, and therefore the most common cancer in this region is adenocarcinoma (90–95 %). At the time of diagnosis, more than 60 % of patients present with locally or regionally advanced disease, while 15 % of patients already have distant metastases. CRC spreads by lymphogenous and haematogenous dissemination, most frequently into the liver, lung and bones (<xref ref-type="bibr" rid="en-b43">43</xref>).</p>
            <p>Following the liver, the peritoneum is the second most frequent metastatic site of CRC. Studies published in the past claim that the peritoneum is the only metastatic site in up to 25 % of cases. Recent studies report 10 %, whereas there are up to 20 % of patients who have metastases in the peritoneum as well as in some other organ (<xref ref-type="bibr" rid="en-b44">44</xref>). Advanced stage of the disease is associated with poor prognosis of the outcome. The average survival without treatment is up to 9 months (<xref ref-type="bibr" rid="en-b44">44</xref>). Unfortunately, in stage IV, the disease advances in 50 % of patients, despite R0 resection (<xref ref-type="bibr" rid="en-b1">1</xref>). In 10–35 % of these patients the disease recurs in the peritoneum. With modern SCTs, which comprise oxaliplatin and irinotecan with the addition of 5-FU and targeted drugs, such as bevacizumab and cetuximab, the average survival of patients with stage IV of the disease may be extended for more than 15 months (<xref ref-type="bibr" rid="en-b42">42</xref>). The quality of life is often worsened by accompanying ascites and frequent bowel obstruction. At the time of diagnosis, for three quarters of patients with PC (due to CRC) the only option is palliative systemic chemotherapy. The remaining quarter of patients without distant metastases and tumour limited to the peritoneum are eligible for treatment with CRS in combination with HIPEC (<xref ref-type="bibr" rid="en-b31">31</xref>).</p>
            <sec id="en-s6.1" sec-type="Treatment">
               <label>6.1</label>
               <title>Treatment</title>
               <p>In the treatment of CRC surgery plays the central role. Adjuvant therapy, however, differs in both types. The standard treatment of locally or regionally advanced CRC is radiotherapy or radiochemotherapy with 5-FU in a continuous infusion, or with capecitabine prior to surgery. With modern combinations of oxaliplatin and irinotecan with the addition of 5-FU and target substances, such as bevacizumab and cetuximab, the average survival of patients with stage IV of the disease is currently from 7 to more than 24 months (<xref ref-type="bibr" rid="en-b1">1</xref>). In the case that metastases are limited to the peritoneum and provided that the aforementioned conditions are met, treatment with CRS and HIPEC is feasible.</p>
               <p>A relative contraindication for CRS and HIPEC is poorly differentiated primary tumour. With inclusion of patients with well and moderately differentiated tumours, the survival is significantly better. Currently, two HIPEC protocols are used in the treatment of these patients. By the first protocol, the treatment is carried out with mitomycin C, heated to 41 °C, for 60–90 minutes, using closed technique. By the second protocol, oxsaliplatin is administered (460 mg/m<sup>2</sup> of oxaliplatin in 2 L/ m<sup>2</sup> of 5 % isoosmotic dextrose) for 30 minutes (precisely, 30 min. from the moment when the minimum temperature of 42 °C is reached in the abdominal cavity, plus 5–8 min. before the infusion is heated from 38 °C to 42 °C, i.e. to 43 °C (range 42–44 °C), using open technique (<xref ref-type="bibr" rid="en-b11">11</xref>). Two-way systemic and intraperitoneal chemotherapy during surgery, combining intraperitoneal oxsaliplatin and i.v. infusion of 5-FU (400 mg/m<sup>2</sup>) with leucovorin (20 mg/m<sup>2</sup>), is primarily used for PC from CRC. Mitomycin has an advantage due to its high molecular weight, good tissue perfusion (up to 5 mm) and a favourable pharmacokinetic profile that allows increased intraperitoneal concentration without causing severe side effects. According to literature reports, the efficacy of both cytostatics in the aforementioned regimen is comparable. Nevertheless, some researchers are in favour of oxaliplatin because it does not cause neutropenia and has a shorter perfusion time (30 min vs. 90 min) as compared to mitomycin-C (<xref ref-type="bibr" rid="en-b11">11</xref>,<xref ref-type="bibr" rid="en-b28">28</xref>).</p>
               <p>A randomised study of 105 patients compared two groups of patients who had either CRS + HIPEC + SCT or only SCT performed. Despite the inclusion problems, the study reported a 22-month average survival rate for the first group and 13 months for the second group (<xref ref-type="bibr" rid="en-b45">45</xref>). After 8 years, the survival rate was the same (<xref ref-type="bibr" rid="en-b46">46</xref>). In another study, Association Francaise de Chirurgie reported on a 30 % 5-year survival rate, which was among the lowest reported in the literature (<xref ref-type="bibr" rid="en-b47">47</xref>). The centres that frequently practice such approaches reported on around 40 % 5-year survival rate. Glehen et al. published their results of using HIPEC and EPIC approach in patients with this disease. Their study included 506 patients from 28 institutions; HIPEC (54 %), EPIC (24 %) and combination (22 %). Patients with CCR0 (complete resection) survived 1, 3 and 5 years in 87 %, 47 % and 31 % respectively; their average survival was 32.4 months. The overall survival rate (OS) was 72 %, 39 % and 19 % for 1-, 3- and 5-year intervals, respectively. The median overall survival was 19.2 months (<xref ref-type="bibr" rid="en-b48">48</xref>). In their study, Elias et al. compared HIPEC and EPIC approaches. The study included 523 patients, but possible differences in their survival unfortunately were not reported (<xref ref-type="bibr" rid="en-b47">47</xref>).</p>
               <p>Some studies report high mortality and morbidity rates associated with CRS and HIPEC in CRC (<xref ref-type="bibr" rid="en-b7">7</xref>,<xref ref-type="bibr" rid="en-b28">28</xref>,<xref ref-type="bibr" rid="en-b49">49</xref>). In 2014, Sugarbaker presented surgery results in patients with metastases from CRC, in whom the mortality rate was 0.6 % and the occurrence of IV degree side effects was 12 %. He concluded that, for selected patients, the combined CRS and HIPEC treatment was the best therapeutic option (<xref ref-type="bibr" rid="en-b7">7</xref>). He also believed that currently there is no evidence to suggest that patients with CRC limited to the peritoneal surface should be treated exclusively by SCT (<xref ref-type="bibr" rid="en-b7">7</xref>). Further to this conclusion, it should be pointed out that in the same year, Sugarbaker emphasised in another article that advances in the development of systemic drugs resulted in the improvement of patients’ condition, and taking into account the progress in CT (oxaliplatin, irinotecan, biological drugs), CRS and HIPEC need not be necessary the best therapeutic choice, but nevertheless, these methods still have their place in the treatment of selected patients (<xref ref-type="bibr" rid="en-b31">31</xref>). He underlined that in any case the patient should be offered a multidisciplinary approach with a range of different treatment options.</p>
            </sec>
         </sec>
         <sec id="en-s7" sec-type="Gastric cancer">
            <label>7</label>
            <title>Gastric cancer</title>
            <p>The outcome of gastric cancer with peritoneal metastases is among the worst ones, with the average survival ranging between 3 to 7 months and a 0 % five-year survival rate (<xref ref-type="bibr" rid="en-b50">50</xref>). Although adjuvant CT, neoadjuvant CT and adjuvant CRT have proven to be useful and provided minimal improvement in patients’ survival, none of these treatment modalities have significantly contributed to reducing the number of recurrences. Patients with gastric cancer (GC) and peritoneal metastases have significantly worse response to chemotherapy. The average survival of patients with SC and PC after treatment is 9.5–12 months. Due to the complexity of treatment and unsatisfactory CT results, interest in HIPEC with CRS has increased (<xref ref-type="bibr" rid="en-b50">50</xref>).</p>
            <p>In the past, some disapproved of the procedure due to a high mortality and morbidity rate. According to the available data, the mortality rate for patients with GC is probably around 3.6–6.5 % (<xref ref-type="bibr" rid="en-b18">18</xref>). Compared to ovarian cancer, mortality is slightly higher due to gastrectomy, because less visceral resections on average are done in ovarian cancer. The main postoperative complications include neutropenia, GIT fistulae, pneumonia, haemorrhage, abdominal abscess, sepsis, wound infection and kidney failure (<xref ref-type="bibr" rid="en-b18">18</xref>).</p>
            <p>There are three potential possibilities of HIPEC use in the treatment of GC: 1) prophylactic – to prevent recurrence after curative gastrectomy in high-risk patients; 2) therapeutic – in patients with PC after CRS, and 3) palliative – in patients with poorly controlled ascites due to severe PC spread that is not suitable for CRS (<xref ref-type="bibr" rid="en-b18">18</xref>). In a prospective study with more than 1,000 patients with adenocarcinoma of the stomach, who later developed metachronous PC, the average survival despite the primary R0 D2 resection was only 3 months. Although a standard systemic therapy in patients with GC and PC extended this period to 7–10 months, GC’s response to SCT is poor (<xref ref-type="bibr" rid="en-b4">4</xref>). In another study, in selected patients, this period was prolonged using CRS and HIPEC method to an average of 9.2 months, and the five-year survival rate was 13 % (<xref ref-type="bibr" rid="en-b51">51</xref>). In a prospective randomised study, systemic chemotherapy was compared with CRS and HIPEC. The systemic chemotherapy was performed according to FOLIFOXIRI schedule (irinotecan, leucovorin, oxaliplatin and 5-FU), the application regimen being irinotecan 165 mg/m<sup>2</sup> for 90 min, followed by leucovorin 200 mg/m<sup>2</sup> and oxaliplatin 85 mg/m<sup>2</sup> for 2 hrs on Day 1, together with a continuous infusion of 5-FU 3,200 mg/m<sup>2</sup> for 48 hrs. After gastrectomy and the removal of liver and lung metastases, the second group of patients underwent CRS and HIPEC (oxaliplatin 460 mg/m<sup>2</sup> at 41°C for 30 min). After 8 months, the second group also started receiving CT according to FOLFOXIRI schedule. Patients in the first group had an average survival of 4.3 months, while those in the second group survived 11.3 months (<xref ref-type="bibr" rid="en-b52">52</xref>).</p>
            <p>It is interesting to note that they also described the strategy of neoadjuvant IP and SCT (NIPS), CRS and HIPEC, and IP CT (EPIC) after surgery. The basic idea was to reduce the tumour burden preoperatively and at the same time use NIPS as a form of chemotherapy that exerts therapeutic effects on peritoneal disease and subperitoneally in the vascular system, in patients with positive peritoneal cytology. This treatment is followed by CRS and HIPEC. The dosage regimen of NIPS was 60 mg/m<sup>2</sup> 
               <italic toggle="yes">per os</italic> S-1 for 21 days followed by one week pause. On Days 1, 8 and 15 they receive taxoter 30 mg/m<sup>2</sup> and CIS 30 mg/m<sup>2</sup> in 500 mL of normal saline (<xref ref-type="bibr" rid="en-b53">53</xref>).</p>
         </sec>
         <sec id="en-s8" sec-type="Ovarian cancer">
            <label>8</label>
            <title>Ovarian cancer</title>
            <p>Ovarian cancer is one of the leading causes of death in women with malignant disease. The incidence rate in Slovenia for 2011 is 14.8 per 100.000 population. Ovarian cancer (OC) represents the seventh most frequent cancer in women. According to the data for 2012, 239 women are diagnosed with OC annually, most of them at an age between 55 and 65 years. The most frequent OC type is malignant epithelial tumour of serous adenocarcinoma subtype (40–45 %), followed by endometroid subtype. Generally it is diagnosed in FIGO III and IV stage, when there are peritoneal metastases already present in 75 % of cases. The standard treatment is CRS and a systemic chemotherapy, which, however, cannot prevent recurrence of the disease in 75 % of patients (<xref ref-type="bibr" rid="en-b54">54</xref>). Recurrent ovarian cancer is the term that applies to a recurrence of the disease after completed therapy; platinum-resistant OC appears within 6 months, while the recurrence of platinum-sensitive type takes longer than 6 months.</p>
            <sec id="en-s8.1" sec-type="Treatment">
               <label>8.1</label>
               <title>Treatment</title>
               <p>In these patients, CRS and HIPEC proved to be an effective treatment method. The optimum regimen of treatment has not yet been defined. Cisplatin, oxaliplatin, mitomycin and doxorubicin were used in various studies. In one of the studies, the protocol with cisplatin 70 mg/m<sup>2</sup> and 1-hour duration of HIPEC at 42 °C was confirmed as most appropriate (<xref ref-type="bibr" rid="en-b28">28</xref>). Recently, the first randomised study that investigated HIPEC for the treatment of ovarian cancer was published. The clinical study included 120 patients with recurrent disease, who were initially treated by CRS and systemic chemotherapy. Those patients who were treated with HIPEC in addition to CRS and systemic chemotherapy had a significantly better median survival than others (26.7 months vs. 13.4 months, p &lt; 0.006). The survival was better in patients with platinum-sensitive as well as in those with platinum-resistant ovarian cancer (<xref ref-type="bibr" rid="en-b55">55</xref>).</p>
            </sec>
         </sec>
         <sec id="en-s9" sec-type="Mesothelioma">
            <label>9</label>
            <title>Mesothelioma</title>
            <p>The term mesothelioma covers a group of malignant tumours that arise from serous membranes (pleura, peritoneum, pericardium, tunica vaginalis testis). Diffuse malignant peritoneal mesothelioma (DMPM) is a locally aggressive primary malignant tumour of the serous peritoneal surface. It represents 7–10 % of all diagnosed mesotheliomas.</p>
            <sec id="en-s9.1" sec-type="Treatment">
               <label>9.1</label>
               <title>Treatment</title>
               <p>Patients, treated by palliative surgery either with or without chemotherapy survived on average one year. Advances in the area of treatment have led to the combination of CRS and HIPEC, which is currently considered to be the most appropriate therapy. In a study comparing cisplatin and carboplatin for the implementation of HIPEC, a longer average survival was observed in patients treated with carboplatin (<xref ref-type="bibr" rid="en-b56">56</xref>). In the study that included 240 patients with DMPM treated with a combination of CRS and HIPEC, the median survival was 53 months, while 3-year survival rate was 60 % and 5-year survival rate 47 % (<xref ref-type="bibr" rid="en-b57">57</xref>).</p>
               <p>Deraco proposed a new system of staging for patients with DMPM, based exclusively on the determination of PCI: Stage I (up to 10), stage II (<xref ref-type="bibr" rid="en-b11">11</xref>-<xref ref-type="bibr" rid="en-b20">20</xref>), stage III (<xref ref-type="bibr" rid="en-b21">21</xref>-<xref ref-type="bibr" rid="en-b30">30</xref>) and stage IV (&gt; 30). Patients with stage III or IV are not eligible for CRS with HIPEC. Five-year survival for stages I, II and III is 87 %, 53 % and 29 %, respectively (<xref ref-type="bibr" rid="en-b58">58</xref>).</p>
            </sec>
         </sec>
         <sec id="en-s10" sec-type="Conclusion">
            <label>10</label>
            <title>Conclusion</title>
            <p>The combination of CRS and HIPEC is one of the most effective options for the treatment of peritoneal metastases originating from different tumours. In the article we presented individual approaches to certain types of cancer. The most important prognostic factors for the success of this treatment approach are cancer type, stage of the disease, and the possibility of complete cytoreduction. Since this is a high-risk procedure, the appropriate selection of patients is also of key importance. It is recommended that this type of treatment be carried out in centres with properly trained and experienced staff.</p>
            <p>Several research studies are needed in this area of oncology, before recommendations for the treatment of individual tumour types, the choice of the most effective drugs and the regimen of its application in HIPEC would be finally adopted. But even at present time, it can already be concluded that in several multinational studies, CRS and HIPEC treatment has been shown to increase the survival of selected patients, while their perioperative or immediate postoperative mortality is comparable with mortality rates in other major surgical procedures in the abdominal cavity.</p>
         </sec>
      </body>
      <back>
         <ref-list>
            <ref id="en-b1">
               <mixed-citation publication-type="unknown" specific-use="parsed">
                  <person-group person-group-type="author">
                     <collab>VIRI IN LITERATURA</collab>
                  </person-group>
               </mixed-citation>
            </ref>
            <ref id="en-b2">
               <label>1. </label>
               <mixed-citation publication-type="book-chapter" specific-use="restruct">
                  <person-group person-group-type="author">
                     <string-name name-style="western">
                        <surname>DeVita</surname> 
                        <given-names>VT</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Lawrence</surname> 
                        <given-names>TS</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Rosenberg</surname> 
                        <given-names>SA</given-names>
                     </string-name>
                  </person-group>. <chapter-title>Peritoneal Metastases and Peritoneal Mesothelioma</chapter-title>. In: <person-group person-group-type="editor">
                     <string-name name-style="western">
                        <surname>Deraco</surname> 
                        <given-names>M</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Elias</surname> 
                        <given-names>DM</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Glehen</surname> 
                        <given-names>O</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Helm</surname> 
                        <given-names>CW</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Sugarbaker</surname> 
                        <given-names>PH</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Verwaal</surname> 
                        <given-names>VJ</given-names>
                     </string-name>, <role>editors</role>
                  </person-group>. <source>DeVita, Hellman, and Rosenberg’s cancer: principles &amp; practice of oncology</source>. <edition>10th ed.</edition> 
                  <year>2015</year>. p. <fpage>2234</fpage>. [<comment>Internet</comment>], Available from <ext-link ext-link-type="uri"
                            xlink:href="https://www.lww.co.uk/devita-hellman-and-rosenbergs-cancer-principles-practice-of-oncology-10-edition">https://www.lww.co.uk/devita-hellman-and-rosenbergs-cancer-principles-practice-of-oncology-10-edition</ext-link>
                  <annotation>
                     <p content-type="warning">Could not find a publisher location in this book chapter reference. (Ref. 1 "DeVita, Lawrence, Rosenberg, 2015")</p>
                     <p content-type="warning">Could not find a publisher name in this book chapter reference. (Ref. 1 "DeVita, Lawrence, Rosenberg, 2015")</p>
                  </annotation>
               </mixed-citation>
            </ref>
            <ref id="en-b3">
               <label>2.	</label>
               <mixed-citation publication-type="journal" specific-use="restruct">
                  <person-group person-group-type="author">
                     <string-name name-style="western">
                        <surname>Lambert</surname> 
                        <given-names>LA</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Harris</surname> 
                        <given-names>A</given-names>
                     </string-name>
                  </person-group>. <article-title>Palliative cytoreductive surgery and hyperthermic intraperitoneal chemoperfusion: current clinical practice or misnomer?</article-title> 
                  <source>J Gastrointest Oncol</source>. <year>2016</year> 
                  <month>Feb</month>;<volume>7</volume>(<issue>1</issue>):<fpage>112</fpage>–<lpage>21</lpage>.<pub-id pub-id-type="pmid">26941989</pub-id>
                  <issn>2078-6891</issn>
               </mixed-citation>
            </ref>
            <ref id="en-b4">
               <label>3.	</label>
               <mixed-citation publication-type="journal" specific-use="restruct">
                  <person-group person-group-type="author">
                     <string-name name-style="western">
                        <surname>Canbay</surname> 
                        <given-names>E</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Yonemura</surname> 
                        <given-names>Y</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Brucher</surname> 
                        <given-names>B</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Baik</surname> 
                        <given-names>SH</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Sugarbaker</surname> 
                        <given-names>PH</given-names>
                     </string-name>
                  </person-group>. <article-title>Intraperitoneal chemotherapy and its evolving role in management of gastric cancer with peritoneal metastases</article-title>. <source>Chin J Cancer Res</source>. <year>2014</year> 
                  <month>Feb</month>;<volume>26</volume>(<issue>1</issue>):<fpage>1</fpage>–<lpage>3</lpage>.<pub-id pub-id-type="pmid">24653620</pub-id>
                  <issn>1000-9604</issn>
               </mixed-citation>
            </ref>
            <ref id="en-b5">
               <label>4.	</label>
               <mixed-citation publication-type="journal" specific-use="restruct">
                  <person-group person-group-type="author">
                     <string-name name-style="western">
                        <surname>Dehal</surname> 
                        <given-names>A</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Smith</surname> 
                        <given-names>JJ</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Nash</surname> 
                        <given-names>GM</given-names>
                     </string-name>
                  </person-group>. <article-title>Cytoreductive surgery and intraperitoneal chemotherapy: an evidence-based review-past, present and future</article-title>. <source>J Gastrointest Oncol</source>. <year>2016</year> 
                  <month>Feb</month>;<volume>7</volume>(<issue>1</issue>):<fpage>143</fpage>–<lpage>57</lpage>.<pub-id pub-id-type="pmid">26941992</pub-id>
                  <issn>2078-6891</issn>
               </mixed-citation>
            </ref>
            <ref id="en-b6">
               <label>5.	</label>
               <mixed-citation publication-type="journal" specific-use="restruct">
                  <person-group person-group-type="author">
                     <string-name name-style="western">
                        <surname>Arjona-Sánchez</surname> 
                        <given-names>A</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Medina-Fernández</surname> 
                        <given-names>FJ</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Muñoz-Casares</surname> 
                        <given-names>FC</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Casado-Adam</surname> 
                        <given-names>A</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Sánchez-Hidalgo</surname> 
                        <given-names>JM</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Rufián-Peña</surname> 
                        <given-names>S</given-names>
                     </string-name>
                  </person-group>. <article-title>Peritoneal metastases of colorectal origin treated by cytoreduction and HIPEC: an overview</article-title>. <source>World J Gastrointest Oncol</source>. <year>2014</year> 
                  <month>Oct</month>;<volume>6</volume>(<issue>10</issue>):<fpage>407</fpage>–<lpage>12</lpage>. <pub-id pub-id-type="doi">10.4251/wjgo.v6.i10.407</pub-id>
                  <pub-id pub-id-type="pmid">25320657</pub-id>
                  <issn>1948-5204</issn>
               </mixed-citation>
            </ref>
            <ref id="en-b7">
               <label>6.	</label>
               <mixed-citation publication-type="journal" specific-use="restruct">
                  <person-group person-group-type="author">
                     <string-name name-style="western">
                        <surname>Brücher</surname> 
                        <given-names>BL</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Piso</surname> 
                        <given-names>P</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Verwaal</surname> 
                        <given-names>V</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Esquivel</surname> 
                        <given-names>J</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Derraco</surname> 
                        <given-names>M</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Yonemura</surname> 
                        <given-names>Y</given-names>
                     </string-name>, <etal>et al.</etal>
                  </person-group> 
                  <article-title>Peritoneal carcinomatosis: cytoreductive surgery and HIPEC—overview and basics</article-title>. <source>Cancer Invest</source>. <year>2012</year> 
                  <month>Mar</month>;<volume>30</volume>(<issue>3</issue>):<fpage>209</fpage>–<lpage>24</lpage>. <pub-id pub-id-type="doi">10.3109/07357907.2012.654871</pub-id>
                  <pub-id pub-id-type="pmid">22360361</pub-id>
                  <issn>0735-7907</issn>
               </mixed-citation>
            </ref>
            <ref id="en-b8">
               <label>7.	</label>
               <mixed-citation publication-type="journal" specific-use="restruct">
                  <person-group person-group-type="author">
                     <string-name name-style="western">
                        <surname>Poskus</surname> 
                        <given-names>E</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Strupas</surname> 
                        <given-names>K</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Gushchin</surname> 
                        <given-names>V</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Sugarbaker</surname> 
                        <given-names>PH</given-names>
                     </string-name>
                  </person-group>. <article-title>Cytoreductive Surgery and HIPEC in the Baltic States: An International Scientific Workshop with Live Surgery</article-title>. <source>Viszeralmedizin</source>. <year>2014</year> 
                  <month>Oct</month>;<volume>30</volume>(<issue>5</issue>):<fpage>353</fpage>–<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1159/000368685</pub-id>
                  <pub-id pub-id-type="pmid">26535046</pub-id>
                  <issn>1662-6664</issn>
               </mixed-citation>
            </ref>
            <ref id="en-b9">
               <label>8.	</label>
               <mixed-citation publication-type="journal" specific-use="restruct">
                  <person-group person-group-type="author">
                     <string-name name-style="western">
                        <surname>Sugarbaker</surname> 
                        <given-names>PH</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Van der Speeten</surname> 
                        <given-names>K</given-names>
                     </string-name>
                  </person-group>. <article-title>Surgical technology and pharmacology of hyperthermic perioperative chemotherapy</article-title>. <source>J Gastrointest Oncol</source>. <year>2016</year> 
                  <month>Feb</month>;<volume>7</volume>(<issue>1</issue>):<fpage>29</fpage>–<lpage>44</lpage>.<pub-id pub-id-type="pmid">26941982</pub-id>
                  <issn>2078-6891</issn>
               </mixed-citation>
            </ref>
            <ref id="en-b10">
               <label>9.	</label>
               <mixed-citation publication-type="journal" specific-use="restruct">
                  <person-group person-group-type="author">
                     <string-name name-style="western">
                        <surname>Carmignani</surname> 
                        <given-names>CP</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Sugarbaker</surname> 
                        <given-names>TA</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Bromley</surname> 
                        <given-names>CM</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Sugarbaker</surname> 
                        <given-names>PH</given-names>
                     </string-name>
                  </person-group>. <article-title>Intraperitoneal cancer dissemination: mechanisms of the patterns of spread</article-title>. <source>Cancer Metastasis Rev</source>. <year>2003</year> 
                  <month>Dec</month>;<volume>22</volume>(<issue>4</issue>):<fpage>465</fpage>–<lpage>72</lpage>. <pub-id pub-id-type="doi">10.1023/A:1023791229361</pub-id>
                  <pub-id pub-id-type="pmid">12884919</pub-id>
                  <issn>0167-7659</issn>
               </mixed-citation>
            </ref>
            <ref id="en-b11">
               <label>10.	</label>
               <mixed-citation publication-type="journal" specific-use="restruct">
                  <person-group person-group-type="author">
                     <string-name name-style="western">
                        <surname>Dubé</surname> 
                        <given-names>P</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Sideris</surname> 
                        <given-names>L</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Law</surname> 
                        <given-names>C</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Mack</surname> 
                        <given-names>L</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Haase</surname> 
                        <given-names>E</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Giacomantonio</surname> 
                        <given-names>C</given-names>
                     </string-name>, <etal>et al.</etal>
                  </person-group> 
                  <article-title>Guidelines on the use of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in patients with peritoneal surface malignancy arising from colorectal or appendiceal neoplasms</article-title>. <source>Curr Oncol</source>. <year>2015</year> 
                  <month>Apr</month>;<volume>22</volume>(<issue>2</issue>):<fpage>e100</fpage>–<lpage>12</lpage>. <pub-id pub-id-type="doi">10.3747/co.22.2058</pub-id>
                  <pub-id pub-id-type="pmid">25908915</pub-id>
                  <issn>1198-0052</issn>
               </mixed-citation>
            </ref>
            <ref id="en-b12">
               <label>11.	</label>
               <mixed-citation publication-type="journal" specific-use="restruct">
                  <person-group person-group-type="author">
                     <string-name name-style="western">
                        <surname>Bhatt</surname> 
                        <given-names>A</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Goéré</surname> 
                        <given-names>D</given-names>
                     </string-name>
                  </person-group>. <article-title>Cytoreductive Surgery plus HIPEC for Peritoneal Metastases from Colorectal Cancer</article-title>. <source>Indian J Surg Oncol</source>. <year>2016</year> 
                  <month>Jun</month>;<volume>7</volume>(<issue>2</issue>):<fpage>177</fpage>–<lpage>87</lpage>. <pub-id pub-id-type="doi">10.1007/s13193-016-0499-z</pub-id>
                  <pub-id pub-id-type="pmid">27065708</pub-id>
                  <issn>0975-7651</issn>
               </mixed-citation>
            </ref>
            <ref id="en-b13">
               <label>12.	</label>
               <mixed-citation publication-type="journal" specific-use="restruct">
                  <person-group person-group-type="author">
                     <string-name name-style="western">
                        <surname>Seshadri</surname> 
                        <given-names>RA</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Glehen</surname> 
                        <given-names>O</given-names>
                     </string-name>
                  </person-group>. <article-title>The Role of Hyperthermic Intraperitoneal Chemotherapy in Gastric Cancer</article-title>. <source>Indian J Surg Oncol</source>. <year>2016</year> 
                  <month>Jun</month>;<volume>7</volume>(<issue>2</issue>):<fpage>198</fpage>–<lpage>207</lpage>. <pub-id pub-id-type="doi">10.1007/s13193-016-0502-8</pub-id>
                  <pub-id pub-id-type="pmid">27065710</pub-id>
                  <issn>0975-7651</issn>
               </mixed-citation>
            </ref>
            <ref id="en-b14">
               <label>13.	</label>
               <mixed-citation publication-type="journal" specific-use="restruct">
                  <person-group person-group-type="author">
                     <string-name name-style="western">
                        <surname>Hayes-Jordan</surname> 
                        <given-names>A</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Green</surname> 
                        <given-names>H</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Prieto</surname> 
                        <given-names>V</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Wolff</surname> 
                        <given-names>JE</given-names>
                     </string-name>
                  </person-group>. <article-title>Unusual cases: melanomatosis and nephroblastomatosis treated with hyperthermic intraperitoneal chemotherapy</article-title>. <source>J Pediatr Surg</source>. <year>2012</year> 
                  <month>Apr</month>;<volume>47</volume>(<issue>4</issue>):<fpage>782</fpage>–<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1016/j.jpedsurg.2011.12.018</pub-id>
                  <pub-id pub-id-type="pmid">22498396</pub-id>
                  <issn>0022-3468</issn>
               </mixed-citation>
            </ref>
            <ref id="en-b15">
               <label>14.	</label>
               <mixed-citation publication-type="journal" specific-use="restruct">
                  <person-group person-group-type="author">
                     <string-name name-style="western">
                        <surname>Cardi</surname> 
                        <given-names>M</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Sammartino</surname> 
                        <given-names>P</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Framarino</surname> 
                        <given-names>ML</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Biacchi</surname> 
                        <given-names>D</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Cortesi</surname> 
                        <given-names>E</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Sibio</surname> 
                        <given-names>S</given-names>
                     </string-name>, <etal>et al.</etal>
                  </person-group> 
                  <article-title>Treatment of peritoneal carcinomatosis from breast cancer by maximal cytoreduction and HIPEC: a preliminary report on 5 cases</article-title>. <source>Breast</source>. <year>2013</year> 
                  <month>Oct</month>;<volume>22</volume>(<issue>5</issue>):<fpage>845</fpage>–<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1016/j.breast.2013.02.020</pub-id>
                  <pub-id pub-id-type="pmid">23523180</pub-id>
                  <issn>0960-9776</issn>
               </mixed-citation>
            </ref>
            <ref id="en-b16">
               <label>15.	</label>
               <mixed-citation publication-type="journal" specific-use="restruct">
                  <person-group person-group-type="author">
                     <string-name name-style="western">
                        <surname>Honore</surname> 
                        <given-names>C</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Goere</surname> 
                        <given-names>D</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Dartigues</surname> 
                        <given-names>P</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Burtin</surname> 
                        <given-names>P</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Dumont</surname> 
                        <given-names>F</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Elias</surname> 
                        <given-names>D</given-names>
                     </string-name>
                  </person-group>. <article-title>Peritoneal carcinomatosis from solid pseudopapillary neoplasm (Frantz’s tumour) of the pancreas treated with HIPEC</article-title>. <source>Anticancer Res</source>. <year>2012</year> 
                  <month>Mar</month>;<volume>32</volume>(<issue>3</issue>):<fpage>1069</fpage>–<lpage>73</lpage>.<pub-id pub-id-type="pmid">22399634</pub-id>
                  <issn>1791-7530</issn>
               </mixed-citation>
            </ref>
            <ref id="en-b17">
               <label>16.	</label>
               <mixed-citation publication-type="journal" specific-use="restruct">
                  <person-group person-group-type="author">
                     <string-name name-style="western">
                        <surname>Salti</surname> 
                        <given-names>GI</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Ailabouni</surname> 
                        <given-names>L</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Undevia</surname> 
                        <given-names>S</given-names>
                     </string-name>
                  </person-group>. <article-title>Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for the treatment of peritoneal sarcomatosis</article-title>. <source>Ann Surg Oncol</source>. <year>2012</year> 
                  <month>May</month>;<volume>19</volume>(<issue>5</issue>):<fpage>1410</fpage>–<lpage>5</lpage>. <pub-id pub-id-type="doi">10.1245/s10434-012-2240-7</pub-id>
                  <pub-id pub-id-type="pmid">22302269</pub-id>
                  <issn>1068-9265</issn>
               </mixed-citation>
            </ref>
            <ref id="en-b18">
               <label>17.	</label>
               <mixed-citation publication-type="journal" specific-use="restruct">
                  <person-group person-group-type="author">
                     <string-name name-style="western">
                        <surname>Randle</surname> 
                        <given-names>RW</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Swett</surname> 
                        <given-names>KR</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Shen</surname> 
                        <given-names>P</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Stewart</surname> 
                        <given-names>JH</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Levine</surname> 
                        <given-names>EA</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Votanopoulos</surname> 
                        <given-names>KI</given-names>
                     </string-name>
                  </person-group>. <article-title>Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy in peritoneal sarcomatosis</article-title>. <source>Am Surg</source>. <year>2013</year> 
                  <month>Jun</month>;<volume>79</volume>(<issue>6</issue>):<fpage>620</fpage>–<lpage>4</lpage>.<pub-id pub-id-type="pmid">23711273</pub-id>
                  <issn>1555-9823</issn>
               </mixed-citation>
            </ref>
            <ref id="en-b19">
               <label>18.	</label>
               <mixed-citation publication-type="journal" specific-use="restruct">
                  <person-group person-group-type="author">
                     <string-name name-style="western">
                        <surname>Beeharry</surname> 
                        <given-names>MK</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Liu</surname> 
                        <given-names>WT</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Yao</surname> 
                        <given-names>XX</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Yan</surname> 
                        <given-names>M</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Zhu</surname> 
                        <given-names>ZG</given-names>
                     </string-name>
                  </person-group>. <article-title>A critical analysis of the cytoreductive surgery with hyperthermic intraperitoneal chemotherapy combo in the clinical management of advanced gastric cancer: an effective multimodality approach with scope for improvement</article-title>. <source>Transl Gastroenterol Hepatol</source>. <year>2016</year> 
                  <month>Oct</month>;<volume>1</volume>:<fpage>77</fpage>. <pub-id pub-id-type="doi">10.21037/tgh.2016.08.05</pub-id>
                  <pub-id pub-id-type="pmid">28138643</pub-id>
                  <issn>2415-1289</issn>
                  <annotation>
                     <p content-type="warning">Edifix has not found an issue number in the journal reference. Please check the volume/issue information. (Ref. 18 "Beeharry, Liu, Yao, Yan, Zhu, 2016")</p>
                  </annotation>
               </mixed-citation>
            </ref>
            <ref id="en-b20">
               <label>19.    </label>
               <mixed-citation publication-type="unknown" specific-use="unparsed">H. Sugarbaker P. Pseudomyxoma peritonei and peritoneal metastases from appendiceal malignancy. In: H. Sugarbaker P, ed. Cytoreductive Surgery &amp; Perioperative Chemotherapy for Peritoneal Surface Malignancy. Woodbury: Cine-Med Publishing; <year>2012</year>. p. 57–78.</mixed-citation>
            </ref>
            <ref id="en-b21">
               <label>20.	</label>
               <mixed-citation publication-type="journal" specific-use="restruct">
                  <person-group person-group-type="author">
                     <string-name name-style="western">
                        <surname>Glehen</surname> 
                        <given-names>O</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Gilly</surname> 
                        <given-names>FN</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Boutitie</surname> 
                        <given-names>F</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Bereder</surname> 
                        <given-names>JM</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Quenet</surname> 
                        <given-names>F</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Sideris</surname> 
                        <given-names>L</given-names>
                     </string-name>, <etal>et al.</etal>; <collab>French Surgical Association</collab>
                  </person-group>. <article-title>Toward curative treatment of peritoneal carcinomatosis from nonovarian origin by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy: a multi-institutional study of 1,290 patients</article-title>. <source>Cancer</source>. <year>2010</year> 
                  <month>Dec</month>;<volume>116</volume>(<issue>24</issue>):<fpage>5608</fpage>–<lpage>18</lpage>. <pub-id pub-id-type="doi">10.1002/cncr.25356</pub-id>
                  <pub-id pub-id-type="pmid">20737573</pub-id>
                  <issn>0008-543X</issn>
               </mixed-citation>
            </ref>
            <ref id="en-b22">
               <label>21.	</label>
               <mixed-citation publication-type="journal" specific-use="restruct">
                  <person-group person-group-type="author">
                     <string-name name-style="western">
                        <surname>Elias</surname> 
                        <given-names>D</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Goéré</surname> 
                        <given-names>D</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Dumont</surname> 
                        <given-names>F</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Honoré</surname> 
                        <given-names>C</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Dartigues</surname> 
                        <given-names>P</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Stoclin</surname> 
                        <given-names>A</given-names>
                     </string-name>, <etal>et al.</etal>
                  </person-group> 
                  <article-title>Role of hyperthermic intraoperative peritoneal chemotherapy in the management of peritoneal metastases</article-title>. <source>Eur J Cancer</source>. <year>2014</year> 
                  <month>Jan</month>;<volume>50</volume>(<issue>2</issue>):<fpage>332</fpage>–<lpage>40</lpage>. <pub-id pub-id-type="doi">10.1016/j.ejca.2013.09.024</pub-id>
                  <pub-id pub-id-type="pmid">24157254</pub-id>
                  <issn>0959-8049</issn>
               </mixed-citation>
            </ref>
            <ref id="en-b23">
               <label>22.	</label>
               <mixed-citation publication-type="journal" specific-use="restruct">
                  <person-group person-group-type="author">
                     <string-name name-style="western">
                        <surname>Newton</surname> 
                        <given-names>AD</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Bartlett</surname> 
                        <given-names>EK</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Karakousis</surname> 
                        <given-names>GC</given-names>
                     </string-name>
                  </person-group>. <article-title>Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: a review of factors contributing to morbidity and mortality</article-title>. <source>J Gastrointest Oncol</source>. <year>2016</year> 
                  <month>Feb</month>;<volume>7</volume>(<issue>1</issue>):<fpage>99</fpage>–<lpage>111</lpage>.<pub-id pub-id-type="pmid">26941988</pub-id>
                  <issn>2078-6891</issn>
               </mixed-citation>
            </ref>
            <ref id="en-b24">
               <label>23.	</label>
               <mixed-citation publication-type="journal" specific-use="restruct">
                  <person-group person-group-type="author">
                     <string-name name-style="western">
                        <surname>Sugarbaker</surname> 
                        <given-names>PH</given-names>
                     </string-name>
                  </person-group>. <article-title>Peritonectomy procedures</article-title>. <source>Ann Surg</source>. <year>1995</year> 
                  <month>Jan</month>;<volume>221</volume>(<issue>1</issue>):<fpage>29</fpage>–<lpage>42</lpage>. <pub-id pub-id-type="doi">10.1097/00000658-199501000-00004</pub-id>
                  <pub-id pub-id-type="pmid">7826158</pub-id>
                  <issn>0003-4932</issn>
               </mixed-citation>
            </ref>
            <ref id="en-b25">
               <label>24.	</label>
               <mixed-citation publication-type="journal" specific-use="restruct">
                  <person-group person-group-type="author">
                     <string-name name-style="western">
                        <surname>Ceelen</surname> 
                        <given-names>WP</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Påhlman</surname> 
                        <given-names>L</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Mahteme</surname> 
                        <given-names>H</given-names>
                     </string-name>
                  </person-group>. <article-title>Pharmacodynamic aspects of intraperitoneal cytotoxic therapy</article-title>. <source>Cancer Treat Res</source>. <year>2007</year>;<volume>134</volume>:<fpage>195</fpage>–<lpage>214</lpage>.<pub-id pub-id-type="pmid">17633055</pub-id>
                  <issn>0927-3042</issn>
                  <annotation>
                     <p content-type="warning">Edifix has not found an issue number in the journal reference. Please check the volume/issue information. (Ref. 24 "Ceelen, Påhlman, Mahteme, 2007")</p>
                  </annotation>
               </mixed-citation>
            </ref>
            <ref id="en-b26">
               <label>25.	</label>
               <mixed-citation publication-type="journal" specific-use="restruct">
                  <person-group person-group-type="author">
                     <string-name name-style="western">
                        <surname>Sticca</surname> 
                        <given-names>RP</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Dach</surname> 
                        <given-names>BW</given-names>
                     </string-name>
                  </person-group>. <article-title>Rationale for hyperthermia with intraoperative intraperitoneal chemotherapy agents</article-title>. <source>Surg Oncol Clin N Am</source>. <year>2003</year> 
                  <month>Jul</month>;<volume>12</volume>(<issue>3</issue>):<fpage>689</fpage>–<lpage>701</lpage>. <pub-id pub-id-type="doi">10.1016/S1055-3207(03)00029-2</pub-id>
                  <pub-id pub-id-type="pmid">14567025</pub-id>
                  <issn>1055-3207</issn>
               </mixed-citation>
            </ref>
            <ref id="en-b27">
               <label>26.    </label>
               <mixed-citation publication-type="unknown" specific-use="linked">
                  <person-group person-group-type="author">
                     <string-name name-style="western">
                        <surname>Benoit</surname> 
                        <given-names>L</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Cheynel</surname> 
                        <given-names>N</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Ortega-Deballon</surname> 
                        <given-names>P</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Giacomo</surname> 
                        <given-names>G</given-names> 
                        <surname>Di</surname>
                     </string-name>, <string-name name-style="western">
                        <surname>Chauffert</surname> 
                        <given-names>B</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Rat</surname> 
                        <given-names>P.</given-names>
                     </string-name>
                  </person-group> 
                  <article-title>Closed hyperthermic intraperitoneal chemotherapy with open abdomen: a novel technique to reduce exposure of the surgical team to chemotherapy drugs.</article-title> Ann Surg Oncol. Springer; <year>2008</year> Feb 10;15(2):542–6. <pub-id pub-id-type="doi">10.1245/s10434-007-9635-x</pub-id>
                  <annotation>
                     <p content-type="warning">Edifix has not updated the authors because of a name mismatch. Please compare "Di" with "Chauffert" and "Chauffert" with "Rat". The Crossref authors are <underline>Benoit L, Cheynel N, Ortega-Deballon P, Giacomo GD, Chauffert B, Rat P</underline>. (Ref. 26 "Benoit, Cheynel, Ortega-Deballon, Giacomo, Di, Chauffert, Rat, 2008")</p>
                  </annotation>
               </mixed-citation>
            </ref>
            <ref id="en-b28">
               <label>27.	</label>
               <mixed-citation publication-type="journal" specific-use="restruct">
                  <person-group person-group-type="author">
                     <string-name name-style="western">
                        <surname>Lemoine</surname> 
                        <given-names>L</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Sugarbaker</surname> 
                        <given-names>P</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Van der Speeten</surname> 
                        <given-names>K</given-names>
                     </string-name>
                  </person-group>. <article-title>Pathophysiology of colorectal peritoneal carcinomatosis: role of the peritoneum</article-title>. <source>World J Gastroenterol</source>. <year>2016</year> 
                  <month>Sep</month>;<volume>22</volume>(<issue>34</issue>):<fpage>7692</fpage>–<lpage>707</lpage>. <pub-id pub-id-type="doi">10.3748/wjg.v22.i34.7692</pub-id>
                  <pub-id pub-id-type="pmid">27678351</pub-id>
                  <issn>1007-9327</issn>
               </mixed-citation>
            </ref>
            <ref id="en-b29">
               <label>28.	</label>
               <mixed-citation publication-type="journal" specific-use="restruct">
                  <person-group person-group-type="author">
                     <string-name name-style="western">
                        <surname>Bhatt</surname> 
                        <given-names>A</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Glehen</surname> 
                        <given-names>O</given-names>
                     </string-name>
                  </person-group>. <article-title>The role of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Ovarian Cancer: A Review</article-title>. <source>Indian J Surg Oncol</source>. <year>2016</year> 
                  <month>Jun</month>;<volume>7</volume>(<issue>2</issue>):<fpage>188</fpage>–<lpage>97</lpage>. <pub-id pub-id-type="doi">10.1007/s13193-016-0501-9</pub-id>
                  <pub-id pub-id-type="pmid">27065709</pub-id>
                  <issn>0975-7651</issn>
               </mixed-citation>
            </ref>
            <ref id="en-b30">
               <label>29.	</label>
               <mixed-citation publication-type="journal" specific-use="restruct">
                  <person-group person-group-type="author">
                     <string-name name-style="western">
                        <surname>Gilly</surname> 
                        <given-names>FN</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Cotte</surname> 
                        <given-names>E</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Brigand</surname> 
                        <given-names>C</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Monneuse</surname> 
                        <given-names>O</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Beaujard</surname> 
                        <given-names>AC</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Freyer</surname> 
                        <given-names>G</given-names>
                     </string-name>, <etal>et al.</etal>
                  </person-group> 
                  <article-title>Quantitative prognostic indices in peritoneal carcinomatosis</article-title>. <source>Eur J Surg Oncol</source>. <year>2006</year> 
                  <month>Aug</month>;<volume>32</volume>(<issue>6</issue>):<fpage>597</fpage>–<lpage>601</lpage>. <pub-id pub-id-type="doi">10.1016/j.ejso.2006.03.002</pub-id>
                  <pub-id pub-id-type="pmid">16617003</pub-id>
                  <issn>0748-7983</issn>
               </mixed-citation>
            </ref>
            <ref id="en-b31">
               <label>30.	</label>
               <mixed-citation publication-type="journal" specific-use="restruct">
                  <person-group person-group-type="author">
                     <string-name name-style="western">
                        <surname>Harmon</surname> 
                        <given-names>RL</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Sugarbaker</surname> 
                        <given-names>PH</given-names>
                     </string-name>
                  </person-group>. <article-title>Prognostic indicators in peritoneal carcinomatosis from gastrointestinal cancer</article-title>. <source>Int Semin Surg Oncol</source>. <year>2005</year> 
                  <month>Feb</month>;<volume>2</volume>(<issue>1</issue>):<fpage>3</fpage>. <pub-id pub-id-type="doi">10.1186/1477-7800-2-3</pub-id>
                  <pub-id pub-id-type="pmid">15701175</pub-id>
                  <issn>1477-7800</issn>
               </mixed-citation>
            </ref>
            <ref id="en-b32">
               <label>31.	</label>
               <mixed-citation publication-type="journal" specific-use="restruct">
                  <person-group person-group-type="author">
                     <string-name name-style="western">
                        <surname>Sugarbaker</surname> 
                        <given-names>PH</given-names>
                     </string-name>
                  </person-group>. <article-title>Colorectal cancer: prevention and management of metastatic disease</article-title>. <source>BioMed Res Int</source>. <year>2014</year>;<volume>2014</volume>:<fpage>782890</fpage>. <pub-id pub-id-type="doi">10.1155/2014/782890</pub-id>
                  <pub-id pub-id-type="pmid">24783222</pub-id>
                  <issn>2314-6133</issn>
                  <annotation>
                     <p content-type="warning">Edifix has not found an issue number in the journal reference. Please check the volume/issue information. (Ref. 31 "Sugarbaker, 2014")</p>
                  </annotation>
               </mixed-citation>
            </ref>
            <ref id="en-b33">
               <label>32.	</label>
               <mixed-citation publication-type="journal" specific-use="restruct">
                  <person-group person-group-type="author">
                     <string-name name-style="western">
                        <surname>Sammartino</surname> 
                        <given-names>P</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Sibio</surname> 
                        <given-names>S</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Biacchi</surname> 
                        <given-names>D</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Cardi</surname> 
                        <given-names>M</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Accarpio</surname> 
                        <given-names>F</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Mingazzini</surname> 
                        <given-names>P</given-names>
                     </string-name>, <etal>et al.</etal>
                  </person-group> 
                  <article-title>Prevention of Peritoneal Metastases from Colon Cancer in High-Risk Patients: Preliminary Results of Surgery plus Prophylactic HIPEC</article-title>. <source>Gastroenterol Res Pract</source>. <year>2012</year>;<volume>2012</volume>:<fpage>141585</fpage>. <pub-id pub-id-type="doi">10.1155/2012/141585</pub-id>
                  <pub-id pub-id-type="pmid">22645605</pub-id>
                  <issn>1687-6121</issn>
                  <annotation>
                     <p content-type="warning">Edifix has not found an issue number in the journal reference. Please check the volume/issue information. (Ref. 32 "Sammartino, Sibio, Biacchi, Cardi, Accarpio, Mingazzini, et al., 2012")</p>
                  </annotation>
               </mixed-citation>
            </ref>
            <ref id="en-b34">
               <label>33.	</label>
               <mixed-citation publication-type="journal" specific-use="restruct">
                  <person-group person-group-type="author">
                     <string-name name-style="western">
                        <surname>Lungoci</surname> 
                        <given-names>C</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Mironiuc</surname> 
                        <given-names>AI</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Muntean</surname> 
                        <given-names>V</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Oniu</surname> 
                        <given-names>T</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Leebmann</surname> 
                        <given-names>H</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Mayr</surname> 
                        <given-names>M</given-names>
                     </string-name>, <etal>et al.</etal>
                  </person-group> 
                  <article-title>Multimodality treatment strategies have changed prognosis of peritoneal metastases</article-title>. <source>World J Gastrointest Oncol</source>. <year>2016</year> 
                  <month>Jan</month>;<volume>8</volume>(<issue>1</issue>):<fpage>67</fpage>–<lpage>82</lpage>. <pub-id pub-id-type="doi">10.4251/wjgo.v8.i1.67</pub-id>
                  <pub-id pub-id-type="pmid">26798438</pub-id>
                  <issn>1948-5204</issn>
               </mixed-citation>
            </ref>
            <ref id="en-b35">
               <label>34.	</label>
               <mixed-citation publication-type="journal" specific-use="restruct">
                  <person-group person-group-type="author">
                     <string-name name-style="western">
                        <surname>Smeenk</surname> 
                        <given-names>RM</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>van Velthuysen</surname> 
                        <given-names>ML</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Verwaal</surname> 
                        <given-names>VJ</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Zoetmulder</surname> 
                        <given-names>FA</given-names>
                     </string-name>
                  </person-group>. <article-title>Appendiceal neoplasms and pseudomyxoma peritonei: a population based study</article-title>. <source>Eur J Surg Oncol</source>. <year>2008</year> 
                  <month>Feb</month>;<volume>34</volume>(<issue>2</issue>):<fpage>196</fpage>–<lpage>201</lpage>. <pub-id pub-id-type="doi">10.1016/j.ejso.2007.04.002</pub-id>
                  <pub-id pub-id-type="pmid">17524597</pub-id>
                  <issn>0748-7983</issn>
               </mixed-citation>
            </ref>
            <ref id="en-b36">
               <label>35.	</label>
               <mixed-citation publication-type="journal" specific-use="restruct">
                  <person-group person-group-type="author">
                     <string-name name-style="western">
                        <surname>Ayantunde</surname> 
                        <given-names>AA</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Parsons</surname> 
                        <given-names>SL</given-names>
                     </string-name>
                  </person-group>. <article-title>Pattern and prognostic factors in patients with malignant ascites: a retrospective study</article-title>. <source>Ann Oncol</source>. <year>2007</year> 
                  <month>May</month>;<volume>18</volume>(<issue>5</issue>):<fpage>945</fpage>–<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1093/annonc/mdl499</pub-id>
                  <pub-id pub-id-type="pmid">17298959</pub-id>
                  <issn>0923-7534</issn>
               </mixed-citation>
            </ref>
            <ref id="en-b37">
               <label>36.	</label>
               <mixed-citation publication-type="journal" specific-use="restruct">
                  <person-group person-group-type="author">
                     <string-name name-style="western">
                        <surname>Valle</surname> 
                        <given-names>M</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Van der Speeten</surname> 
                        <given-names>K</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Garofalo</surname> 
                        <given-names>A</given-names>
                     </string-name>
                  </person-group>. <article-title>Laparoscopic hyperthermic intraperitoneal peroperative chemotherapy (HIPEC) in the management of refractory malignant ascites: A multi-institutional retrospective analysis in 52 patients</article-title>. <source>J Surg Oncol</source>. <year>2009</year> 
                  <month>Sep</month>;<volume>100</volume>(<issue>4</issue>):<fpage>331</fpage>–<lpage>4</lpage>. <pub-id pub-id-type="doi">10.1002/jso.21321</pub-id>
                  <pub-id pub-id-type="pmid">19697441</pub-id>
                  <issn>0022-4790</issn>
               </mixed-citation>
            </ref>
            <ref id="en-b38">
               <label>37.	</label>
               <mixed-citation publication-type="journal" specific-use="restruct">
                  <person-group person-group-type="author">
                     <string-name name-style="western">
                        <surname>Turaga</surname> 
                        <given-names>KK</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Pappas</surname> 
                        <given-names>SG</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Gamblin</surname> 
                        <given-names>T</given-names>
                     </string-name>
                  </person-group>. <article-title>Importance of histologic subtype in the staging of appendiceal tumors</article-title>. <source>Ann Surg Oncol</source>. <year>2012</year> 
                  <month>May</month>;<volume>19</volume>(<issue>5</issue>):<fpage>1379</fpage>–<lpage>85</lpage>. <pub-id pub-id-type="doi">10.1245/s10434-012-2238-1</pub-id>
                  <pub-id pub-id-type="pmid">22302267</pub-id>
                  <issn>1068-9265</issn>
               </mixed-citation>
            </ref>
            <ref id="en-b39">
               <label>38.	</label>
               <mixed-citation publication-type="journal" specific-use="restruct">
                  <person-group person-group-type="author">
                     <string-name name-style="western">
                        <surname>Sugarbaker</surname> 
                        <given-names>PH</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Ronnett</surname> 
                        <given-names>BM</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Archer</surname> 
                        <given-names>A</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Averbach</surname> 
                        <given-names>AM</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Bland</surname> 
                        <given-names>R</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Chang</surname> 
                        <given-names>D</given-names>
                     </string-name>, <etal>et al.</etal>
                  </person-group> 
                  <article-title>Pseudomyxoma peritonei syndrome</article-title>. <source>Adv Surg</source>. <year>1996</year>;<volume>30</volume>:<fpage>233</fpage>–<lpage>80</lpage>.<pub-id pub-id-type="pmid">8960339</pub-id>
                  <issn>0065-3411</issn>
                  <annotation>
                     <p content-type="warning">Edifix has not found an issue number in the journal reference. Please check the volume/issue information. (Ref. 38 "Sugarbaker, Ronnett, Archer, Averbach, Bland, Chang, et al., 1996")</p>
                  </annotation>
               </mixed-citation>
            </ref>
            <ref id="en-b40">
               <label>39.	</label>
               <mixed-citation publication-type="journal" specific-use="restruct">
                  <person-group person-group-type="author">
                     <string-name name-style="western">
                        <surname>Bryant</surname> 
                        <given-names>J</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Clegg</surname> 
                        <given-names>AJ</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Sidhu</surname> 
                        <given-names>MK</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Brodin</surname> 
                        <given-names>H</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Royle</surname> 
                        <given-names>P</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Davidson</surname> 
                        <given-names>P</given-names>
                     </string-name>
                  </person-group>. <article-title>Systematic review of the Sugarbaker procedure for pseudomyxoma peritonei</article-title>. <source>Br J Surg</source>. <year>2005</year> 
                  <month>Feb</month>;<volume>92</volume>(<issue>2</issue>):<fpage>153</fpage>–<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1002/bjs.4862</pub-id>
                  <pub-id pub-id-type="pmid">15685704</pub-id>
                  <issn>0007-1323</issn>
               </mixed-citation>
            </ref>
            <ref id="en-b41">
               <label>40.	</label>
               <mixed-citation publication-type="journal" specific-use="restruct">
                  <person-group person-group-type="author">
                     <string-name name-style="western">
                        <surname>Chua</surname> 
                        <given-names>TC</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Moran</surname> 
                        <given-names>BJ</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Sugarbaker</surname> 
                        <given-names>PH</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Levine</surname> 
                        <given-names>EA</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Glehen</surname> 
                        <given-names>O</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Gilly</surname> 
                        <given-names>FN</given-names>
                     </string-name>, <etal>et al.</etal>
                  </person-group> 
                  <article-title>Early- and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy</article-title>. <source>J Clin Oncol</source>. <year>2012</year> 
                  <month>Jul</month>;<volume>30</volume>(<issue>20</issue>):<fpage>2449</fpage>–<lpage>56</lpage>. <pub-id pub-id-type="doi">10.1200/JCO.2011.39.7166</pub-id>
                  <pub-id pub-id-type="pmid">22614976</pub-id>
                  <issn>0732-183X</issn>
               </mixed-citation>
            </ref>
            <ref id="en-b42">
               <label>41.	</label>
               <mixed-citation publication-type="journal" specific-use="restruct">
                  <person-group person-group-type="author">
                     <string-name name-style="western">
                        <surname>Ferlay</surname> 
                        <given-names>J</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Steliarova-Foucher</surname> 
                        <given-names>E</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Lortet-Tieulent</surname> 
                        <given-names>J</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Rosso</surname> 
                        <given-names>S</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Coebergh</surname> 
                        <given-names>JW</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Comber</surname> 
                        <given-names>H</given-names>
                     </string-name>, <etal>et al.</etal>
                  </person-group> 
                  <article-title>Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012</article-title>. <source>Eur J Cancer</source>. <year>2013</year> 
                  <month>Apr</month>;<volume>49</volume>(<issue>6</issue>):<fpage>1374</fpage>–<lpage>403</lpage>. <pub-id pub-id-type="doi">10.1016/j.ejca.2012.12.027</pub-id>
                  <pub-id pub-id-type="pmid">23485231</pub-id>
                  <issn>0959-8049</issn>
               </mixed-citation>
            </ref>
            <ref id="en-b43">
               <label>42.	</label>
               <mixed-citation publication-type="journal" specific-use="restruct">
                  <person-group person-group-type="author">
                     <string-name name-style="western">
                        <surname>Klaver</surname> 
                        <given-names>CE</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Musters</surname> 
                        <given-names>GD</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Bemelman</surname> 
                        <given-names>WA</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Punt</surname> 
                        <given-names>CJ</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Verwaal</surname> 
                        <given-names>VJ</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Dijkgraaf</surname> 
                        <given-names>MG</given-names>
                     </string-name>, <etal>et al.</etal>
                  </person-group> 
                  <article-title>Adjuvant hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with colon cancer at high risk of peritoneal carcinomatosis; the COLOPEC randomized multicentre trial</article-title>. <source>BMC Cancer</source>. <year>2015</year> 
                  <month>May</month>;<volume>15</volume>(<issue>1</issue>):<fpage>428</fpage>. <pub-id pub-id-type="doi">10.1186/s12885-015-1430-7</pub-id>
                  <pub-id pub-id-type="pmid">26003804</pub-id>
                  <issn>1471-2407</issn>
               </mixed-citation>
            </ref>
            <ref id="en-b44">
               <label>43.	</label>
               <mixed-citation publication-type="journal" specific-use="restruct">
                  <person-group person-group-type="author">
                     <string-name name-style="western">
                        <surname>Tariq</surname> 
                        <given-names>K</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Ghias</surname> 
                        <given-names>K</given-names>
                     </string-name>
                  </person-group>. <article-title>Colorectal cancer carcinogenesis: a review of mechanisms. Cancer Biol Med. Tianjing China</article-title>. <source>Chinese Anti-Cancer Association</source>. <year>2016</year> 
                  <month>Mar</month>;<volume>13</volume>(<issue>1</issue>):<fpage>120</fpage>–<lpage>35</lpage>.<annotation>
                     <p content-type="warning">Edifix does not recognize the journal "Chinese Anti-Cancer Association". If this is a valid journal title, please send this reference to journals@inera.com for addition to our journal database. (Ref. 43 "Tariq, Ghias, 2016")</p>
                  </annotation>
               </mixed-citation>
            </ref>
            <ref id="en-b45">
               <label>44.    </label>
               <mixed-citation publication-type="unknown" specific-use="linked">
                  <person-group person-group-type="author">
                     <string-name name-style="western">
                        <surname>März</surname> 
                        <given-names>L</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Piso</surname> 
                        <given-names>P</given-names>
                     </string-name>
                  </person-group>. <article-title>Treatment of peritoneal metastases from colorectal cancer.</article-title> Gastroenterol Rep. Oxford University Press; <year>2015</year> Nov 30;3(4):298–302. <pub-id pub-id-type="doi">10.1093/gastro/gov044</pub-id>
               </mixed-citation>
            </ref>
            <ref id="en-b46">
               <label>45.	</label>
               <mixed-citation publication-type="journal" specific-use="restruct">
                  <person-group person-group-type="author">
                     <string-name name-style="western">
                        <surname>Verwaal</surname> 
                        <given-names>VJ</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>van Ruth</surname> 
                        <given-names>S</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>de Bree</surname> 
                        <given-names>E</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>van Sloothen</surname> 
                        <given-names>GW</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>van Tinteren</surname> 
                        <given-names>H</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Boot</surname> 
                        <given-names>H</given-names>
                     </string-name>, <etal>et al.</etal>
                  </person-group> 
                  <article-title>Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer</article-title>. <source>J Clin Oncol</source>. <year>2003</year> 
                  <month>Oct</month>;<volume>21</volume>(<issue>20</issue>):<fpage>3737</fpage>–<lpage>43</lpage>. <pub-id pub-id-type="doi">10.1200/JCO.2003.04.187</pub-id>
                  <pub-id pub-id-type="pmid">14551293</pub-id>
                  <issn>0732-183X</issn>
               </mixed-citation>
            </ref>
            <ref id="en-b47">
               <label>46.	</label>
               <mixed-citation publication-type="journal" specific-use="restruct">
                  <person-group person-group-type="author">
                     <string-name name-style="western">
                        <surname>Verwaal</surname> 
                        <given-names>VJ</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Bruin</surname> 
                        <given-names>S</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Boot</surname> 
                        <given-names>H</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>van Slooten</surname> 
                        <given-names>G</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>van Tinteren</surname> 
                        <given-names>H</given-names>
                     </string-name>
                  </person-group>. <article-title>8-year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer</article-title>. <source>Ann Surg Oncol</source>. <year>2008</year> 
                  <month>Sep</month>;<volume>15</volume>(<issue>9</issue>):<fpage>2426</fpage>–<lpage>32</lpage>. <pub-id pub-id-type="doi">10.1245/s10434-008-9966-2</pub-id>
                  <pub-id pub-id-type="pmid">18521686</pub-id>
                  <issn>1068-9265</issn>
               </mixed-citation>
            </ref>
            <ref id="en-b48">
               <label>47.	</label>
               <mixed-citation publication-type="journal" specific-use="restruct">
                  <person-group person-group-type="author">
                     <string-name name-style="western">
                        <surname>Elias</surname> 
                        <given-names>D</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Gilly</surname> 
                        <given-names>F</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Boutitie</surname> 
                        <given-names>F</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Quenet</surname> 
                        <given-names>F</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Bereder</surname> 
                        <given-names>JM</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Mansvelt</surname> 
                        <given-names>B</given-names>
                     </string-name>, <etal>et al.</etal>
                  </person-group> 
                  <article-title>Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: retrospective analysis of 523 patients from a multicentric French study</article-title>. <source>J Clin Oncol</source>. <year>2010</year> 
                  <month>Jan</month>;<volume>28</volume>(<issue>1</issue>):<fpage>63</fpage>–<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1200/JCO.2009.23.9285</pub-id>
                  <pub-id pub-id-type="pmid">19917863</pub-id>
                  <issn>0732-183X</issn>
               </mixed-citation>
            </ref>
            <ref id="en-b49">
               <label>48.	</label>
               <mixed-citation publication-type="journal" specific-use="restruct">
                  <person-group person-group-type="author">
                     <string-name name-style="western">
                        <surname>Glehen</surname> 
                        <given-names>O</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Kwiatkowski</surname> 
                        <given-names>F</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Sugarbaker</surname> 
                        <given-names>PH</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Elias</surname> 
                        <given-names>D</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Levine</surname> 
                        <given-names>EA</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>De Simone</surname> 
                        <given-names>M</given-names>
                     </string-name>, <etal>et al.</etal>
                  </person-group> 
                  <article-title>Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multi-institutional study</article-title>. <source>J Clin Oncol</source>. <year>2004</year> 
                  <month>Aug</month>;<volume>22</volume>(<issue>16</issue>):<fpage>3284</fpage>–<lpage>92</lpage>. <pub-id pub-id-type="doi">10.1200/JCO.2004.10.012</pub-id>
                  <pub-id pub-id-type="pmid">15310771</pub-id>
                  <issn>0732-183X</issn>
               </mixed-citation>
            </ref>
            <ref id="en-b50">
               <label>49.	</label>
               <mixed-citation publication-type="journal" specific-use="restruct">
                  <person-group person-group-type="author">
                     <string-name name-style="western">
                        <surname>Park</surname> 
                        <given-names>DG</given-names>
                     </string-name>
                  </person-group>. <article-title>Is Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy a Safe and Effective Procedure for Treating Patients With a Peritoneal Surface Malignancy?</article-title> 
                  <source>Ann Coloproctol</source>. <year>2017</year> 
                  <month>Feb</month>;<volume>33</volume>(<issue>1</issue>):<fpage>3</fpage>–<lpage>4</lpage>. <pub-id pub-id-type="doi">10.3393/ac.2017.33.1.3</pub-id>
                  <pub-id pub-id-type="pmid">28289655</pub-id>
                  <issn>2287-9714</issn>
               </mixed-citation>
            </ref>
            <ref id="en-b51">
               <label>50.	</label>
               <mixed-citation publication-type="journal" specific-use="restruct">
                  <person-group person-group-type="author">
                     <string-name name-style="western">
                        <surname>Seshadri</surname> 
                        <given-names>RA</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Glehen</surname> 
                        <given-names>O</given-names>
                     </string-name>
                  </person-group>. <article-title>Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in gastric cancer</article-title>. <source>World J Gastroenterol</source>. <year>2016</year> 
                  <month>Jan</month>;<volume>22</volume>(<issue>3</issue>):<fpage>1114</fpage>–<lpage>30</lpage>. <pub-id pub-id-type="doi">10.3748/wjg.v22.i3.1114</pub-id>
                  <pub-id pub-id-type="pmid">26811651</pub-id>
                  <issn>1007-9327</issn>
               </mixed-citation>
            </ref>
            <ref id="en-b52">
               <label>51.	</label>
               <mixed-citation publication-type="journal" specific-use="restruct">
                  <person-group person-group-type="author">
                     <string-name name-style="western">
                        <surname>Glehen</surname> 
                        <given-names>O</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Gilly</surname> 
                        <given-names>FN</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Arvieux</surname> 
                        <given-names>C</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Cotte</surname> 
                        <given-names>E</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Boutitie</surname> 
                        <given-names>F</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Mansvelt</surname> 
                        <given-names>B</given-names>
                     </string-name>, <etal>et al.</etal>; <collab>Association Française de Chirurgie</collab>
                  </person-group>. <article-title>Peritoneal carcinomatosis from gastric cancer: a multi-institutional study of 159 patients treated by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy</article-title>. <source>Ann Surg Oncol</source>. <year>2010</year> 
                  <month>Sep</month>;<volume>17</volume>(<issue>9</issue>):<fpage>2370</fpage>–<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1245/s10434-010-1039-7</pub-id>
                  <pub-id pub-id-type="pmid">20336386</pub-id>
                  <issn>1068-9265</issn>
               </mixed-citation>
            </ref>
            <ref id="en-b53">
               <label>52.	</label>
               <mixed-citation publication-type="journal" specific-use="restruct">
                  <person-group person-group-type="author">
                     <string-name name-style="western">
                        <surname>Rudloff</surname> 
                        <given-names>U</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Langan</surname> 
                        <given-names>RC</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Mullinax</surname> 
                        <given-names>JE</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Beane</surname> 
                        <given-names>JD</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Steinberg</surname> 
                        <given-names>SM</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Beresnev</surname> 
                        <given-names>T</given-names>
                     </string-name>, <etal>et al.</etal>
                  </person-group> 
                  <article-title>Impact of maximal cytoreductive surgery plus regional heated intraperitoneal chemotherapy (HIPEC) on outcome of patients with peritoneal carcinomatosis of gastric origin: results of the GYMSSA trial</article-title>. <source>J Surg Oncol</source>. <year>2014</year> 
                  <month>Sep</month>;<volume>110</volume>(<issue>3</issue>):<fpage>275</fpage>–<lpage>84</lpage>. <pub-id pub-id-type="doi">10.1002/jso.23633</pub-id>
                  <pub-id pub-id-type="pmid">25042700</pub-id>
                  <issn>0022-4790</issn>
               </mixed-citation>
            </ref>
            <ref id="en-b54">
               <label>53.	</label>
               <mixed-citation publication-type="journal" specific-use="restruct">
                  <person-group person-group-type="author">
                     <string-name name-style="western">
                        <surname>Yonemura</surname> 
                        <given-names>Y</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Elnemr</surname> 
                        <given-names>A</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Endou</surname> 
                        <given-names>Y</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Hirano</surname> 
                        <given-names>M</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Mizumoto</surname> 
                        <given-names>A</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Takao</surname> 
                        <given-names>N</given-names>
                     </string-name>, <etal>et al.</etal>
                  </person-group> 
                  <article-title>Multidisciplinary therapy for treatment of patients with peritoneal carcinomatosis from gastric cancer. World J Gastrointest Oncol. Baishideng Publishing Group Co</article-title>. <source>Limited</source>. <year>2010</year> 
                  <month>Feb</month>;<volume>2</volume>(<issue>2</issue>):<fpage>85</fpage>–<lpage>97</lpage>.<annotation>
                     <p content-type="warning">Edifix does not recognize the journal "Limited". If this is a valid journal title, please send this reference to journals@inera.com for addition to our journal database. (Ref. 53 "Yonemura, Elnemr, Endou, Hirano, Mizumoto, Takao, et al., 2010")</p>
                  </annotation>
               </mixed-citation>
            </ref>
            <ref id="en-b55">
               <label>54.	</label>
               <mixed-citation publication-type="journal" specific-use="restruct">
                  <person-group person-group-type="author">
                     <string-name name-style="western">
                        <surname>Doubeni</surname> 
                        <given-names>CA</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Doubeni</surname> 
                        <given-names>AR</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Myers</surname> 
                        <given-names>AE</given-names>
                     </string-name>
                  </person-group>. <article-title>Diagnosis and Management of Ovarian Cancer</article-title>. <source>Am Fam Physician</source>. <year>2016</year> 
                  <month>Jun</month>;<volume>93</volume>(<issue>11</issue>):<fpage>937</fpage>–<lpage>44</lpage>.<pub-id pub-id-type="pmid">27281838</pub-id>
                  <issn>1532-0650</issn>
               </mixed-citation>
            </ref>
            <ref id="en-b56">
               <label>55.	</label>
               <mixed-citation publication-type="journal" specific-use="restruct">
                  <person-group person-group-type="author">
                     <string-name name-style="western">
                        <surname>Spiliotis</surname> 
                        <given-names>J</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Halkia</surname> 
                        <given-names>E</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>de Bree</surname> 
                        <given-names>E</given-names>
                     </string-name>
                  </person-group>. <article-title>Treatment of peritoneal surface malignancies with hyperthermic intraperitoneal chemotherapy-current perspectives</article-title>. <source>Curr Oncol</source>. <year>2016</year> 
                  <month>Jun</month>;<volume>23</volume>(<issue>3</issue>):<fpage>e266</fpage>–<lpage>75</lpage>. <pub-id pub-id-type="doi">10.3747/co.23.2831</pub-id>
                  <pub-id pub-id-type="pmid">27330364</pub-id>
                  <issn>1198-0052</issn>
               </mixed-citation>
            </ref>
            <ref id="en-b57">
               <label>56.	</label>
               <mixed-citation publication-type="journal" specific-use="restruct">
                  <person-group person-group-type="author">
                     <string-name name-style="western">
                        <surname>Shetty</surname> 
                        <given-names>SJ</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Bathla</surname> 
                        <given-names>L</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Govindarajan</surname> 
                        <given-names>V</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Thomas</surname> 
                        <given-names>P</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Loggie</surname> 
                        <given-names>BW</given-names>
                     </string-name>
                  </person-group>. <article-title>Comparison of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy with mitomycin or carboplatin for diffuse malignant peritoneal mesothelioma</article-title>. <source>Am Surg</source>. <year>2014</year> 
                  <month>Apr</month>;<volume>80</volume>(<issue>4</issue>):<fpage>348</fpage>–<lpage>52</lpage>.<pub-id pub-id-type="pmid">24887664</pub-id>
                  <issn>1555-9823</issn>
               </mixed-citation>
            </ref>
            <ref id="en-b58">
               <label>57.	</label>
               <mixed-citation publication-type="journal" specific-use="restruct">
                  <person-group person-group-type="author">
                     <string-name name-style="western">
                        <surname>Yan</surname> 
                        <given-names>TD</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Deraco</surname> 
                        <given-names>M</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Baratti</surname> 
                        <given-names>D</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Kusamura</surname> 
                        <given-names>S</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Elias</surname> 
                        <given-names>D</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Glehen</surname> 
                        <given-names>O</given-names>
                     </string-name>, <etal>et al.</etal>
                  </person-group> 
                  <article-title>Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience</article-title>. <source>J Clin Oncol</source>. <year>2009</year> 
                  <month>Dec</month>;<volume>27</volume>(<issue>36</issue>):<fpage>6237</fpage>–<lpage>42</lpage>. <pub-id pub-id-type="doi">10.1200/JCO.2009.23.9640</pub-id>
                  <pub-id pub-id-type="pmid">19917862</pub-id>
                  <issn>0732-183X</issn>
               </mixed-citation>
            </ref>
            <ref id="en-b59">
               <label>58.	</label>
               <mixed-citation publication-type="journal" specific-use="restruct">
                  <person-group person-group-type="author">
                     <string-name name-style="western">
                        <surname>Yan</surname> 
                        <given-names>TD</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Deraco</surname> 
                        <given-names>M</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Elias</surname> 
                        <given-names>D</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Glehen</surname> 
                        <given-names>O</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Levine</surname> 
                        <given-names>EA</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Moran</surname> 
                        <given-names>BJ</given-names>
                     </string-name>, <etal>et al.</etal>; <collab>Peritoneal Surface Oncology Group</collab>
                  </person-group>. <article-title>A novel tumor-node-metastasis (TNM) staging system of diffuse malignant peritoneal mesothelioma using outcome analysis of a multi-institutional database*</article-title>. <source>Cancer</source>. <year>2011</year> 
                  <month>May</month>;<volume>117</volume>(<issue>9</issue>):<fpage>1855</fpage>–<lpage>63</lpage>. <pub-id pub-id-type="doi">10.1002/cncr.25640</pub-id>
                  <pub-id pub-id-type="pmid">21509762</pub-id>
                  <issn>0008-543X</issn>
               </mixed-citation>
            </ref>
            <ref id="en-b60">
               <label>59.	</label>
               <mixed-citation publication-type="journal" specific-use="restruct">
                  <person-group person-group-type="author">
                     <string-name name-style="western">
                        <surname>Cotte</surname> 
                        <given-names>E</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Passot</surname> 
                        <given-names>G</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Gilly</surname> 
                        <given-names>FN</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Glehen</surname> 
                        <given-names>O</given-names>
                     </string-name>
                  </person-group>. <article-title>Selection of patients and staging of peritoneal surface malignancies. World J Gastrointest Oncol. Baishideng Publishing Group Co</article-title>. <source>Limited</source>. <year>2010</year> 
                  <month>Jan</month>;<volume>2</volume>(<issue>1</issue>):<fpage>31</fpage>–<lpage>5</lpage>.<annotation>
                     <p content-type="warning">The reference title appears to be set in title case rather than sentence case. (Ref. 59 "Cotte, Passot, Gilly, Glehen, 2010")</p>
                     <p content-type="warning">Edifix does not recognize the journal "Limited". If this is a valid journal title, please send this reference to journals@inera.com for addition to our journal database. (Ref. 59 "Cotte, Passot, Gilly, Glehen, 2010")</p>
                  </annotation>
               </mixed-citation>
            </ref>
         </ref-list>
      </back>
   </sub-article>
</article>
